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 ABSTRACT 
 
 
Ultra-short, Single-walled Carbon Nanotube Capsules for Diagnostic Imaging and 
Radiotherapy 
 
by 
 
Michael Lee Matson 
 
This thesis is centered on the Gadonanotubes (GNTs), an ultra-high-performance 
magnetic resonance imaging (MRI) contrast agent material discovered in our laboratories 
in 2005. The GNTs are a new paradigm in MRI contrast agent design with small clusters 
of Gd
3+
 ions within ultra-short carbon nanocapsules (ca. 50 nm) cut from full-length 
single-walled carbon nanotubes. Here, the factors underlying the performance efficacy of 
the GNTs have been investigated for the first time by variable-field (-50,000 Oe to 
50,000 Oe at 2K) and variable-temperature (2K to RT at 100 Oe) magnetic susceptibility 
measurements using a Magnetic Property Measurement System (MPMS, based on a 
SQUID magnetometer). Additionally, experiments focused on the effects of 
hydroxylation of the GNTs’ exterior surface regarding water-solubility are examined. 
Finally, the use of the GNTs as potential replacements for traditional metal-
chelating/sequestering agents is explored. More specifically, the internal Gd
3+
-ion 
clusters of the GNTs have been radiolabeled: (1) with
 153
Gd
3+ 
ions to test Gd
3+
-ion 
stability to simulated biological challenge, (2) with 
225
Ac
3+
 ions to generate a new 
concept for a GNT-based agent for α-radiotherapy, and finally (3) with 64Cu2+ ions to 
produce the first bimodal MRI/PET (PET = positron emission tomography) imaging 
agent derived from the GNTs.  
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Just for Fun: 
 
At the “Center” of Nanotechnology 
Dr. Curl (of Rice University) and Sir Kroto (now of Florida State University, then of 
University of Sussex) with the late Dr. Richard Errett Smalley (also of Rice University) 
who won the 1996 Nobel Prize in Chemistry for their “discovery of 
iv 
buckminsterfullerene.” 
 
Pictured: Dr. Robert (Bob) Floyd Curl, Jr. (left) and Sir Harold (Harry) Walter 
Kroto (right).  
 
Scrabble Dictionary 
Currently, the scrabble dictionary does not recognize “nanotube” as a legitimate word. 
This needs to be changed! 
 
 
Pictured: Words with Friends app denying submission of “nanotube” in play. 
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 PREFACE 
I wish to preface this thesis by noting that much of the material included in the literature 
review found in Chapter One comes from a published review article 
1
 and book chapter 
2
 
for which I am the first author. 
1 
CHAPTER ONE: INTRODUCTION  
 
“If we can reduce the cost and improve the quality of medical technology through 
advances in nanotechnology, we can more widely address the medical conditions that are 
prevalent and reduce the level of human suffering.”  
~ Ralph Merkle, American Nanotechnologist 
 
INTRODUCTION 
 
One of the exciting trends in modern drug design is the merging of traditional diagnostics 
(drugs that define a disease state) and therapeutics (drugs that treat a disease state) into a 
new field of multi-functional platforms known as “theranostics.”3,4  This form of 
integrated medicine allows physicians the unique ability to diagnose disease while 
simultaneously monitor therapeutic response.  Aside from saving the patient valuable 
time and money, the physician has the ability to customize the patient’s treatment 
regimen based on diagnostic feedback. 
 
Just as a compounding pharmacist uses a gelatin capsule to deliver multiple drugs unique 
to a specific patient, this thesis examines the continued development of ultra-short carbon 
nanotube capsules (US-tube nanocapsules) as nanoscale molecular capsules for medical 
imaging, specifically magnetic resonance imaging (MRI) and positron emission 
tomography (PET), as well as therapeutic agents (specifically, α-particle therapy).5  
Stemming from a single-walled carbon nanotube (SWNT) precursor, US-tube 
2 
nanocapsules maintain a bio-inert carbon exterior surface prime for chemical 
derivitization for biocompatibility and cellular targeting.
5-7
  Furthermore, US-tube 
nanocapsules have shown ability to permeate cell membranes and accumulate within 
cells; this accrual will enhance efficacy of both diagnostic and therapeutic agents.
8
  
Finally, US-tube nanocapsules have previously been studied as diagnostic agents 
following the encapsulation of Gd
3+
 ions for MRI contrast enhancement, known as 
“Gadonanotubes” (GNTs),9 and I2 (s) for X-ray Computed Tomography (CT) contrast 
enhancement,
10
 as well as therapeutic agents through encapsulation of 
211AtCl for α-
radionuclide therapy.
11
  For these reasons, the US-tube nanocapsules have potential for 
becoming the platform from which numerous future theranostic agents can be 
constructed.  
 
This thesis explores the US-tube nanocapsules in further detail: specifically, the magnetic 
properties of the nanocapsules loaded with lanthanide ions, attempts at hydroxylation of 
the nanocapsules’ exterior, retention studies of both lanthanide ions and actinide ions, and 
their ability to encapsulate both Gd
3+
 and Cu
2+
 ions to prove useful as a bimodal 
MRI/PET imaging agent. 
 
CARBON NANOSTRUCTURES 
 
Definition 
This chapter begins with an overview of carbon nanostructures, such as the US-tube 
nanocapsules, that exhibit the unique properties explored in this thesis.    First, a proper 
3 
definition for nanotechnology must be established, as the media and popular culture 
commonly fails to properly define the term.  For example, the web-based collaborative 
Wikipedia defines nanotechnology as: “Nanotechnology (sometimes shortened to 
"nanotech") is the study of manipulating matter on an atomic and molecular scale.”12  For 
the scope of this thesis, however, the following definition for Nanotechnology will be 
utilized: “the study of any man-made device or material, with at least one dimension 
under 100 nm, which exhibits unique or enhanced properties made possible by the 
nanoscale size.”1  This definition is employed as it more accurately confines the field of 
chemistry into what is (or is not) classified as “nanotechnology;”  the more general 
definition of simply manipulating matter on a molecular scale would categorize almost all 
chemistry as nanotechnology.  This added distinction of “unique or enhanced properties” 
offered by carbon nanotubes will be revisited multiple times throughout this thesis.     
 
Fullerenes 
Although fullerenes (Figure 1) are not a focus of this thesis, they are introduced here for 
three primary reasons:  
(1) fullerenes are a natural, chronological introduction to carbon nanotubes due to 
similar synthetic pathways.  
(2) endohedral metalofullerenes are used as sources of comparison to the GNTs in 
Chapters Two and Appendix IV.  
(3) fullerenes were discovered (here) at Rice University in 1985.
13
 
4 
 
Figure 1: Representative fullerene molecules (adapted from 
2
). 
 
While traditional modeling of fullerenes renders beautiful structures (Figure 1), 
traditional naming regimens aren’t as attractive.  For example, following the systematic 
naming of the International Union of Pure and Applied Chemistry (IUPAC) Rule A-32 
for bridged, cyclic hydrocarbons (also known as the von Baeyer System) renders C60 
(Figure 1 upper-left) as:
14
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]hexaconta-1,3,5(10),6,8,11,13(18),14,16,19,21,23,25,27,29(45), 
30,32(44),33, 35(43),36,38(54),39(51),40(48),41,46,49,52,55,57,59-triacontaene. 
 
Luckily, the discovers of C60 offered a more eloquent name that is still in use today: 
“buckminsterfullerene.”13  Named after the American architect who popularized the 
geodesic dome in the 1960’s (Figure 2),15 buckminsterfullerene (“buckyball” for short) is 
traditionally reserved specifically for the C60 molecule.  “Fullerenes” is now commonly 
5 
used to describe the entire class of closed cage molecules consisting of only three 
coordinate carbon atoms.
16,17
  Fullerene classification is further guided by Euler’s 
theorem, which states that for a closed structure to be purely composed from pentagons 
and hexagons, it must contain twelve pentagons.  This limits the smallest fullerene to a 
C20 structure and renders C60 the smallest stable fullerene according to the Isolated 
Pentagon Rule (IPR), which states the most stable fullerenes have pentagons that do not 
contact each other. 
 
 
Figure 2: The Montréal Biosphère by Buckminster Fuller for the 1967 
International and Universal Exposition (Open-Source from 
18
). 
 
Synthesis of Fullerenes 
Fullerenes have been discovered both in naturally-occurring carbon-rich rocks like 
shungite of Shunga, Russia,
19
 and following powerful, geological events like wild fires 
along the K-T boundary in New Zealand,
20
 lightning strikes,
21
 and meteor strikes.
22
  
However, despite their natural existence, it wasn’t until the mid-1980’s that they were 
first discovered by a collaborative team of scientists at Rice University.
13
 
6 
 
Figure 3: Schematic diagram of the pulsed supersonic nozzle used to produce 
fullerenes (adapted from 
13
). 
 
The original synthesis of C60 focused a pulsed neodymium-doped yttrium aluminum 
garnet (Nd:YAG) laser on a solid disk of graphite under high-density helium gas flow,
13
 
as shown in Figure 3.  Collaboration between Profs. Richard Smalley and Bob Curl and 
the astrophysicist Prof. Harry Kroto of Sussex University began, using this technology to 
recreate the atmosphere of early red stars in an attempt to identify and better understand 
their unique infrared (IR) emission.
13,16,23
  From the resulting soot from this experiment, 
fullerenes (C60/C70) were discovered.  Later, scientists determined that lanthanum ions 
(La
3+
) atoms could be entrapped inside of these fullerenes by doping the graphite disk 
with La salts,
24
 creating a new material known as metallofullerenes (denoted La@C60).  
The gadofullerenes (Gd@C60) discussed later in this chapter are another form of 
lanthanide-ion-based metallofullerenes. 
 
Macroscopic quantities of fullerenes were first generated using resistive heating between 
two graphite rods in a Krätschmer arc reactor.
25
  Simply applying a voltage between these 
two rods produced fullerene-enriched (~4% C60/C70) carbon soot.  Modified to use an arc 
welder with alternating current (AC) as a power supply, the Wudl reactor,
26
 also known 
7 
as a “contact-arc” apparatus,16 is the most commonly used resistive heating method use in 
the laboratory for its ease of construction and relatively low cost.
27
  The primary 
alternative to the Wudl reactor in a laboratory setting is the arc-discharge technique, a 
similar technique which separates the carbon rods by a 4 mm fixed gap to allow an 
electric arc to form.
28
  Other methods of fullerene synthesis include: solar furnaces,
29
 
hydrocarbon pyrolysis,
30
 inductive heating,
31
  coalescence reactions,
32
 the combustion 
synthesis method,
33
 and even simply lighting candles.
34
 
 
Single-walled Carbon Nanotubes 
An arc-discharge apparatus, similar to the one used for fullerene synthesis, also 
synthesizes hollow, cylindrical structures that resemble a single sheet of graphene rolled 
up seamlessly into a tube.
35-37
  These structures, as shown in Figure 4, are called single-
walled carbon nanotubes (SWNTs).  With a high aspect ratio and large surface area, 
SWNTs possess interesting optical, mechanical, electrical and thermal properties.
38-42
  
This section will briefly describe:  (A) the synthetic techniques used on the precursor 
SWNTs utilized within this thesis, (B) the various techniques used to purify these 
materials, and (C) the multiple available SWNT-characterization methods available. 
 
Figure 4: Ball-and-stick model of a single-walled carbon nanotube (SWNT) 
(adapted from 
2
). 
8 
Syntheses of SWNTs 
This thesis utilizes SWNTs manufactured by three unique methods: (1) electric arc-
discharge (2) chemical vapor deposition (CVD), and (3) the high-pressure carbon 
monoxide process (HiPCO).  The laser ablation method used for fullerene production in 
the section above is also commonly used for SWNT production, yet not analyzed within 
this thesis.
43-45
  Each of these methods yields SWNTs of varying dimensions and 
chiralities (a term used to describe the chiral vector that represents how the SWNT is 
oriented relative to an infinite graphene sheet as shown in Figure 5). 
 
Figure 5: Diagram representing SWNT chirality using the (n,m) naming scheme.  
T represents the axis of the SWNT, n and m are the chiral indices that make up 
the Ch vector, and a1 and a2 are unit vectors (public domain from 
46
). 
 
The first reported technique for the synthesis of SWNTs was the electric arc-discharge 
technique.
36,47
  Small quantities of metal particles (Fe, Co, etc) at the cathode of the arc 
results in the synthesis of SWNTs, multi-walled carbon nanotubes (MWNTs),
35
 and 
fullerenes.  The vaporization of metal atoms into the gas phase stabilizes the elongating 
fullerene structures in the vapor phase resulting in SWNT production.
47
  Advancements 
in the use of mixed-metal catalysts such as Co-Ni, Co-Pt, Ni-Y, and Ni-CO results have 
9 
resulted in significant improvement in yield and purity of SWNTs produced by this 
process.
48
   
SWNTs can also be synthesized using a CVD technique known as CoMoCat® by 
SouthWest NanoTechnologies Inc., shown in Figure 6.  CoMoCat® derives its name 
from its use of cobalt-molybdenum (Co-Mo) catalyst particles for the Boudouard 
disproportionation reaction of CO feed stock:
49,50
  
2 CO (g) → 2 CO2 (g)  + C (s) 
This technique is a continuous-flow technique, as opposed to a “batch method,”51-53 
which allows an ease of scalability that in turns lowers the cost significantly.  
Molybdenum trioxide (MoO3) stabilizes the Co
2+
 ion for reaction with eventual reduction 
by the CO.  Following the reduction, the nanoscale clusters of now metallic Co (under 2.0 
nm) act as the catalyst for SWNT growth.   
 
 
Figure 6: CoMoCat® fluidized bed SWNT reactor (adapted from 
54
). 
 
10 
Finally, studies found within this thesis also employ SWNTs produced by the HiPCO 
process, made on Rice’s campus in the reactor shown in Figure 7.  Like in the 
CoMoCAT® process, CO is the feed stock; however, HiPCO uses iron pentacarbonyl 
(Fe(CO)5) as catalyst.
55,56
  This method produces SWNTs in high yield (>90 %) with high 
purity (no amorphous carbon coating).   
 
 
 
 Figure 7: HiPCO SWNT reactor at Rice University.  
 
In summary, the three precursor SWNTs used throughout this thesis are: (1) Arc-
produced SWNTs, (2) CoMoCAT® produced SWNTs, and (3) HiPCO produced SWNTs.  
Of these, unless specifically noted otherwise, the SWNTs will be Arc-produced as these 
were the most cost-effective form of SWNTs available.  Perhaps the most significant 
difference between these techniques for the scope of this thesis is their average internal 
diameter: 0.8 nm for HiPCO-produced SWNTs, 1.0 nm for CoMoCAT-produced 
SWNTs, and 1.4 nm for electric-arc-produced SWNTs (Ni:Y catalyst).  This thesis will 
demonstrate that this key difference is negligible for the projects herein; however, future 
works, as described in Chapter 5, will likely show bias towards HiPCO synthesized tubes.  
11 
The smaller diameter of HiPCO-produced SWNTs results in greater structural strain,
57
 
which correlates to more facile functionalization routes of the US-tube nanocapsules 
sidewalls. This feature will become important when functionalizing the US-tube 
nanocapsules with medical targeting moieties in the future. 
 
Purification of SWNTs 
To remove the metal catalyst nanoparticles and amorphous carbon impurities of the 
produced SWNTs, numerous purification techniques have been employed including: 
hydrothermal treatment,
58,59
 microfiltration and chromatographic separation,
60-63
 
inorganic nanoparticles purification,
64-66
 and gas-phase oxidative procedures.
57,67-69
  The 
purification of large batches of SWNTs was first reported by oxidation in strong acids (3-
5 M nitric acid).
70
  Many reports have been published since with different temperatures, 
reaction times and acid conditions.
71
  These oxidizing agents convert metal catalyst 
particles into their corresponding metal oxides, which are larger in volume than their 
metal counterparts.  This results in the disruption of the carbon sheath surrounding the 
metal particles and the subsequent leaching of metal catalyst impurities.
72
  Along with the 
metal catalyst particles, the oxidation process also removes a majority of the 
carbonaceous impurities. The relative chemical inertness of SWNT materials permits 
much harsher oxidation conditions than are tolerated by other carbonaceous materials 
such as fullerenes, graphitic shells, and amorphous carbon. For biomedical applications, 
the presence of carbonaceous impurities and metal catalyst particles will result in 
undesirable inhomogenity and potential metal-mediated toxicity, respectively.
73,74
  Acid 
treatment was the purification method employed throughout this thesis for arc-ablation-
12 
synthesized and CoMoCAT-synthesized SWNTs. 
 
A special situation is encountered with HiPCO SWNTs due to their increased reactivity.  
To account for this situation, a purification protocol involving liquid Br2 has been shown 
to be very effective in removing the metal catalytic impurities from HiPco SWNTs 
without compromising their sidewall structure.
75
  This technique was used exclusively for 
the purification of HiPco SWNTs within this thesis.  
 
Characterization of SWNTs 
Common analytical techniques for the characterization of SWNTs include: Raman 
spectroscopy, near infrared (NIR) spectroscopy, thermal gravimetric analysis (TGA), and 
electron microscopy techniques (TEM, SEM, etc.). 
 
SWNTs have four signature peaks in the Raman spectrum useful for 
characterization,
57,76,77
 as shown in Figure 8:  (1) The radial breathing mode (RBM) 
(150-300 cm
-1
, diameter dependent) gives information about the diameter and packing of 
the SWNTs.  (2) The tangential mode (G-band; from 1515 cm
-1
 to 1590 cm
-1
) gives 
information about the sp
2
-hybridized carbons and can be useful in determining purity.  (3) 
The disorder mode (D-band; from 1280 cm
-1
 to 1320 cm
-1
) is a measure of the sidewall 
defects, amorphous carbon, and degree of functionalization, etc.  (4) The G’ mode is the 
second overtone of the D-band, yet has a name that stems from being the second 
strongest peak in graphite.  As this mode is diameter dependent, it is most often used to 
examine SWNT sample diameter. 
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Figure 8: Representative Raman spectra for SWNTs. Shown are characteristic 
spectra for both metallic and semiconducting HiPCO-produced SWNTs using a 
785 nm laser excitation. Inserts on left and right represent atomic displacement 
occurring from vibration modes (adapted from 
78
). 
 
NIR spectroscopy can also been used to characterize SWNT materials.
79,80
 Metallic and 
semiconducting SWNTs can be separately identified,
81
  and this technique can also be 
used to check for functionalization as functionalized SWNTs do not fluoresce in the NIR 
region.  This loss of fluorescence is due to a disruption of the SWNT electronic structure; 
the same is true for the US-tube capsules described below, therefore NIR won’t be 
employed within this thesis.  
 
TGA is one of the most widely used methods to check for the purity and the extent of 
functionalization, since carbonaceous materials and organic substituents decompose at a 
lower temperature than SWNTs.  However, TGA cannot differentiate between different 
forms of carbonaceous materials such as amorphous carbon and organic functional 
groups.  Hence, quantification of functional groups by TGA depends on the pre-
functionalization purity of SWNT materials and the use of other characterization 
methods, as well.  Other techniques, such as X-ray photoelectron spectroscopy (XPS) and 
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nuclear magnetic resonance (NMR) spectroscopy, can also be used to identify functional 
groups covalently attached to SWNTs.
7
  Microscopy techniques such as transmission 
electron microscopy (TEM), scanning electron microscopy (SEM) and atomic force 
microscopy (AFM) have been widely used for the visualization of SWNT materials to 
study their structural properties.  However, electron microscopy techniques use a small, 
localized fraction of the sample, and hence, such measurements have to be repeated 
multiple times at different sampling sites to generalize the observation. 
 
US-TUBE NANOCAPSULES 
 
Introduction 
The overarching scope of this thesis involves the ability for ultra-short SWNTs (US-tubes 
nanocapsules, Figure 9) to encapsulate medically-active ions; therefore, a brief 
introduction to this modified-SWNT material is required.  Numerous techniques have 
been utilized for the shortening of SWNTs, including applying a voltage pulse to the tip 
of a scanning tunneling microscope (STM);
82,83
 fluorination followed by oxidation with 
piranha and ammonium persulfate solutions;
84
 and treatment with oleum (100% H2SO4 
with excess SO3) and nitric acid.
85,86
   Herein, we cut SWNTs into US-tube nanocapsules 
of 20-80 nm in length by fluorination followed by pyrolysis at 1000 °C in an inert Ar 
atmosphere.
5
  A more detailed synthesis is described below.   
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Figure 9: Pictorial representations of US-tube nanocapsules. 
 
The synthesis of this material is included in this “background” chapter for two reasons: 
(1) the US-tube nanocapsules are used in every chapter of the thesis, and (2) it should be 
clearly noted that this synthesis is not a unique contribution, but rather a well-established 
prcoedure. Three separate apparatus for the fluorination of SWNTs were used within this 
thesis (two are displayed in Figure 10, while the third was owned by a private 
corporation, Nanoridge Materials).  Optimizing the conditions of each instrument renders 
a final material, in all cases, that behave similarly to one another.  Also, it should be 
noted that electric-arc-synthesized and CoMoCAT-synthesized SWNTs behaved 
identically in the three fluorinating apparatus, while more reactive HiPCO SWNTs 
required less reaction time (in all three apparatus) to have the same fluorination effect. 
16 
  
Figure 10: Example fluorination apparatus. Left is the custom fluorination built 
by the late Prof. Margrave, and right is the current fluorination apparatus at Rice 
named the John L. Margrave Fluorination Facility in honor of Prof. Margrave. 
 
 
Synthesis of US-Tube Nanocapsules 
US-tube nanocapsules were prepared following previously-established synthetic methods 
(Figure 11AB).
5
  This synthesis will follow the conditions optimized for the John L. 
Margrave Fluorination Facility at Rice University for two commercially-available SWNT 
materials: CoMoCat® SWNTs (SWeNT® CG200 Grade, SouthWest NanoTechnologies 
Inc., Norman, OK) and electric-arc discharge SWNTs with Ni/Y catalyst (AP Grade, 
CarboLex, Inc., Lexington, Kentucky).  To determine the protocol for fluorination of 
HiPCO SWNTs in the reactor, simply decrease the reaction time by 40%. 
 
17 
 
Figure 11: Synthesis of US-tube nanocapsules.  
 
US-tube nanocapsules were prepared following the literature fluorination/pyrolysis 
method.
5,87,88
  Approximately 1.0 g of raw, full-length SWNTs was split between two 
Monel boats and inserted into a fluorination apparatus (Figure 10).  After purging the 
system with He gas for 45 minutes while raising the system temperature to 125 
o
C, the 
SWNTs were exposed to a fluorinating gas mixture (2.7% argon-diluted F2) at 125 °C for 
12 hr (7 hr for HiPCO SWNTs).  SWNTs synthesized from electric arc ablation techniques 
were predominantly used in this thesis for their relatively large diameter (1.3-1.5 nm),
9
 a 
property originally hypothesized to be important when considering loading potential 
(capacity for internalization).  Once the system was allowed to return to room 
temperature and all unreacted F2 gas has purged the system, fluorination was confirmed 
18 
via weight increase (approximately 25-30%) and increase in the relative intensity ratio of 
the Disordered Mode peak around 1300 cm
-1
 (representative of sp
3
-hybridised carbon) to 
the G-Band Mode around 1590 cm
-1
 (representative of sp
2
-hybridised carbon), known as 
the D:G ratio, using Raman spectroscopy.
89
  
 
A Renishaw Raman microscope using a 633 nm excitation laser employing an 1800 l/mm 
grating, available through Rice’s Shared Equipment Authority (SEA), was utilized for 
collection of Raman spectra.  All spectra were obtained on oven-dried samples that were 
mounted on a glass microscope slide using double-sided tape.  Once the sp
2
-hybridized 
carbon atoms of the carbon nanotube sheath become sp
3
-hybridized when bound to 
fluorine, a visible shift occurs in the resulting Raman spectra.  The proposed mechanism 
for this fluorination reaction is a (1,4) addition.90   Moreover, the higher deformation 
energy of separating the fluorine attachments to the SWNT sheath provide an 
energetically-favored condition of forming banded structures,
90
 which original scanning 
tunneling microscope (STM)  images support, as shown in Figure 12.  
 
 
Figure 12: STM image of a carbon nanotube fluorinated at 250°C for 12 h 
(bright areas represent fluorine atoms, 860 Å by 180 Å, adapted from 
91
). 
 
 
Immediately following removal from the reactor (to prevent unwanted dehalogenation), 
the fluorinated SWNTs were heated to 1000 
o
C in a tube furnace under inert argon gas for 
3 hr.  Cutting is made possible due to the fluorine deposition occurring in a banded 
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structure (Figure 12), circling the nanotube and leaving approximately 20-80 nm of 
relatively unfunctionalized nanotube between these bands.  Volatile fluorocarbons, in the 
form of carbon tetrafluoride (CF4) and carbonyl fluoride (COF2), are driven off the tubes 
rendering US-tubes approximately 20-80 nm in length (Figure 11B).
9,11,92
  The few 
fluorine depositions along these US-tube nanocapsule segments, however, result in defect 
sites in the US-tube nanocapsule sidewalls that will facilitate the loading ions and small 
molecules.
93
  Successful pyrolysis is confirmed via weight decrease (approximately 33%) 
and a large decrease in the D/G ratio using a Renishaw Raman microscope.  This 
decrease occurs as many of the sp
3
-hybridized carbons left the US-tube nanocapsules in 
the form of volatile fluorocarbons as described above.   
 
Removal of metal catalyst impurities occurs via bath sonication in 100 mL of 
concentrated HCl for one hour.
35
  These purified US-tube nanocapsules are gravity-
filtered using a coarse (‘C’) fritted glass filter, being washed several times with 150 mL 
aliquots of HPLC grade deionized water until the pH of the filtrate becomes ~7.0. 
Finally, these tubes will be left in an 80 
o
C oven to dry overnight. The removal of catalyst 
is confirmed via SEA’s Phi Quantera X-ray Photoelectron Spectroscopy (XPS) 
spectrometer, as well as weight loss. 
 
Debundling of US-tube Nanocapsules 
These purified US-tube nanocapsules must be debundled to maximize the surface area 
allowing for a maximum loading of payload.  Due to strong van der Waals interactions 
between these US-tube nanocapsules, a force of approximately 0.5 eV exists for every 
20 
nanometer of full-length carbon nanotube.
74
  These US-tube nanocapsules will be 
debundled following chemical Birch reduction using sodium metal in tetrahydrofuran 
(THF).
7
  The US-tube nanocapsules are be added to dry, distilled THF with an equal 
mass of Na
0
 at a maximum of 60.0 mg of US-tube nanocapsules.  Following one hour of 
bath sonication, the reaction will be quenched by the addition of deionized (DI) water. 
The US-tube nanocapsules are washed following the same filtration and drying method 
used for the purification.  Debundling of the resulting US-tube nanocapsules is confirmed 
via a Digital Instruments IIIa Nanoscope Atomic Force Microscopy (AFM) instrument. 
Individualized US-tubes, or nanocapsules, should show lengths from 20-80 nm and a 
height ca. 1.2-1.6 nm, as shown in Figure 13. 
 
 
Figure 13. Atomic Force Microscopy data for US-tube nanocapsules. (a) An 
AFM height image of nanocapsules. (b) z-scan resolution height analysis of (a). 
(adapted from 
7
). 
 
This debundling process is very important for the US-tube nanocapsules for in vivo 
applications as they have been shown to safely escape the reticuloendothelial system and 
be excreted through the kidneys and bile ducts in mouse models.
74
  Additionally, US-tube 
21 
nanocapsules display neither fibrinous deposits nor ascite retention within peritoneal 
cavities.  Finally, the US-tube nanocapsules show no acute toxicity in vivo.
74
 
 
THESIS SUMMARY 
This main body of this thesis is subdivided into three primary chapters that revolve 
around the US-tube nanocapsules previously described.  The first of these chapters 
focuses on the magnetic properties that underlie the high-performance efficacy of the 
GNTs (an MRI contrast agent based upon the US-tube nanocapsules).  The second of 
these chapters examines the stability of the Gd
3+
-ion clusters of the GNTs under 
simulated physiological challenges utilizing the radionuclide 
153
Gd.  Additionally, this 
chapter explores the synthesis of GNTs with embedded 
225
Ac
3+
 ions as a new, highly-
potent α-radiotherapy agent.  The final chapter investigates the use 64Cu2+ ions to produce 
the first bimodal MRI/PET imaging agent derived from the GNTs, the 
64
Cuprogadonanotubes (
64
CuGNTs).  
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CHAPTER TWO: MAGNETIC PROPERTIES OF GADONANOTUBES 
 
“Oh no! Not the magnet!!!”  
~ Bender Bending Rodriguez of Futurama 
 
INTRODUCTION 
 
The main purpose of Chapter Two is to examine the magnetic properties of the 
Gadonanotubes (US-tube nanocapsules with internalized Gd
3+
 ions, GNTs, Figure 14): 
 
Figure 14: Pictorial representation of a Gadonanotube. Green spheres represent 
Gd
3+
 ions, drawn roughly to scale (anions omitted for clarity).  
 
An in-depth examination of the magnetic state of both the nanoscale catalyst particles of 
SWNTs and the internalized Gd
3+
 ions of the GNTs using a Magnetic Property 
Measurement System (MPMS) based on a Superconducting Quantum Interference 
Device (SQUID) magnetometer was required.  The GNTs were originally characterized 
as being superparamagnetic, and it was proposed that their high-performance contrast 
agent (CA) capability was related to superparamagnetic Gd
3+
-ion clusters within US-
23 
tubes.
9
  The originally reported GNTs were derived from single-walled carbon nanotubes 
(SWNTs) produced by an electric-arc discharge process.
48
  The studies reported herein 
include US-tubes nanocapsules (as described in Chapter 1) derived from both SWNTs 
produced by the high-pressure carbon monoxide process (HiPCO) and electric-arc 
discharge process (Arc), GNTs from each precursor, and lutetium (Lu
3+
) analogs of the 
GNTs (Lutetonanotubes, or LNTs).  Lu
3+
 ion was selected as it has identical solution 
chemistry to Gd
3+
 solutions, yet is diamagnetic.  Ultimately, the GNTs were determined 
to be a system comprised of two separate magnetic contributions: (1) a diamagnetic 
carbon nanotube sheath with remnant nanoscale metal catalyst particles that are 
superparamagnetic, resulting in a superparamagnetic US-tube nanocapsule and (2) 
paramagnetic Gd
3+
-ion clusters within the nanocapsule. These contributions are displayed 
pictorially in Figure 15: 
 
 
Figure 15. Magnetic contributions to the Gadonanotubes. 
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BACKGROUND INFORMATION 
 
Prior to introducing this chapter’s study on the magnetic properties of US-tube 
nanocapsules, GNTs, and LNTs, this section describes critical background information 
on the fundamental properties of magnetic resonance imaging (MRI), as well as provides 
a description of CAs with similar properties compared to the GNTs and a short synopsis 
of the magnetic properties that will be discussed further throughout the chapter.  
 
Magnetic Resonance Imaging 
First, this section briefly introduces to the physical properties that underlie an MRI 
scanner, as well as clarifies the key distinctions between T1- and T2-weighted images, as 
the GNTs are a unique, simultaneous mixture of both a T1 and a T2 CA. 
 
Introduction to MRI 
Physicians cannot always diagnosis a patient purely by the signs and symptoms the 
patient presents.  Visualization of a patient’s internal structures is often required to 
determine appropriate treatment strategies and follow-up therapies.  MRI has proven to 
be an effective diagnostic tool used by physicians around the world for this visualization.  
MRI evolved from the principles of Nuclear Magnetic Resonance (NMR) and essentially 
images water within the human body, a great target for imaging considering human fat-
free body weight (FFWW) contains 73.2% water.
94
  Clinical MRI scanners use strong 
homogenous magnetic fields to align proton spins found in a patient, perturb these spins 
using specific radio frequency (RF) pulse sequences dependent on the strength of the 
25 
instrument’s magnet, and measure the time it takes the spins to equilibrate, a process 
known as relaxation,
95
 as shown in Figure 16:  
 
 
Figure 16: Fundamental MRI Principles (adapted from 
96
 ). 
 
Mathematical algorithms filter the relaxation data, apply tomographic reconstruction, and 
finally render a grayscale image.  With spatial resolution under 100 μm in preclinical 
systems and 1 mm in human subjects,
97
 MRI has advanced beyond even high-resolution 
computed tomography’s (CT’s) 2-3 mm clinical resolution without the need for Röntgen 
equivalents (rem) of ionizing radiation.  More importantly, MRI has the advantage of 
enhanced contrast resolution, allowing superior soft tissue contrast.  Additionally, MRI 
has a wider diagnostic range of detection than most other medical imaging modalities, 
allowing for both physiological and metabolic studies.
98
  Finally, MRI is effectively a 
multimodal diagnostic within itself.  By viewing a proton spin as a vector comprised of 
26 
both longitudinal and transverse components, MRI has the capability to measure the 
relaxation time of each individual component, T1 and T2 respectively. 
 
MRI Fundamentals 
MRI is based on NMR principles that earned Drs. Felix Block and Edward Mills Purcell 
the Nobel Prize in Physics for 1952.  In short, an external magnetic field (B0) used in 
MRI aligns the wealth of randomly-oriented nuclear spin of water protons in human body 
in a process known as excitation that ultimately creates a current in sensitive detector 
coils.
96
  This excitation results in a Boltzmann distribution of low-energy spins parallel to 
the field and high-energy spins anti-parallel to the field.
99
  The low-energy state 
dominates, and the summation of the individual nuclear spins results in a net 
magnetization vector (NMV).  This NMV precess around B0 at a frequency known as the 
Larmor frequency (ω), given by the expression: 
ω = γB0 
where γ is the gyromagnetic ratio specific for hydrogen (please note, γ will also be used 
to describe γ radiation in Chapters 3 and 4).  
 
An external radiofrequency (RF) pulse equal to ω (known as the resonant frequency) is 
applied in a direction perpendicular to the B0 and causes the NMV to goes from being 
aligned with B0 to the being perpendicular to B0.  The process by which these nuclear 
spins return to the Boltzman distribution prior to perturbment by the RF pulse is known 
as relaxation.  This process is subdivided into spin-lattice (T1) and spin-spin (T2) 
relaxation. T1 relaxation is a process by which the NMV returns to alignment with B0 by 
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releasing the energy obtained from the RF pulse to the surrounding lattice.  The time 
required for this relaxation to occur (T1) is dependent upon the mobility of the 
surrounding lattice (lattices of higher mobility cause a longer T1).  Fluids have the longest 
T1, followed by water-based tissue, fat-based tissue, and finally solids, respectively.  In a 
1.5 T clinical MRI scanner, subcutaneous fat will have a T1 of approximately 343 ms, 
nearly four times faster than the more mobile tissue of the uterus with a T1 of 
approximately 1,309 ms.
100
  
 
While T1 relaxation focuses on the return to status quo, T2 relaxation concentrates on the 
process of decoherence of the nuclear spins that compose the NMV.  Immediately 
following the RF pulse, the nuclear spins have instantaneous phase coherence, yet local 
interactions with neighboring nuclear spins (hence ‘spin-spin’) and fluctuations in the 
local magnetic field cause the nuclear spins to gradually dephase.  The time required for 
this perpendicular magnetization to relax is denoted as T2.  Since every tissue in the body 
has its own T1 and T2, radiologists can choose specific instrument parameters that will 
create resultant MRI scans which depend predominantly on only one of the two 
relaxation times; T1–weighted images cause areas of short T1 to appear bright, while T2–
weighted images cause areas of short T2 to appear dark.  T2–weighted images are often 
used for physiological studies such as fluids (blood plasma, cerebrospinal fluid, etc) since 
the fluid will appear hyperintense compared to surrounding tissues.  The application of 
the physics of NMR to biomedical imaging has been so important to the field of 
medicine, that Drs. Paul C. Lauterbur and Peter Mansfield were jointly awarded a Nobel 
Prize, the 2003 Nobel Prize in Medicine, for their work with MRI. 
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MRI Contrast Agents 
Next, a brief introduction of both T1 and T2 MRI CAs, the units of comparison of MRI 
CA efficacy known as relaxivity, Gd
3+
-ion-based CAs in current clinical use, and two 
novel Gd
3+
-ion-containing, carbon-based nanostructures: the gadofullerenes and the 
GNTs is presented. 
 
Introduction 
MRI alone can yield insufficient diagnosis when cancerous tissue resembles surrounding 
tissue, such as gliomas,
101
 brain metastasis,
102
 meningiomas,
103,104
 and pituitary tumors.
105
  
For enhanced image contrast, radiologists use passive CAs, such as paramagnetic MnCl2 
and toxic Gd
3+ 
ion safely chelated or encapsulated within bio-inert molecules,
95,106-108
 as 
well as superparamagnetic CAs like small particles of iron oxide (SPIO).
109
  Of the 27.5 
million MRI procedures performed annually in the United States, 43% used a CA as part 
of the imaging procedure.
110
  CAs in conventional radiography provide a direct effect; for 
example, radiocontrast agents used in computed tomography will directly scatter photons 
due to their high electron density.  The CAs used for MRI, however, provide indirect 
contrast by altering the T1 and T2 of nuclei in close proximity.
111
 
 
Paramagnetic CAs, or CAs that only display magnetic properties when a magnetic field is 
introduced, cause a decrease in both the T1 and the T2 of surrounding protons.  This results 
in a whiter spot on longitudinal MRI scans (T1-weighted scans) and a darkening on 
transverse scans (T2-weighted scans).  Conversely, ferromagnetic materials, or magnetic 
materials that retain magnetic polarization after the magnetic field is removed, will cause 
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a “dramatic decrease” in T2 values, yet have little effect on T1 values.
112
  Finally, a special 
magnetic state occurs when ferromagnetic materials exist as isolated, single domain 
nanoparticles.  While still retaining ‘magnetic memory,’ these materials can actually 
misalign with the magnetic field due to thermal fluctuations, causing them to behave like 
paramagnetic materials.  This special state is known as superparamagnetism and, like 
ferromagnetism, can cause a significant decrease in T2 values while having little effect on 
T1 values.  Generally physicians prefer T1 CAs, as it easier to distinguish features in a 
brightened image versus a darkened image. 
 
Unpaired electrons have magnetic dipoles 650 times larger than those of unpaired protons 
(hydrogen nuclei), so ionic transition metals with a large number of unpaired electrons 
are the most obvious candidates for MRI contrast enhancement.  Of all T1 CAs, chelated 
Gd
3+
-ion compounds are by far the most-widely used in clinical practice due to the 
gadolinium ion’s seven unpaired electrons, making it the most paramagnetic, stable metal 
ion known (Table 1).  Additionally, this helps contribute to the large intrinsic magnetic 
moment of the Gd
3+ 
ion and long electron spin-relaxation time (the time electron spins 
will jointly stay aligned with the magnetic field).  
 
The problem that originally arose, however, with using Gd
3+
 ion as a CA is its toxicity:  
“These metals are moderately to highly toxic. The symptoms of toxicity of 
the rare earth elements include writhing, ataxia, labored respiration, 
walking on the toes with arched back and sedation. The rare earth 
elements exhibit low toxicity by ingestion exposure. However, the 
intraperitoneal route is highly toxic while the subcutaneous route is poison 
to moderately toxic.” ~ Gadolinium Nitride (GdN) MSDS 
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For this reason, chemical chelating agents were designed to sequester the toxic 
Gd
3+
 ions (discussed in greater detail in Chapter 3). 
 
Table 1: Electronic configuration and corresponding magnetic moment data for 
selected paramagnetic ions  (adapted from
95
). 
 
 
Relaxivity 
To compare the concentration-dependent efficacies of CAs, a standard known as 
“relaxivity” (units: mM-1s-1) is used, with typical values around 4 mM-1s-1 for 
commercially available CAs at 37 
o
C (physiological temperature) and 1.5 Tesla field 
strength (standard for many clinical MRI instruments).
113
  A relaxivity value, r, is derived 
from the following relationship: 
 
              
 = 
 
             
 + ri [M
n+
], i = 1, 2 
where [M
n+
] corresponds to the molar concentration of metal ion (mmol/L).
114
 Relaxivity 
is also dependent on the magnetic field strength and temperature, so most calculations of 
r1,2 values are reported holding these parameters constant at 1.5 T and 37 °C, 
respectively.  Higher relaxivity values for a CA increases the relative contrast offered per 
unit of CA, thus lowering the dose required for imaging.  A lower dose, in turn, increases 
patient safety.  Moreover, CAs with much improved r1,2 values are required for cellular 
31 
and molecular imaging applications.
115,116
 
 
MRI CAs on the nanoscale have a twofold advantage:  (1) nanoscale materials have a 
large surface-area-to-volume ratio and (2) nanoscale materials are small enough to cross 
cell membranes to allow for an accumulation of a CA within cells.  Firstly, since 
relaxation enhancement occurs at the surface of MRI CAs, having a larger surface area to 
volume ratio equates to potentially higher-performance.  Higher performance CAs can 
conceivably decrease  dose (and, hence, toxicity risks) and costs.
117
  Moreover, cell 
internalization of MRI CAs can allow for imaging of intracellular processes and for 
magnetic cell labeling, important roles for both in vitro cell separation and in vivo cell 
tracking studies.
118
  
 
The highest recorded relaxivity at clinical field strength (1.5 T) and a temperature of 40 
o
C is found with the GNTs at a value of 170 mM
-1
s
-1
.
9
  By this measure, the GNTs 
dramatically outperform current Gd
3+
-ion-based clinical agents at 4.3 mM
-1
s
-1
 for 
Magnevist and 3.6 mM
-1
s
-1
 for Prohance under similar conditions.
108
  The difference in 
T1- weighted contrast that occurs between Gd-DTPA (Magnevist) and the GNTs can be 
seen in Figure 17.  These record values are likely caused, in part, by the fast flow rate of 
water through a carbon nanotube.
119
  The US-tube nanocapsules have proven an effective 
T2 agent as well.
120
  The combination of Gd
3+
 ions and superparamagnetic clustering, 
therefore, develops the GNTs into a CA capable of enhancing both T1- and T2-weighted 
images.
121
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Figure 17. T1-weighted MRI phantoms of (A) DI water, (B) Gd-DTPA 
(Magnevist™) and (C) the GNTs obtained using a 1.5 T Philips MR imager. 
[Gd
3+
] = 0.04 mM for B and C (adapted from 
122
). 
 
Relaxation can arise between a CA to surrounding water molecules through two primary 
mechanisms: (A) an inner-sphere mechanism where water molecules bond directly to the 
metal ion causing a direct proton relaxation or (B) an outer-sphere mechanism where the 
random translation diffusion of water protons surrounding the CA, though not directly 
bound to the metal ion, cause indirect proton relaxation.  
 
Gadolinium 
Gd
3+
 ion is the most common metal ion used for MRI CA design, because it contains the 
greatest number of unpaired f electrons (seven) and the electrons are distributed 
symmetrically about the atom.
114
  This distribution results in a symmetrical electronic 
ground state and a favorably long electron-spin relaxation time. Moreover, the magnetic 
moment (μ) of the Gd3+ ion is: 
μ2 = 63μB
2 
 
where μB is the Bohr magneton (a solitary electron magnetic dipole moment).
114
  For 
these reasons, the Gd
3+
 ion provides appreciable relaxivity; however, the aquated Gd
3+ 
ion is extremely toxic (see “Gadolinium Toxicity” in Chapter 3 for more information). 
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Because of this toxicity, Gd
3+
 ion requires chelation or encapsulation to sequester its 
toxicity for in vivo use, with encapsulation usually being a preferred method as it 
completely prevents dissociation of the metal ion in vivo.  
 
Chelated Gd
3+
 ions traditionally decrease the relaxation times of surrounding water 
protons through a combination of both inner- and outer-sphere mechanisms.
123
  Inner-
sphere proton relaxation mechanisms involve bonding of water molecules to the Gd
3+
 
ion. No direct binding of water to Gd
3+
 ion is needed for an outer-sphere relaxation 
mechanism.  
 
Gadofullerenes (GFs) 
Leading to the discovery of the GNTs was another potential MRI CA based on 
carbonaceous nanomaterials, endohedral gadofullerenes (Gd
3+
-ion-containing fullerene 
cages, or GFs).
1
  Note: for the remainder of this thesis, the @ symbol will represent 
“within;” therefore Gd@C60 would represent a Gd atom within a fullerene molecule. 
Only a week after C60’s discovery, the same laboratory determined that a single 
lanthanide ion could be trapped within the fullerene’s hollow interior.24  GFs are 
synthesized by soaking carbon rods in Gd
3+
-ion salt solutions prior to carbon-arc 
ablation.  The Gd atoms donate three electrons to the electronegative carbon cage to 
become trivalent (Gd
3+
) ions, resulting in electron spin density on the fullerene surface.  
 
The encapsulated Gd
3+
 ion in GFs can only act through an outer-sphere mechanism as the 
carbon cage prevents any direct bonding of the Gd
3+
 ion with surrounding water 
34 
molecules.  Despite lacking an inner-sphere mechanism, water-solubilized GFs 
(Gd@C60[C(COOH)2]10 and Gd@C60(OH)x) have proven to be significantly more 
efficacious than current clinically-approved CAs (relaxivity values approaching 20 fold 
greater).
124
  The paramagnetic carbon cage of a water-soluble GF molecule causes 
simultaneous relaxation of many water molecules on its surface resulting in the largest 
outer-sphere relaxation process of any known Gd
3+
-ion-based CA, likely owed to the 
large, paramagnetic surface area-to-volume ratio.
125
  
 
Nuclear Magnetic Relaxation Dispersion (NMRD) measurements are valuable for 
determining relaxation mechanisms and dynamic processes influencing MRI CA 
relaxivity.  The classical Solomon, Bloembergen and Morgan (SBM) theory of proton 
relaxation only fits the GF CA NMRD profile when treating the GFs as slow tumbling 
molecules in solution.
123,126
  Water-solubilized GFs exhibit a rotational tumbling time in 
nanoseconds (1.2 ns).  The NMRD profile of GFs at different temperatures has shown 
that the molecular tumbling rate is most likely the relaxivity-limiting step.
125
  Relaxivity 
of the GFs is also influenced by pH, with a decreasing pH causing an increase in 
relaxivity.  Theoretically, a decrease in pH causes an increase in the aggregate size; an 
increase in aggregate size slows the tumbling time.
125
  
 
Relaxivity of the GFs is also affected by salt concentration.
123
  High salt concentration 
breaks up GF aggregates, which results in faster tumbling times.  This disaggregation is 
dependent not only on the ionic strength of the solution, but also on salts with hydrogen 
bonding capacity such as phosphate.  
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GFs have been effectively used for magnetically labeling of cells.  Specifically, anionic 
Gd@C60[C(COOH)2]10 reduced the T1 of labeled mesenchymal stem cells (MSC) and 
NIH3T3 cells to allow for distinct differentiation between labeled and unlabeled cells.
127
  
Additionally, a special class of GFs known as Hydrochalarones, a surface-modified 
Gd3N@C80 containing three Gd
3+
 ions bound to a central nitride ion,
128-130
 have 
demonstrated in vivo tolerance and provided excellent MRI enhancement.
131
  
 
Although GFs seem attractive agents for contrast enhancement in MRI, difficulties with 
synthesis such as poor yields and complicated steps of purification have not yet been 
successfully overcome, making gadofullerenes unlikely candidates for widespread 
clinical use in the near future. 
 
Gadonanotubes (GNTs) 
The fluorination/pyrolysis cutting process used prepare US-tube nanocapsules results in 
defect sites in the sidewalls of the US-tubes that can allow internalization of both small 
molecules and ions.
9-11
  Gd
3+
 ions are internalized within US-tube nanocapsules as 
clusters of less than ten Gd
3+
 ions as confirmed by TEM.
9
  The darkly-contrasted areas in 
the TEM were analyzed using energy dispersive X-ray spectroscopy (EDS) and shown to 
be electron-rich Gd
3+
-ion clusters. These Gd
3+
-ion doped US-tube nanocapsules are 
denoted as gadonanotubes (GNTs, Figures 14 and 15).  Both the US-tube nanocapsules 
and the subsequent GNTs have been shown to be superparamagnetic from 
superconducting quantum interference device (SQUID) measurements.
9,121
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Relaxometry studies reveal that GNTs have efficacies 40 times larger than any current 
clinically-approved MRI CA.
9,122
  The r1 values of GNTs have been reported as high as 
174 mM
-1
 s
-1
 per Gd
3+
 ion at 60 MHz and 37 
o
C.  For comparison: the relaxivity values 
for GFs  range between 20 - 100 mM
-1
 s
-1
 and commercially-available Magnevist
TM 
(Gd-
DTPA) is ca. 4 mM
-1
 s
-1
 under the same conditions.
9
  Furthermore, the GNTs produce an 
MR signal intensity about 200 times greater than Magnevist
TM
 for the same Gd
3+
-ion 
concentration in T1-weighted MRI images (Figure 16).  Finally, the GNTs show a 
remarkable dependence on pH and exhibit exceedingly high relaxivities at 
physiologically-relevant pH.  GNT relaxivity values nearly double from pH 7.4 to 7.0 (65 
mM
–1
s
–1
 to 105 mM
–1
s
–1
) and nearly triple from pH 7.4 to 6.7.
132
  This pH-sensitivity 
could potentially detect small, metastasized cancerous lesions, as tumors have a lower pH 
(≤ 0.5 pH units) in their immediate vicinity compared to normal tissue.133 
 
In an attempt to understand the mechanisms involved in proton relaxation occurring for 
GNTs, an NMRD study was performed.
134
  The shape of the resulting NMRD plot, 
however, is unlike that of any other reported CA.  The SBM theory of paramagnetic 
relaxation used to explain the GFs has not proven successful at modeling the GNTs.  This 
is likely due to nanoscale confinement of the naked/aquated Gd
3+
-ion clusters within the 
GNTs complimented by the ballistic flow of water in-and-out of the sidewall defects and 
through the Gd
3+
-ion clusters.
135
  Another Nanotechnology effect occurs because of the 
nanoscale catalyst particles within the US-tube nanocapsules which renders excellent T2-
weighted MRI CAs (with or without Gd
3+
 ions!).
121
  Theoretically, the T1-enhancing 
Gd
3+
-ion clusters combined with the external, T2-enhancing US-tube nanocapsule creates 
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an MRI CA capable of dual-weighted MR imaging enhancement. 
 
Moreover, the unparalleled relaxivity values for the GNTs at both current clinical and 
lower field strengths make the GNTs attractive materials for a universal MRI CA. The 
GNTs show fairly constant relaxivities at various high-field strengths, which may provide 
a major advantage for GNTs as higher-field MRI continues to gain popularity in clinical 
settings.
136
  Additionally, the GNTs exceptionally good performance at very low field-
strengths, as required for microtesla imaging, may help overcome the poor signal-to-
noise ratio characteristic of low-field imaging.
137,138
 
 
The exterior carbon surface of the US-tube nanocapsules can further be functionalized for 
water solubility and biocompatibility.
10,139
  Various moieties (water-solubilizing agents, 
biocompatible coverings, antibodies, peptides, etc.) can be attached to the external 
surface of the US-tube nanocapsules for active targeting of specific cell types.  For 
example, cyclic RGD, a peptide sequence noted for selective binding to metastatic cancer 
cells,
140
 has been covalently attached to GNT sidewalls.
141
  Similar to lipophilic, water-
soluble GFs,
127
 water-soluble GNTs (specifically, GNTs covalently functionalized with 
DL-serine) readily cross cell membranes and accumulate inside cells.
142
  This 
accumulation allows for the possibility of both molecular MR imaging and magnetic cell 
labeling for in vivo cellular trafficking.  
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Magnetism 
This section introduces the properties of magnetism; specifically, the units and methods 
of measurement, the types of magnetism commonly encountered, including 
diamagnetism, paramagnetism, ordered magnetism, and a special type of magnetism, 
superparamagnetism, that arises from nanoscale magnetic domains. 
 
Units 
A short note on the units used in Chapter 2: while the rest of this thesis will use Système 
international (SI) units, this chapter uses Gaussian centimeter, gram, second (CGS) units 
to describe magnetism (Table 2).
143
  
 
Table 2. Magnetic terms, units, and conversion factors.
143
  
Term Symbol SI Unit CGS Unit Conversion Factor 
Magnetic induction B Tesla (T) Gauss (G) 1 T = 10
4
 G 
Magnetic field H A/m Oersted (Oe) 1 A/m =4π/103 Oe 
Magnetization M A/m emu/cm
3
 1 A/m = 10
-3
 emu/cm
3
 
Permeability of 
free space 
μ0 H/m dimensionless 4π x 10
-7
 H/m = 1 
 
The reason that CGS units have been selected primarily stems from the values the 
Magnetic Property Measument System (MPMS) reports: CGS units of emu 
(electromagnetic units).  Additionally, the unique relationship between M 
(magnetization), H (magnetic field), and B (magnetic induction): 
B = μ0 (H+M)   [SI] 
B = H + 4πM   [CGS] 
where μ0 is the permeability of free space with a value of  4π x 10
-7
 H/m in SI units and a 
value of unity in CGS units.  For this reason, when using CGS units, B and H values (but 
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not units) can be used interchangeably; this is not true for SI units.
143
  For example: 
0.5 Gauss = 50 μT [B fields]     
0.5 Oe = 39.8 A/m [H fields]  
 
Magnetic Measurements 
A better understanding of the magnetophysics of the GNTs should help understand the 
source of the the amazing relaxivity values the GNTs possess as an MRI CA.  For the 
scope of this thesis, two primary magnetic measurements will be employed on the 
MPMS: (1) magnetization as a function of temperature or M(T) and (2) magnetization as 
function of the applied magnetic field or M(H).
144
  An M(T) measurement is made by 
fixing the value of H; similarly, an M(H) measurement is made by fixing the temperature. 
If the M(H) curve is linear, a useful quantity known as magnetic susceptibility (or the 
measure of magnetization of a material in response to the applied magnetic field, χ) can 
be determined for the material with: 
   
 
 
 
Types of Magnetism 
Though an oversimplification, for the scope of this thesis one can consider three main 
types of magnetism: diamagnetism, paramagnetism, and ordered magnetism.  Diamagnets 
are repelled by a magnetic field, and almost all materials contain some inherent 
diamagnetism resulting from paired electrons.  A negative χ (or a reversible M(H) plot 
with a negative, linear slope) is indicative of a paramagnetic material. Conversely, a 
positive χ (or a reversible M(H) plot with a negative, linear slope) is indicative of a 
paramagnetic material.  While there are numerous other forms of paramagnetism (Curie-
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Weiss, Pauli, Van Vleck, etc.), this thesis will examine simple paramagnetic materials 
that obey the Curie law:  
   
 
 
 
where C is a constant known as the Curie constant.  Using this, plotting inverse 
susceptibility (1/χ) vs T will result with a linear plot of slope 1/C passing through the 
origin (0 K). 
 
The other forms of magnetism include materials that have long-range magnetic ordering, 
specifically ferromagnetism, ferrimagnetism, and antiferromagnetism.  Ferromagnets are 
the strongest magnetic materials and are noted for their lack of magnetic reversibility 
known more commonly as magnetic hysteresis (Figure 18): 
 
Figure 18. Example magnetic hysteresis loop. M(H) at a fixed field below the 
Curie temperature, MS = saturation magnetization, Mrem = remnant 
magnetization, and HC = coercive force. The curve within the loop is known as 
the virgin curve. 
 
Hysteresis loops will form below a ferromagnetic sample’s Curie point (temperature 
where a ferromagnet becomes paramagnetic on heating) due to the ferromagnetic 
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domains attempting to minimize the energy of the system.
145,146
  Starting at the origin in 
Figure 18, as H is increased, the corresponding M increases to a maximum known as the 
saturation magnetization (MS); the curve leading to the MS is known as the virgin curve, 
and is often omitted  as little useful information is rendered aside from showing that the 
measurements started with no remnant magnetization (Mrem).  Mrem refers to the amount 
of magnetization remaining in the material after removing H, and the amount of H in the 
reverse direction required to return the materials net M to zero is known as the coercive 
force/field or HC.  It is also important to note that this magnetic hysteresis will only occur 
for a ferromagnet below a critical temperature known as the Curie temperature, TC. 
Above this temperature, the material will display paramagnetic behavior; below this 
temperature, all of the magnetic moments are aligned in the same direction, as shown in 
Figure 19. 
 
 
Figure 19. Schematic representation of magnetic moments of ordered magnetic 
states. 
  
If, however, the magnetic moments align so adjacent moments are in opposite directions 
(canceling out the net M), the material is known as antiferromagnetic.  Similiarly, if the 
opposite orientation of antiferromagnetism is followed using magnetic moments of 
differing magnitude, the material is said to be ferrimagnetic. 
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Superparamagnetism 
If a ferromagnetic particle becomes small enough, thermal energy can overcome the 
sample domains’ anisotropy energy, first described by Néel in 1949.147  At this point, the 
particles themselves begin to behave like a single domain as the thermal energy 
overcomes the benefits of maintaining domains:  
 
E = KV sin
2θ 
 
where K is the anisotropy energy density, V is the volume of the particle, and θ is the 
angle between the M and the sample domain’s easy axis (magnetic anisotropy creates 
easy and hard directions of M, with a strong preference for alignment with the easy axis). 
Once the value of KV becomes small enough, thermal energy fluctuations can overcome 
E. This will result in spontaneous changes in the magnetization of a sample, which will 
resemble a paramagnet.  The only key difference is that the displayed paramagnetism is 
seen for thousands of atoms making up the sample particle, and not an isolated atom, 
hence the term superparamagnetism. 
 
 
MATERIALS AND METHODS 
 
This section describes the materials and methods used for the synthesis of GNTs and 
LNTs, as well as the instrumentation and data analysis sequences utilized to gather the 
magnetic properties and relaxivity measurements of the resulting materials. 
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GNTs and Lutetium Analogs 
The GNTs (Gd
3+
 is paramagnetic) and their lutetium analogs (the Lutetonanotubes, 
LNTs, note: Lu
3+
 is diamagnetic) were synthesized using the previously published 
protocol for GNTs.
148
  Individualized US-tube nanocapsules (synthesis discussed in detail 
in Chapter 1) were loaded with either Gd
3+ 
ions or Lu
3+
 ions using a simple aqueous 
loading method. Two different precursors were utilized for the study: (a) SWNTs 
produced using the electric-arc discharge technique (Arc) with a Y-Ni alloy as catalyst 
(Carbolex Inc.) and (b) SWNTs produced using the high-pressure carbon monoxide 
method (HiPCO) with Fe as catalyst (Rice University).  The materials as purchased (Raw) 
were further purified from metal catalyst particles through bath sonication in 
concentrated HCl (aq) and liquid bromine treatment under N2 (g) for Arc and HiPCO 
tubes, respectively. 
 
Briefly, 100 mg of US-tubes were added to 100 mL of aqueous 5.0 mM GdCl3 or 5.0 mM 
LuCl3 solution prepared with HPLC-grade water (1 mg of US-tube nanocapsules/mL 
solution, pH = 2.5) and bath sonicated for 60 minutes.  The solution was allowed to settle 
overnight.  The lanthanide-ion-loaded US-tubes flocculated at the bottom and were 
washed with HPLC-grade water (pH = 7.0) over a coarse fritted-glass filter until the 
filtrate showed no detectible levels (< 1 ppb) of lanthanide ion as determined by 
inductively-coupled plasma mass spectrometry (ICP-MS) (experimentally determined to 
be 8 washings of 150 mL of HPLC-grade water).  
 
Samples were removed from the coarse fritted-glass filter via pipette aspiration with 
44 
HPLC-grade water, collected on a watch glass, and dried overnight in an 80 
o
C oven.  
The dried samples were then collected; catalyst and encapsulated lanthanide metal 
percentages were determined using ICP-MS.  
 
Hydroxylated GNTs 
Appendix IV sequences unsuccessful attempts to water-solubilize the GNTs (thus 
preventing the need for a biocompatible surfactant in vivo).  Despite being unsuccessful, 
a new material, a GNT with hydroxyl (-OH) groups functionalized to the US-tube 
nanocapsules’ exterior or hydroxylated GNTs, was developed.  Details about the 
synthetic route for obtaining the hydroxylated GNTs can be found within Appendix IV. 
 
Metal Analysis 
With the exception of the radionuclides of Chapter 4, all metal analysis in this thesis was 
performed on a Perkin-Elmer Optima 4300DV inductively-coupled plasma optical 
emission spectroscopy (ICP-OES) instrument with ppb sensitivity.  For the analysis of 
powder samples of the US-tube nanocapsules, approximately 250.0 μg of material was 
oxidized in boiling 30% chloric acid (HClO3) to completion (the HClO3/US-tube 
nanocapsules mixture would go from black to colorless upon completion).  The digestion 
vessel was washed ten times using 0.5 mL aliquots of 2% HNO3 prepared with HPLC-
grade water, with the resulting solution collected in a 10.00 mL volumetric flask.  Upon 
completion of the washings, the remainder of volumetric flask was filled with 2% HNO3, 
and the entirety was filtered using a 0.22 μm PTFE syringe filter to remove any US-tube 
nanocapsules that were not completely destroyed by the oxidation reaction.  For metal 
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concentrations of surfactant-suspended US-tube nanocapsules samples, the same 
procedure was followed except 250.0 μL of suspended solution was analyzed instead of 
powdered sample. 
 
MPMS Sample Preparation and Measurements 
Eight samples (Raw SWNT, US-tube nanocapsules, LNTs, and GNTs from both Arc and 
HiPCO synthesis) were packaged into diamagnetic low-density polyethylene (LDPE) 
thermoplastic, self-made capsules ca. 1 cm in length.  Sample size ranged from 3-8 mg of 
nanomaterials.  Samples were demagnetized prior to measurement. 
 
Magnetic properties of the samples were characterized with a Quantum Design MPMS-
XL magnetometer based on a liquid-helium cooled superconducting quantum 
interference device (SQUID) with a liquid nitrogen jacket.  Zero-field-cooled–field-
cooled (ZFC-FC) magnetization curves were taken over the temperature range of 5 – 300 
K using a magnetic field of 0.1 T.  For hysteresis curves, samples were subjected to a 
range of applied magnetic fields of –5.0 T ≤ H ≤ 5.0 T at 2 K.  All samples were 
encapsulated in diamagnetic cellulose for measurements and run in duplicate.  
 
Relaxivity Measurements 
All relaxivity measurements were taken with a bench-top SpinTrack Process 1.5 T 
Relaxometer; relaxivity measurements of randomly selected samples were confirmed on 
Bruker Minispec mq 60 at 60 MHz.  Samples were suspended in a 1.7 % Pluronic 
solution (a nonionic triblock copolymer with surfactant properties) via probe tip 
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sonication.  All samples were measured at 37 
o
C using an inversion recovery pulse 
sequence, and relaxivity measurement of a control consisting of HPLC-grade water was 
used for calculations of r1 and r2 values.  
 
RESULTS AND DISCUSSIONS 
 
Metal Analysis 
The weight percentage data for both catalyst particle (Fe and Ni for HiPCO and Arc 
synthesized SWNTs, respectively) and loaded lanthanide are summarized in Table 3. 
Additionally, HC for each sample, as determined from its magnetic hysteresis loop 
measured at 2K (graphically represented in Figure 21), is also represented numerically in 
Table 3. 
 
Table 3. Weight percent (wt%) catalyst and lanthanide as determined by ICP-
OES. Coercivity (HC) was measured at 2K.  
 
Sample 
HiPCO Arc 
wt% Fe wt% La HC (Oe) wt% Ni wt% La Hc (Oe) 
Raw SWNTs 17.15 N/A 250 22.76 N/A 130 
Purified SWNTs 6.08 N/A 200 15.68 N/A 120 
US-tube Nanocapsules 2.32 N/A 140 4.23 N/A 120 
LNTs 2.10 4.96 120 2.94 4.38 110 
GNTs 1.96 4.87 10 2.70 4.29 10 
 
Magnetism 
Figure 20 presents the temperature dependence of both zero-field-cooled (ZFC) and 
field-cooled (FC) measurements for HiPCO (left) and Arc (right) synthesized SWNTs in a 
100 Oe applied magnetic field.  Both the raw SWNTs (top) and US-tubes (upper-center) 
are consistent with superparamagnetism in that the ZFC curves are characterized by a 
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mean blocking temperature (TB): 
TB = KV / 25kB 
 
above which the material is superparamagnetic and below which magnetic viscosity gives 
rise to a hysteretic magnetization loop and reduced ZFC magnetization (kB is the 
Boltzmann constant).
149
  This cusp is a signature of a superparamagnetic state.  Using the 
TB of 40 K and the magnetic anisotropy constant K for bulk Fe3O4, 4 x 10
5
 erg/cm
3
 (the 
majority of residual catalyst in raw HiPCO SWNTs exists as magnetite),
150,151
 the mean 
particle volume V = 3.45 x 10
-19
 cm
3
, or a mean particle radius r = 4.35 nm.  With nine 
known intermetallic nickel-yttrium alloys as possible precursors, mean catalyst radius is 
indeterminable for arc samples; regardless, the data indicate an increase of TB following 
the cutting procedure (35 K before, Figure 20e; 55 K after, Figure 20f), suggesting 
either fluorination or conc. HCl (aq.) purification results in not only a decrease in overall 
catalyst percentage (Table 3), but also in mean catalyst radius.  These samples have a TB 
similar to superparamagnetic small particles of iron oxide (SPIO) that are used currently 
for clinical MRI T2 enhancement (ca. 60 K).
152
  
 
Furthermore, the maximum blocking temperature TB,max,
153
  or the temperature where 
bifurcation between the ZFC and FC curves occurs, decreases with purification from raw 
SWNTs to US-tubes (Figure 20).  As TB,max approaches TB, the net distribution of 
superparamagnetic domain sizes become more uniform; this suggests that the 
purifications remove larger catalyst particles, while smaller particles/domains remain 
protected within the carbon sheath (recall the internal diameter of the HiPCO and Arc 
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SWNTs are ca. 1.0 and 1.4 nm, respectively).  The reproducible magnetic transition at 
approximately 75 K for the Arc-synthesized US-tube nanocapsules, GNTs, and LNTs 
(Figure 20 (right)) needs further investigation.  The raw data for all M(H) and M(T) 
plots can be found in Appendix III.  
49 
  
Figure 20. Magnetization versus temperature for raw SWNTs, US-tubes, 
Lutetonanotubes, and Gadonanotubes from HiPCO (left) and Arc (right) 
synthesis. Magnetization normalized to catalyst wt%. Field strength = 1000 Oe. 
ZFC (black) and FC (white). 
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After loading HiPCO US-tube nanocapsules with diamagnetic Lu
3+
 ions, the resulting 
LNTs (Figure 20c) displayed the same FC/ZFC bifurcation as empty US-tubes (Figure 
20b) with similar magnetization values.  This demonstrates that the superparamagnetic 
US-tube nanocapsule is essentially unaffected by internal loading with a diamagnetic 
material; however, after loading US-tube nanocapsules with Gd
3+
 ions, the GNTs’ FC 
and ZFC curves show no divergence (Figure 20d), demonstrating that the Gd
3+
-ion 
clusters alter the magnetic state of the US-tube material.  
 
To better examine the effects of these Gd
3+
-ion clusters, it was important to first remove 
the magnetic effects occurring due to superparamagnetic US-tube nanocapsules.  
Important to note is paramagnetic susceptibility is inversely proportional to temperature, 
allowing paramagnetic effects to dominate at very low temperatures where most 
superparamagnetic materials are blocked and have low susceptibility.
154
  Subtracting the 
M(T) plot for the US-tube nanocapsules (normalized to catalyst mass) from the M(T) plot 
for the GNTs (also normalized to catalyst mass) rendered an M(T) plot for the GNTs that 
excluded the effects of the US-tube capsule.  Then, by normalizing the sample to moles 
of Gd
3+
 ions present in the sample, a more accurate M(T) plot for just the effects of the 
Gd
3+
 ions was produced (Figure 21 (left)). 
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Figure 21. Magnetization versus temperature for Gadonanotubes from HiPCO  
synthesis. Left: Magnetization of US-tube nanocapsules subtracted from the 
magnetization of GNTs normalized to molar content Gd
3+
 ion. Right: Inverse 
molar susceptibility with linear fit over 5 < T < 75. Field strength = 1000 Oe.  
 
It is important to note that at about 75 K, the difference between the M(T) plot of the US-
tube nanocapsules and the M(T) plot of the GNTs was nearly negligible, likely 
suggesting that the magnetic properties of the GNTs are dominated by the US-tube 
capsule beyond that temperature.  By dividing the molar Gd
3+
-ion M(T) plot (Figure 21 
left) by H (1000 Oe), the plot became a plot of molar magnetic susceptibility; the inverse 
of that plot is shown in Figure 21 right for the non-negligible data points from 5 K to 75 
K.  A linear regression resulted in an excellent fit (R
2
 = 0.9958) that almost perfectly 
intercepts the origin (x-intercept value of -0.309 K).  The slope of this regression fit (and 
hence, 1/Cm) was 0.1315, which corresponds to a peff  (or effective magnetic moment) of 
7.78 μB according to: 
          √   
 
where Cm = is the molar Curie constant with units of emu-K/mol.
144
  This is only slightly 
smaller (ca. 2 %) than the theoretical magnetic moment of free Gd
3+
 ion, S= 7/2, of 7.94 
μB.
155
  Moreover, previous experimental results have shown that the Gd
3+
 ion of 
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hydroxylated GFs to be 7.7 ± 0.1 μB and of Gd-DTPA (Magnevist®) to be 7.9 ± 0.3 
μB.
156
  This paramagnetic character for Gd
3+
 ions is not only characteristic of MRI CAs, 
but of Gd@C82 GFs as well.
157
 
 
 
Figure 22. Magnetization versus applied magnetic field (T) for raw SWNTs 
(white), US-tubes (black), and Gadonanotubes (grey) from both HiPCO (left) and 
arc (right) synthesis. Measurements taken at 2K after cooling in zero field. 1 T = 
1000 Oe. 
 
For further examination of the effect of the Gd
3+
-ion clusters, normalized magnetization 
versus applied magnetic field data were collected at 2K (Figure 22; note: these figures 
utilize Tesla instead of Oersted to keep the number of digits on the graph reduced).  For 
the raw SWNTs, the samples rapidly reach magnetic saturation with some coercivity, HC 
(Table 3).  Upon purification and cutting, both steps removing additional metal catalyst 
impurities, the saturated magnetization logically decreases with decreasing metal 
fraction; similarly, the HC of the sample decreases with the removal of catalyst.  Finally, 
upon loading with Gd
3+
 ions, the hysteresis curve for GNTs becomes more hyperbolic 
and looses the sharp saturation displayed for both raw SWNTs and US-tube 
nanocapsules.  This, coupled with an HC consistent for no hysteresis within instrument 
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error, further suggests that the nanoscale Gd
3+
-ion clusters (less than ten Gd
3+
-ions with a 
cluster size of [1 nm x 2-5 nm]) of the GNTs are paramagnetic.  
 
Relaxivity Measurements 
Our laboratories have recently shown that the US-tube nanocapsules perform as excellent 
T2-weighted CAs.
120
  As the GNTs have already been determined to be an excellent T1-
weighted CA,
9
 a quick examination of the T2 relaxation effects of the GNTs was 
performed.  In short, a T2 relaxation time of ca. 80 ms was obtained for both Arc and 
HiPCO GNTs suspended in a 1.7 % pluronic solution at 37 
o
C. Using a Gd
3+
-ion 
concentration as determined by ICP-OES (Table 3), the superparamagnetic GNTs 
possess an r2 of 230 mM
-1
s
-1
 per Gd
3+
 ion. From this r2 value and an r1 value of ~180 
mM
-1
s-1 per Gd
3+
 ion,
9
 the GNTs have an r2/r1 ratio of 1.28. Traditionally, when r2/r1 < 
2.0, the CA is said to be a positive CA, whereas r2/r1 > 2.0 is indicative of negative 
CAs;
158
  however, a recent CA design with nanoscaled, Gd
3+
-ion centers and an r2/r1 ratio 
of 1.6 (a traditional positive CA) has proven to be both a positive and negative CA.
159
  
Likewise, with an r2/r1 ratio of 1.28, the GNTs are a traditional, positive CA, but one 
which also exhibits high-performance negative contrast depending on the MR sequence 
employed. 
 
Hydroxylation Study 
Further probing of the GNTs relaxivity properties occurred on the hydroxylated GNTs 
(Gadonanotubols) described in Appendix IV.  The average relaxivity values for the 
GNTs jumped an impressive 25 % following hydroxylation, suggesting that as much as 
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one fourth of the relaxation effects of GNTs are being transferred through the carbon 
side-walls of the nanocapsules and not direct contact of water protons with the 
paramagnetic gadolinium clusters, as shown in Figure 23.  These results will help define 
the GNTs incredible relaxation when considering the large surface area of the 
nanocapsules compared to the clusters of only a few ions (6-10 Gd
3+
 ions per cluster).  
 
 
Figure 23. Effects of hydroxylation on GNT relaxivity values.  
 
The GNTs’ relaxivity is highly pH sensitive, a feature that could be potentially be 
employed to allow for diagnostic molecular imaging of cancerous cells, as their external 
pH values can get as low as 6.3 compared to a healthy physiological pH value of 7.4.
132
  
The expected pH of a cancerous cell would be around pH 7.0, slightly more acidic than 
healthy tissue due to the cancerous cell’s increased necessity for glycolysis to maintain 
tumor growth, which results in a higher production of lactic acid.  Over this pH range, the 
GNTs display strong differences in relaxivity measurements (the slope of the change 
between pH 7.4 and 7.0 is 98 mM
-1
 s
-1
/unit of pH) which makes the GNTs one of the 
most dramatic pH-responsive agent in the literature.  To ensure this sensitivity remained 
intact, the pH sensitivity of GNTs was compared to the Gadononatubols, with 
representative data being shown in Figure 24.  These measurements were performed on 
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all samples tested for relaxivity measurements (n = 5), and it was noted that the rate of 
efficacy increase from pH 7.0 to pH 6.0 for the Gadonanotubols compared to the GNTs 
was approximately 12%.   
 
Figure 24. pH sensitivity of GNTs compared to the Gadonanotubols. 
 
CONCLUSIONS 
 
The results of these studies suggest that the GNT is comprised of two magnetic 
components (Figure 15): (1) nanoscale, superparamagnetic catalyst particles inherent of 
the US-tube capsules that enhance T2-weighted imaging and (2) nanoscale, paramagnetic 
Gd
3+
-ion clusters that enhance T1-weighted imaging. Monte Carlo simulations have 
suggested that SWNT materials, like the GNTs, cause a ballistic diffusion of water 
molecules through their hollow interior,
135
 which would effectively allow more water 
molecules to interact with the magnetic field of the internalized Gd
3+
-ion clusters, 
increasing their effective volume.  This ballistic diffusion of water through paramagnetic 
Gd
3+
-ion clusters probably underlies the high r1 values, while the remnant 
superparamagnetic catalyst particles from the synthesis of US-tube nanocapsules 
56 
reasonably accounts for the large r2 values. The hydroxylation studies suggest that the 
Gadonanotubols: (a) can increase relaxivity of the GNTs by 25%, (b) retain the pH 
sensitivity of the unfunctionalized GNTs, and (c) hold increased ability to offer pH-
basesd cellular differentiation between a pH range of 6.0 and 7.0 pH units. Together, 
these cooperative properties render a uniquely powerful, yet versatile, bimodal MRI CA. 
The subsequent chapters of this thesis will explore the stability and range of ions that can 
form clusters internalized within US-tube nanocapsules. 
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CHAPTER THREE: RADIOACTIVE LANTHANIDES & ACTINIDES 
WITHIN US-TUBES
 
 
“True stability results when presumed order and presumed disorder are balanced. A 
truly stable system expects the unexpected, is prepared to be disrupted, waits to be 
transformed.” 
~ Tom Robbins, American Novelist 
 
INTRODUCTION 
While the previous chapter explored the magnetic properties underlying the Gd
3+
-ion 
clusters of the GNTs, this chapter transitions into examining the stability of those 
clusters, as well as the stability of actinides doped within GNTs, under simulated in vivo 
conditions that the GNTs will encounter in the future.  Specifically, Chapter Three is 
divided into two main parts.  The first part of this chapter examines the stability of the 
US-tubes for the retention of Gd
3+ 
ions within the GNTs by using the γ-emitting 
radioinuclide 
153
Gd (Figure 25, left).  Previous physiological challenges of the GNTs 
have shown no leaking of Gd
3+
 ions from the GNTs to the limit of detection for ICP-OES 
(as described in Chapter Two).  While promising and at an impressive 1 ppb sensitivity, 
the ICP-OES can only confirm 99% retention of the Gd
3+
 ions by mass. The present 
chapter confirms that the other 1% of Gd
3+
-ion clusters is stable to physiological 
conditions as well.  Additionally, a closer examination of the Gd
3+
-ion-loading process 
for the US-tube nanocapsules is also explored.  The second part of the chapter examines 
the ability of US-tube nanocapsules to encapsulate the potent α-particle (4He2+) generator 
225
Ac
3+
 ion (Figure 25, right). 
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Figure 25: Pictorial representation of a Gadonanotube (left) and actinium-doped 
Gadonanotube (right). Green spheres represent Gd
3+
 ions, drawn roughly to scale. 
Green sphere with radioactive sign represents 
153Gd
3+
 ion, red curved line 
represents emitted gamma radiation, yellow sphere with radioactive sign 
represents 
225
Ac
3+
 ion, and yellow/orange cluster represents an emitted 
alpha particle. 
 
GADOLINIUM ION TOXICITY 
This section aims to stress the importance of ensuring Gd
3+
 ions do not leak after 
internalization within US-tube nanocapsules, since toxicity arising from Gd
3+
 ions can be 
lethal. 
 
In January 2006, Dr. Thomas Grobner, a nephrologist at the General Hospital of Wiener 
Neustadt, published an iconic paper that began a global response to Gd
3+
-ion-based CAs 
entitled: “Gadolinium – a specific trigger for the development of nephrogenic fibrosing 
dermopathy and nephrogenic systemic fibrosis?”160  This publication, classified as an 
“Interesting Case” by the Journal, documents nine (9) patients suffering from end stage 
renal disease who underwent a special technique known as Magnetic Resonance 
Angiography (MRA).  MRA utilizes MRI to image blood vessels, most commonly 
examining arteries for occlusions and/or aneurisms through heavy use of Gd
3+
-ion-based 
CAs. Of the nine (9) patients in the report, five (5) patients developed a dermatopathic 
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disease associated with renal disease known as Nephrogenic Systemic 
Fibrosis/Nephrogenic Fibrosing Dermopathy (NSF/NFD).  NSF/NFD is a newly-
discovered disease, first documented in 1997 and first declared a unique disease in 
2000,
161,162
 which involves painful hardening of the patient’s skin with fibrosis at 
extremities.    
 
In response to the report, the United States Food and Drug Administration (FDA), a 
branch of the US Department of Health and Human Service tasked, in part, with 
protecting public health through the regulation and supervision of biopharmaceuticals, 
issued a Public Health Advisory (PHA) for Gd
3+
-ion-containing CAs in use for clinical 
MRIs on June 8
th, 2006 (less than 6 months after Grobner’s publication).161   The PHA 
noted that “the dose of gadolinium-containing [CA] given to patients undergoing an 
MRA test is often higher (up to three times) than the approved dose for MRI.” 
Furthermore, the PHA specifically noted that none of the then-approved MRI agents 
(Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance; Figure 26) were FDA 
approved for MRA and warned against use of Gd
3+
-ion-containing CAs for “patients with 
advanced kidney failure,” citing 25 cases (5 from Grobner’s publication) of NSF/NFD 
linked to Omniscan® (gadodiamide, Figure 26).  
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Figure 26:  Approved (Europe and/or United States) Gd
3+
-ion-based contrast 
agents for use in MRI (from 
108
). 
 
Gadodiamide is one of the many clinically-approved nine-coordinate chelation 
complexes (ligand occupies eight binding sites at the metal center, while the ninth 
coordination site is occupied by a solvent water molecule).
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  Please note: the focus of 
comparison to Magnevist
TM
 (gadopentetic acid or Gd-DPTA) throughout this thesis stems 
purely from Magnevist’s dominant market share: with over 20 years of clinical 
administration, Gd-DTPA has been used in at least 50% of all contrast-enhanced MRI’s 
in the US, administered over 100 million times worldwide since launch, and represented 
56% of the US market share in 2009.
163
  
 
By December 21
st
, 2006, the FDA had raised the number of NSF/NFD cases from 25 to 
90 for patients with moderate to end-stage kidney disease following a Gd
3+
-ion-CA-
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enhanced MRA.
164
  The FDA also noted that “NSF/NFD has been reported for only three 
(3) of the five (5) gadolinium-based contrast agents,” yet warned against all the potential 
of NSF/NFD for all five (5).
164
  Six months later, the FDA issued a “boxed warning” for 
all five (5) approved agents.
165
 
 
This boxed warning, “one of the more extreme mechanisms that the FDA may invoke for 
calling attention to observed serious adverse reactions,”166 sparked a response from Dr. 
Emanuel Kanal, a co-author of one of the first MR safety textbooks, in the journal 
Radiology.  Within, Dr. Kanal and coauthors list ten (10) itemized reasons for the unjust 
blanket warning of Gd
3+
-ion-based CAs. The most critical to this chapter of the thesis 
states: 
“The dominant theory regarding NSF development and gadolinium 
deposition in tissues of patients with renal disease is related to the 
possibility of transmetallation and release of free gadolinium from the 
chelating agent. The thermodynamic conditional stability constant defines 
the affinity of the various gadolinium-based agents, at physiologic pH, to 
bind the gadolinium ion and prevent its release as toxic free gadolinium. 
Subject to considerations of in vitro versus in vivo comparison, it is 
notable that this constant varies substantially among the FDA-approved 
contrast agents and is lowest for Omniscan and OptiMARK by 100- to 
1000-fold, compared with the values for Magnevist, MultiHance, and 
ProHance.
167
 Omniscan and OptiMARK are also the only contrast agents 
with a substantial amount of excess chelating agent added to the 
commercially distributed preparation (with Omniscan containing less 
excess chelating agent than OptiMARK.
167)”166     
 
This comparison can be seen with the difference in stability constants shown for Gd
3+
 ion 
with the linear chelate DTPA (Magnevist
TM
) and the cyclic chelate DOTA (Dotarem
TM
) 
shown in Figure 27. 
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Figure 27:  Difference in stability constant for trivalent lanthanide ions for the 
chemical chelators DOTA and DTPA (note: scale is logarithmic. Adapted from 
168
). 
 
This stability constant is important when examining in vivo transmetallation of the 
trivalent gadolinium ions with Zn
2+
, Cu
2+
, and Ca
2+
 ions.  Toxicity studies show that the 
smaller stability constants (which correspond to an increase in in vivo transmetallation) 
correlates with an increased median lethal dose (or LD50).
117
 
 
Around the same time as Dr. Kanal’s objection to the FDAs blanketed boxed warning, 
the UK’s equivalent to the FDA, the Medicines and Healthcare products Regulatory 
Agency (MHRA), summarized the Gd
3+
-ion-based CAs and corresponding NSF/NFD in 
a Drug Safety Update that reiterated the importance of thermodynamic chemical stability, 
as shown in Table 4. 
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Table 4:  Properties of Gd
3+
-ion-containing contrast agents and reported cases of 
NSF (from 
169
). 
 
Brand name (generic 
name) 
Chemical 
structure 
Charge 
Elimination 
pathway 
Protein 
binding 
Cases of 
NSF 
Omniscan 
(gadodiamide) 
Linear 
Non-
ionic 
Kidney None Yes 
OptiMARK 
(gadoversetamide) 
Linear 
Non-
ionic 
Kidney None Yes 
Magnevist 
(gadopentetate 
dimeglumine) 
Linear Ionic Kidney None Yes 
MultiHance 
(gadobenate 
dimeglumine) 
Linear Ionic 
97% Kidney 
3% Bile 
<5% Yes 
Primovist 
(gadoxetic acid 
disodium salt) 
Linear Ionic 
50% Kidney 
50% Bile 
<15% No 
Vasovist 
(gadofosveset 
trisodium) 
Linear Ionic 
91% Kidney 
9% Bile 
>85% No 
ProHance 
(gadoteridol) 
Cyclic 
Non-
ionic 
Kidney None No 
Gadovist 
(gadobutrol) 
Cyclic 
Non-
ionic 
Kidney None No 
Dotarem 
(gadoterate 
meglumine) 
Cyclic Ionic Kidney None No 
 
The MHRA summarized the Gd
3+
-ion-containing contrast agents into three categories 
relating the risk of NSF (which they define as the likelihood of releasing free Gd
3+
 ion 
into the body: 
(1) High Risk: linear chemical structure with excess chelate which carry no 
molecular charge (eg, Omniscan
TM
 and OptiMARK
TM
) 
(2) In Between: linear chemical structure with molecular charge (eg, MagnevistTM, 
MultiHance
TM
, Primovist
TM
, and Vasovist
TM
) 
(3) Low Risk: cyclical structure (eg, ProHanceTM, GadovistTM, and DotaremTM). 169 
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Since the publication of the MHRA’s results, the FDA has limited the warnings for 
Magnevist, Omniscan, and Optimark for patients with kidney disease and has permitted 
approved the US’s first MRA agent, ABLAVAR (generic: gadofosveset), as shown in 
Figure 28: 
 
 
Figure 28:  ABLAVAR® (previously: Vasovist
TM
, generic: gadofosveset) - first 
FDA approved Gd
3+
-ion-based MRA contrast agent (from official drug label). 
 
The chemical modifications to DTPA’s linear backbone (compare Figure 28 to Gd-
DTPA in Figure 26) allow gadofosveset to bind to blood proteins (as shown in Table 4). 
Additionally, since the FDA’s and MHRA’s warnings have been issued, the global 
number of reports of NSF/NFD has decreased steadily per annum.
163   The approval of 
ABLAVAR® and the witnessed decrease in cases suggest that the issues of NSF/NFD 
induced from free Gd
3+
 ion has been properly addressed; however, the importance of 
sequestering Gd
3+
 ions in vivo has clearly been stressed over the past five years. 
 
Knowing this, the GNTs need examination to understand their likelihood of leaking Gd
3+
 
ions under in vivo conditions.  The GNTs have previously been introduced to three (3) in 
vitro challenges designed to best simulate conditions experienced in vivo: phosphate-
65 
buffered saline solution (PBS), bovine serum, and heat.
93
  Using membrane dialysis for 
each of the simulated challenge experiments for 48 hours resulted in no measurable loss 
of Gd
3+
 ion as determined by ICP-OES.  With a Gd
3+
-ion detection limit of ca. 1-2 parts-
per-billion (ppb), these early results demonstrate that the GNTs retained 99% of their 
Gd
3+
-ion concentration upon exposure to the pH, serum, and temperature challenges.  
While ppb accuracy is amazing (as a century is 3.1556926 × 10
9
 seconds, 1 ppb would be 
ca. 3 seconds in a century!), a gamma counter (or γ-ray counter) shows no concentration-
dependence for sensitivity since the instrument measures actual events.  Repeating these 
earlier retention studies with a γ counter and γ-emitting gadolinium radionuclides 
(specifically, 
153
Gd) has the potential to extend the current understanding in vitro 
retention of Gd
3+
 ions in GNTs from 99% to beyond 99.99%. 
 
PART ONE: 
153
Gd EXPERIMENTS 
 
Materials and Methods 
This section explains the synthesis of 
153
GNTs, describes the microcentrifugation devices 
used to wash and challenge the GNTs, explains the simulated physiological challenges 
used to analyze 
153
Gd
3+
-ion retention, and introduces the instrumentation used to quantify 
153
Gd
3+
-ion decay. 
 
Materials 
Debundled US-tube nanocapsules from electric-arc discharge SWNTs with Ni/Y catalyst 
(AP Grade, CarboLex, Inc., Lexington, Kentucky) were prepared as discussed in 
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Chapter 1.  Carrier-free 
153
GdCl3 (half-life: 241.6 days) was purchased from 
PerkinElmer New England Nuclear (Boston, MA, Activity: 1.020286 mCi in 36 µL on 
27NOV09 [28.33 mCi/µL] and 60.88 mCi/mg specific activity).  Carrier-free 
radionuclides (or radionuclides that are free of more stable isotopes of the same element) 
are usually preferred for radiolabeling inorganic drugs, as the percentage of radiolabeling 
will naturally increase when you remove competing isotopes that are chemically-
equivalent.
170
  As will be established for both 
153
Gd
3+
-ions and 
225
Ac
3+
-ions later in this 
Chapter, the unique clustering of lanthanide metal ion within the US-tube nanocapsules 
will require a concentration of radionuclide that carrier-free samples cannot safely 
provide. 
 
Millipore Centrifugal Filters 
Both this chapter and the subsequent chapter, Chapter 4, employ the use of centrifugal 
filters to separate free radionuclide from the US-tube nanocapsules.  Specifically, 
Amicon® Ultra Centrifugal Filter Units (Millipore, Billerica, MA) with a nominal 
molecular weight limit (NMWL) of 100 kDa (the bovine serum albumin protein (BSA) 
has a molecular weight of 66.7 kDa, while the Immunoglobin G antibody (IgG) has a 
molecular weight of 156 kDa, for reference).  These filters feature two key components 
(as shown in Figure 29): (1) a 1.5 mL microcentrifuge tube (commonly known as 
“eppendorfs” due to the major manufacturer: Eppendorf) and (2) a removable filter insert 
with a cellulose (a common hydrophilic, polysaccharide polymer) filter membrane.  
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Figure 29:  Top: Drawings of centrifugal spin devices showing separation of 
free 
153
Gd
3+
-ions from 
153
GNTs. This Eppendorf-based model is used for the 
153
Gd
3+
-ion studies in this section, the 
225
Ac
3+
-ion studies in the second half of 
this chapter, and for the 
64
Cu challenge experiments of Chapter 5. Bottom: 
Photograph of actual centrifugal filter used for the 
153
Gd
3+
-ion studies. 
 
153
Gd Loading Study 
First, a suspension of 10.0 mg of US-tube nanocapsules was created in 10.0 mL acidic 
water (~10 mM HCl) to give an approximate concentration of 1 mg/mL.  From this, 250 
µL of the US-tube suspension was added to a scintillation vial with 125 µL of 10 mM 
GdCl3 solution and 125 µL of 
153
GdCl3.  This mixture was then vortexed to effectively 
mix the samples.  These studies compared a loading technique employing both carrier-
free and carrier-added 
153
GdCl3.  The final mixtures consisted of: 0.25 mg US-tubes 
nanocapsules, 0.33 mg GdCl3, and 111 µCi of radioactivity.  Following a one hour bath 
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sonication, the mixture was incubated for 1 to 12 days.  
The following day, the prepared solution was vortexed again and transferred in full to a 
micropore filter inside a centrifuge tube.  Make a tube containing 0.5 mL water that can 
counter balance with the sample tube for centrifuging in a Hettich Model EBA 20 
Centrifuge.  Following centrifugation at 6,000 RPM for five (5) minutes, the collected 
filtrate was counted via γ-counter.  The filter was then returned to the centrifuge tube, 
washed with another 0.5 mL of DI water, centrifuged, and the filtrate again was checked 
for activity.  This process continued until there was no activity in the filtrate.  Usually, 
this process required 6 to 7 washings.  The final, washed US-tube samples were also 
counted via γ counter, and a final loading % (wt/wt) was calculated from the total counts 
and the amount (from carrier and carrier-added) of GdCl3 used.  
 
Note: a parallel control experiment examined the non-specific binding of 
153
GdCl3/GdCl3 
to the walls of the centrifugal micro filter device. 
 
Gamma Counting 
Initial gamma counting was performed using a 1282 CompuGamma Gamma Counter 
(LKB), shown in Figure 30, top, a universal γ counter capable of counting γ-emitting 
isotopes with energies ranging from 10 to 2000 KeV.  An example spectrum is displayed 
in Figure 30, bottom with the arrow designating the energy range scanned to determine 
153
Gd
3+
-ion concentration.  Subsequent measurements were taken using a Wallac (Perkin-
Elmer) 2470 Wizard
2
 Gamma Counter. 
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Figure 30:   Top: 1282 Compugamma CS Universal Gamma Counter. Bottom: 
Representative spectra for 
153
Gd on gamma counter. 
 
Human Plasma Stability Studies 
Centrifugal microfiltration devices were employed to separate human plasma (Sigma) 
from GNTs.  500 μL of human plasma sample was added to each centrifugal 
microfiltration device containing carrier-added 
153
GdCl3-loaded US-tube nanocapsules, 
carrier-free 
153
GdCl3-loaded US-tubes, and the control solution of carrier-added 
153
GdCl3 
(no US-tube nanocapsules).  All filters were centrifuged for 15 minutes following a 2 h 
incubation period.   The filtrate and the microfiltration devices were γ counted, and the 
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percentage of 
153
Gd
3+
-ion released was determined comparing counts in the filter and 
filtrate.   The filtrate was replaced with fresh plasma and in the same microfiltration 
device, incubated for an additional 48 h, and then centrifuged again for 15 minutes. 
Again, the percentage of 
153
Gd
3+
 ion released was determined comparing counts in the 
filter and filtrate. 
 
Results and Discussion 
Loading Studies 
Despite attempts with both carrier-added and carrier-free 
153
GdCl3 for our loading 
studies, all attempts with carrier-free 
153
GdCl3 proved unsuccessful in synthesizing GNTs 
(99.9% of 
153
Gd was removed by the fourth washing).  This is likely owed to the fact that 
with no carrier, 111 µCi correlates to approximately 1.8 µg of Gd
3+
 ion for 250 µg of US-
tube nanocapsules.  Using a rough molecular weight of 72000 g/US-tube nanocapsules 
(estimating 120 C atoms per nm at an average length of 50 nm per US-tube nanocapsule), 
there was a rough molar ratio of 3.3 (3.3 Gd
3+
 ions per US-tube nanocapsule).  As all 
previous TEM imaging suggest Gd
3+
-ion cluster sizes of 6-10 Gd atoms per US-tubes 
(discussed in further detail in Chapter 2), the most-likely reason that the carrier-free 
loading techniques failed is simply due to a lack of concentration to successfully form 
stable Gd
3+
-ion clusters within the US-tube nanocapsules.  Due to the relatively low 
concentration of Gd
3+
 ions present within the GNTs, previous attempts at better 
understand the true chemical nature of these clusters have not proven fruitful.   
 
Gd
3+
-ion complexes have been previously synthesized at low concentrations in aqueous 
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solutions through the formations of hydroxyl bridges;
171
 binuclear gadolinium complexes 
are formed via hydroxyl bridges in most compounds over 0.5 nm in diameter. An 
example of a more complex gadolinium cluster can be seen in the hydroxyl- and oxo-
bridged cation shown in Figure 31 (Note: the cluster shown in Figure 31 is of a Nd
3+
-ion 
cluster that is isomorphous with the Gd
3+
-ion cluster).
172
   
 
 
Figure 31: Oak Ridge Thermal Ellipsoid Plot Program (ORTEP) molecular 
modeling of the [Nd6( 6-O)( 3-OH)8]
8+
 cation cluster. This cluster is 
isomorphous with the [Gd6( 6-O)( 3-OH)8]
8+
 cation cluster (adapted from 
172
). 
 
This cluster is an oxo-centered octahedron that is synthesized in similar conditions to the 
GNTs.  In short, Gd(ClO4)3 is added to an acidic solution of L-serine, and the pH is 
adjusted to above 6.0 by the addition of NaOH (aq).  Recall from Chapter 2 that the 
GNTs are synthesized by placing US-tube nanocapsules in acidic GdCl3 (aq.), and the pH 
is adjusted to above 5.0 following washings with DI water.  As the magnetic studies of 
Chapter 2 suggest that the Gd
3+
 ions within GNTs have isolated magnetic spins, it is 
unlikely that this is the exact cluster one would expect within the GNTs, primarily as the 
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central μ6-oxo ligand would be expected to facilitate magnetic exchange coupling 
interactions between the Gd
3+
 ions (note: magnetic susceptibility measurements for the 
cluster and isomorphs of Figure 31 do not currently exist).
173
  However, having the 
proper number of expected Gd
3+
 ions (the cluster of Figure 31 has 6 lanthanide ions and 
the Gd
3+
-ion clusters within the GNTs contain 6-10 ions) and having formed in similar, 
aqueous environments, the Gd
3+
-ion-based analog of the cluster in Figure 31 is currently 
among the best models for how the Gd
3+
 ions exist within the GNTs.  This large cluster 
further supports the hypothesis that individual Gd
3+
 ions enter the US-tube nanocapsules 
and form clusters that are too large to escape, hence their high stability even under 
physiological challenge.  For a short description on the general properties of gadolinium, 
see Appendix VI. 
 
Moreover, concentrating carrier-free 
153
GdCl3 to mimic cold loading protocols would be 
both cost prohibited and, with a 242 day half-life, generate far too much radioactive 
waste.  This failure to retain ions under a critical concentration will be seen to repeat with 
carrier-free 
225
Ac
3+
-ions later in this chapter. The results of the loading over various 
incubation times are summarized in Table 5.  
Table 5:  Loading percentages (w/w) of 
153
Gd
3+
-ions varying addition of carrier 
ions and incubation time. 
 
153
GdCl3 Used Incubation Period % Retained by US-tube Nanocapsules 
Carrier Free 24 hr 0.24 
Carrier Added 72 hr 10.0 
Carrier Added 288 hr (12 d) 17.6 
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While the result of 17.6 % retention is significantly higher than previously recorded 2.8 
% (w/w) retention of the available Gd
3+
 ions in solution, this value also corresponds to 
roughly the same number of Gd
3+
 ions per US-tube nanocapsules: using the 72000 g/US-
tube nanocapsule of length 50 nm assumption described above, the published 2.84% 
retention of the high concentration GdCl3 loading corresponds to 13.0 Gd
+
 ions per 
nanocapsule, which is roughly the same as the 12.5 Gd
3+
 ions per nanocapsule using the 
same assumptions for the lower concentration 
153
GdCl3 loading.  
 
Plasma Stability 
The results from the plasma stability studies are summarized in Table 6.  In short, these 
studies show that there are two distinct populations of Gd
3+
 ions: (a) one population is 
removable following a 2 hour incubation in human serum and (b) another population is 
unremoved despite a 48 hour serum challenge.  
 
Table 6:  Plasma stability study results. 
 
Sample 
% Counts in filtrate 
(after 2 hr) 
% Counts in filtrate 
(after 48 hr) 
Control 35.8 50.6 
153
GNTs 41.6 35.6 
 
The significance of this data is demonstrated via the 48 hr time-point, with the 
153
GNTs 
retaining a significantly higher percentage (15% more) of initial activity than free 
153
Gd
3+
 
ions in serum. This suggests that some stabilization beyond the standard two hours is 
required when loading with significantly low concentrations of ions.  
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Conclusions 
All of the results of these radiolabeling/loading studies suggest a key conclusion about 
the GNTs: there are a critical minimum number of Gd
3+
 ions required per US-tube 
nanocapsules to produce stable clustering. Synthesizing GNTs with more than the critical 
number per US-tube nanocapsules, however, does render any significant differences in 
the final GNT product. This fact is incredibly useful in attempts to minimize the amounts 
of precursor GdCl3 used for synthesis.  
 
Another important conclusion is that the stability of the GNTs in vitro under conditions 
that would be experienced in vivo (previously established with 99 % certainty) show NO 
leakage of toxic Gd
3+
 ions following 48 hour plasma challenge. This conclusion solidifies 
earlier claims that the GNTs should prove stable under in vivo conditions which should 
encourage future development of the GNTs as viable in vivo MRI CAs.  
 
PART TWO: 
225
Ac EXPERIMENTS 
 
As the first part of this chapter exploited a radionuclide (
153
Gd
3+
 ion) to monitor potential 
leakage of the Gd
3+
 ions from GNTs under physiological conditions, the second part of 
this chapter aims to exploit a significantly more potent radionuclide, the α-particle 
generator 
225
Ac
3+
-ion, for potential use in radiotherapy within US-tube nanocapsules.  
Many of the conclusions and proposed explanations for the Gd
3+
-ion-loading process for 
the US-tube nanocapsules used in the previous part of this chapter will carry over into the 
225
Ac
3+
-ion section. 
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Alpha Radiotherapy 
Following cancer diagnosis, one common treatment approach used by oncologists is 
radiotherapeutics.  As opposed to surgery, which is highly invasive and specific for large 
tumors, radiotherapeutics, similar to traditional chemotherapeutics, offer a noninvasive 
form of cancer treatment.  Unfortunately, also like traditional chemotherapeutics, 
radiotherapeutics are toxic to all cells (both healthy and cancerous/diseased).  The 
ultimate goal of the radiotherapeutics is to impair cellular mitosis via targeting cells that 
divide rapidly. Unfortunately, certain healthy cells in the body also divide rapidly, which 
results in the painful collateral damage of healthy cells that is associated with 
chemotherapy;
174,175
 these include the cells found in bone marrow (which produce red 
blood cells, so this collateral damage results in a decrease in red blood cell production, 
known as myelosuppression) and the cells that line the intestinal tract (which results in 
painful inflammation known as mucostitis).  Perhaps the most visually apparent sign of 
collateral damage is the hair loss (alopecia) associated with chemotherapy due to 
chemotherapeutics attacking the hair follicles.  
 
Unlike chemotherapeutics, however, cancerous cells do not become immune to the 
radiotherapeutics.  So with this drawback to chemotherapeutics alleviated, the other 
primary goal for radioimmunotherapy of cancer (RAIT) is to eliminate unwanted 
collateral damage.
176,177
  One method is to create a targeted drug via attachment of 
moieties (antibodies, peptide sequences, etc.) that will have an affinity for cancerous 
cells.  The US-tube nanocapsules’ graphitic carbon sheath allows for covalent 
functionalization with disease-targeting agents.
7,141,178-181
  This feature renders SWNT-
76 
based materials ideal as delivery platforms for targeted α-particle therapy (TαT), a 
specific branch of RAIT (10, 11).  This part of Chapter 3 specifically examines the 
ability of US-tube nanocapsules to encapsulate the potent, in vivo α-particle (4He2+) 
generator 
225
Ac whose decay sequence is shown in Figure 32. 
 
 
Figure 32: Simplified decay scheme for 
225
Ac. Each arrow represents an α-
particle emission with the average energy to each arrow (adapted from 
182
). 
 
 
α-particle emitters, such as 213Bi, 211At, and 225Ac, possess a significantly higher linear 
energy transfer (LET) (5,000 – 8,000 keV) and shorter range (50–80 μm, or a few cell 
diameters,) than the β-particle (e-) emitters, such as the FDA-approved 90Y and 131I, 
which are currently used in RAIT 
11,176,183
.  For these reasons, α-particle emitters are  
preferred for the specific killing of small volume cancers such as single cells or 
micrometastatic lesions.  Moreover, Monte Carlo simulations suggest that a solitary α-
particle can have an equivalent cytotoxic effect as over a thousand β-particles.184  225Ac’s 
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potency is further enhanced by the yield of 3 daughter α-particle emitting radionuclides 
that are also lethal to targeted cells (Figure 32).   
 
Traditional radiometal-labeling requires the use of chelates, such as DOTA or DTPA, to 
sequester the free radionuclides to the targeting ligand; these ligands have two primary 
drawbacks: (1) traditional chelating agents are only capable of transporting a single 
radiometal and (2) loss of 
225
Ac
3+
 ion from these agents results in poor body clearance 
and accumulation of 
225
Ac
3+
 ion in the liver.
185
  The stability constant for a EDTA-Ac 
complex is only 10
14.2 
(well below the minimum threshold of 10
20 
for safe in vivo use), 
and EDTA, DTPA, and DOTA show similar instability in vivo.
186
 
 
The first drawback causes limitations in accumulating potent 
225
Ac
3+
 ions to targeting 
agents, such as monoclonal antibodies (mAbs), for the delivery of therapeutics to specific 
sites in vivo may decrease the toxicity via minimizing nonspecific tissue damage (the 
aforementioned collateral damage).
177
  For example, EDTA antibody constructs and 
DTPA antibody constructs have been synthesized with 4 chelates per antibody before 
substantial effects occurred in radionuclide stability and biodistribution.
186
  The empty, 
available interior of the US-tube nanocapsules allows for multiple radiometals per 
targeted drug molecule.  As only one Gd
3+
-ion cluster within an US-tube has up to 10 
Gd
3+
 ions on average and each GNT has multiple Gd
3+
-ion clusters on average, US-tube 
nanocapsules internalized with chemically-similar Ac
3+
-ion clusters hold potential to 
concentrate significantly more radioactivity per targeting moiety.  As there is an inherent 
preference for intracellular uptake and retention of radiometals over radiohalides,
187
 and 
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the US-tube nanocapsules are also relatively bio-inert, intracellular agents,
74,142
 the 
successful targeting of a US-tube nanocapsule/
225
Ac
3+
-ion construct could lead to a rapid 
uptake of radiometal within the targeted diseased cells.  Furthermore, Rituximab and 
Lintuzumab antibodies have successfully been attached to the carbon-sidewall exterior of 
SWNTs for in vivo targeting.
6
  The key difference the US-tube nanocapsules provide 
compared to previous targeting of SWNT-based materials with radiolabels is the fact that 
the radionuclide of choice is internalized within the carbon sheath (and in significant 
number) as opposed to being bound to externally-functionalized chelating agents.  
 
The second drawback to traditional chelating agents is one of toxicity.  Specifically, high 
toxicity stems from free 
225
Ac
3+
 ions which deposits in the liver and bone tissue.
185
  
Traditional chelating agents have proven unstable under in vivo conditions, resulting in 
toxic free 
225
Ac
3+
 ion.  For example, the acyclic chelating agent DTPA bound to 
225
Ac
3+
 
ion and an antibody specific for lung cancer (
225
Ac-CHX-DTPA-mAb 201B) results in 
100% mouse mortality 8 days post-injection at only a dose of 185 kBq (5 μCi).188  While 
no chemical agent will likely survive the high energy of the first α-decay in the 225Ac3+-
ion decay sequence (Figure 32), the potential for the US-tube nanocapsules to retain 
225
Ac
3+
 ions similar to the Gd
3+
 ions within the GNTs discussed in the previous part of 
this chapter would prevent the loss of 
225
Ac
3+
 ion experienced by traditional chelating 
agents in vivo.   
 
Herein is reported a novel synthetic pathway for the internalization and stabilization of 
225
Ac
3+
 ions within US-tube nanocapsules (accomplished through the addition of Gd
3+
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ions). 
Materials and Methods 
Materials 
A dried 
225
AcNO3 residue obtained from the Department of Energy (Oak Ridge National 
Laboratory, Oak Ridge, TN) was dissolved in 0.1 ml of 0.2 M HCl (Optima grade, Fisher 
Scientific, Pittsburgh, PA).  
225
Ac activity was measured using a drop well dose calibrator 
(CRC-17 Radioisotope Calibrator, E.R. Squibb and Sons, Inc., Princeton, NJ) set at 775, 
with displayed activity value multiplied by 5.  
 
Individualized US-tube nanocapsules were prepared following previously-established 
synthetic methods (Chapter 1) from full-length SWNTs produced in an electric arc 
discharge with Ni/Y catalyst (AP Grade, CarboLex, Inc., Lexington, Kentucky).
5
  
 
225
Ac@US-tubes  
US-tube nanocapsules were dispersed via bath sonication to a concentration of 5 g/L in 
metal-free water obtained from a Purelab Plus system (United States Filter Corp., Lowell, 
MA).  Three separate aqueous loading techniques were examined: (1) addition of 
225
Ac
3+
 
ions alone, (2) addition of a mixture of Gd
3+
 ions and 
225
Ac
3+
 ions, and (3) sequential 
addition of Gd
3+
 ions followed by 
225
Ac
3+
 ions.  For 
225
Ac
3+
 ions alone, 3.0 μL of 
225
AcCl3 (7.0 MBq) were diluted in 200.0 μL of metal-free water and mixed with 50 μL 
of a US-tube suspension.  For the mixture, 3.0 μL of 225AcCl3 (7.0 MBq) were diluted in 
150.0 μL of metal-free water, mixed with 50 μL of 19 mM GdCl3 (Aldrich Chemical 
Milwaukee, WI, USA) and 50.0 μL of the US-tube suspension.  Finally, for the 
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sequential addition, 150.0 μL of metal-free water was mixed with 50.0 μL of 19 mM 
GdCl3 (previously established method for creation of the GNTs); 12 hours later, 7.0 MBq 
of 
225
AcCl3 was added to the GdCl3/US-tube solution.  Activity was determined using a 
Packard Cobra γ counter (Packard Instrument Company, Inc., Meriden, CT) with a 340-to 
540-KeV window. 
 
All loading techniques underwent bath sonication for two hours and were allowed to 
equilibrate overnight. The following day, all samples were washed with 250.0 μL of 
metal-free water and filtered using a Handee
TM
 Micro-Spin Column (Thermo Scientific 
Pierce) with a paper membrane (pore size ~10 μm) until no activity was detected in the 
filtrate via drop well dose calibrator. Following filtration, all samples were removed from 
the filter with 200.0 μL distilled water by pipette aspiration and measured for activity. All 
loading techniques were performed in triplicate. 
 
Human Serum Challenge Experiments 
To simulate in vivo conditions, challenge experiments were conducted monitoring the 
effect of heat, time, and human serum on the 
225
Ac@US-tube nanocapsules suspensions.  
For each serum challenge, 20.0 μL of the resulting 225Ac@US-tube nanocapsules (12.5 
μg) suspension from the three loading techniques above was added to 180.0 μL of normal 
human AB serum (Sigma Chemical Co., St. Louis, MO).  The mixture was stirred and 
incubated at 37 ºC for two hours.  After incubation, the mixture was filtered using a 
centrifugal filter devices (100xg, 5 min.), and the serum filtrate was counted in 
scintillation fluid using a β counter (samples were allowed to reach equilibrium 
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overnight).  Standards of the 
225
Ac@GNTs (loading technique (2) from above) were 
counted as reference.  For re-challenging the samples, 200.0 μL of serum was again 
added to the filter device, and the mixture was re-suspended and re-incubated at 37 ºC for 
2 hours.  The filtration process was repeated. As a control, 
225
AcCl3 alone in serum was 
spun in the filter device. Samples also were challenged for longer time durations (4 hr 
and 12 hr) and at both room temperature (RT) and 37 ºC to compare the effects of 
temperature and time. 
 
Results and Discussion 
Serial washings via centrifugation filtration resulted in over 95% of the added activity 
remaining with the US-tube nanocapsules.  For both loading techniques involving Gd
3+
 
ions with 
225
Ac
3+
 ions, approximately 50% of the activity remained associated with the 
US-tubes.  All three loading experiments showed no radioactivity in the centrifugal 
filtrate following the third wash, indicating that only 750.0 μL of metal-free water is 
required to separate the 
225
Ac
3+
 ions not bound to the US-tube nanocapsules in 
suspension.  
 
The results of the serum challenge experiments are summarized in Figure 33.  In short, 
there was little difference in 
225
Ac
3+
 ion retention observed between sequential and 
simultaneous loading of 
225
Ac
3+
 and Gd
3+
 ions within the US-tube nanocapsules. 
Moreover, the additional challenges of time (both 4 hr and 12 hr) and elevated 
temperature (37 ºC) on the 
225
Ac@GNTs synthesized via simultaneous loading technique 
did not promote additional losses of 
225
Ac
3+
 ions. 
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Figure 33: Results of human serum challenge experiments. Time/Temp challenge 
experiments performed on 
225
Ac@GNTs synthesized via simultaneous loading. Sim. = 
simultaneous loading, Seq. = sequential loading, and RT = room temperature.  
 
 
Finally, subsequent challenges of the 
225
Ac@GNTs revealed no measurable quantity of 
225
Ac
3+
 ions in the filtrate and ~100% retention of the 
225
Ac
3+
 ions with the 
225
Ac@GNTs 
in the filter.  However, subsequent challenges of the 
225
Ac@US-tubes continued to 
remove 
225
Ac
3+
 ions, until only 5% of 
225
Ac
3+
-ion activity remained bound to the US-tube 
nanocapsules. 
 
The above results were consistent with the hypothesis that the 
225
Ac
3+
 ions would behave 
similarly to the Gd
3+
 ions within US-tube nanocapsules due to the similar solution 
chemistry of both trivalent actinide ions and trivalent lanthanide ions.
189
  One exception 
was the continual leaking of 
225
Ac
3+
 ions from the US-tube nanocapsules upon repetitive 
serum challenges, while 
153
Gd
3+
 ions did not leak under similar conditions (see Part I of 
this chapter).
132
  Therefore, it is unclear whether the internalization of the 
225
Ac
3+
 ions 
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directly mimics the Gd
3+
 ion internalization of the GNTs.  Previous high-resolution 
transmission electron microscopy (HRTEM) images revealed that Gd
3+
 ions existed in 
small (1 nm x 2-5 nm) clusters that corresponded to roughly 6-10 Gd
3+
 ions per cluster;
9
 
additionally, the GNTs averaged 2-5% Gd by mass as determined ICP-OES.  Assuming a 
mean length of 50 nm and a minimum of 112 carbon atoms per nanometer (a (7,7) 
chirality with diameter of ca. 0.95 nm, the mean diameter of HiPco),
190
 each US-tube 
nanocapsule contains roughly 9-21 Gd
3+
 ions.  The synthesis method herein utilizes the 
maximum concentration of 
225
Ac
3+
 ion commercially available and the minimum 
concentration of US-tubes that can be reliably manipulated for filtration experiments, yet 
only provides one 
225
Ac
3+
 ion for roughly every 250 US-tube nanocapsules.  At this low 
concentration, there is not enough 
225
Ac
3+
 ions present to form 
225
Ac
3+
-ion clusters that 
would directly mimic the Gd
3+
-ion clusters inside the GNTs.  However, the 
225
Ac
3+
 ions 
do behave similarly to the Gd
3+
 ions when admixed into the US-tube nanocapsules with 
Gd
3+
 carrier metal, allowing for use of the cold Gd
3+
 ion for the majority of the cluster 
atoms within the US-tube nanocapsules.  Interestingly, the methodology of loading 
(sequential vs. simultaneous) appears to have little to no effect on the final product.  This 
proves beneficial to future synthesis routes with regards to the time of production of 
225
Ac
3+
-ion clusters within the US-tube nanocapsules, and the solution chemistry of the 
225
Ac
3+
 ions within the GNTs further supports the hypothesis that a cluster of ions is 
critical for their embedment and retention within the US-tube nanocapsules and their 
resistance to serum challenge.  
 
Conclusions 
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In summary, the 
225
Ac@GNTs provide a novel alternative to chelation for radiometal 
ions useful for TαT.  The resistance of the 225Ac@GNTs to physiological challenges 
strongly suggests that this agent would not suffer the release of highly toxic, free 
225
Ac
3+
 
ions in vivo currently associated with traditional chelating agents.
185,188
  Furthermore, as 
the demand for 
225
Ac
3+
 ion rises resulting in an decrease of supply, the US-tube 
nanocapsules hold potential to contain a concentration of the isotope that will net over 
100 α-particle emissions from a single, targeted US-tube nanocapsules.  Until higher 
concentrations become commercially available, the doping of the 
225
Ac
3+
 ions within the 
Gd
3+
-ion clusters of the GNTs provides a new technology that could be especially useful 
for those cases (for 
225
Ac
3+
 RAIT) where in vivo retention of radiometals within chelating 
agents remains problematic.  The next chapter of the thesis further explores the doping of 
radionuclides within the GNTs’ stable Gd3+-ion clusters. 
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CHAPTER FOUR: POSITRON EMISSON TOMOGRAPHY 
RADIONUCLIDES WITHIN US-TUBES 
 
“The world is an old woman, and mistakes any gilt farthing for a gold coin; whereby 
being often cheated, she will thenceforth trust nothing but the common copper” 
 ~ Thomas Carlyle, Scottish Essayist 
 
INTRODUCTION 
Similar to the previous chapter’s exploitation of the stable Gd3+-ion clusters in the GNTs 
to stabilize the encapsulation of the 
225
Ac
3+
 ion, this chapter aims to extend that 
exploitation to include the 
64
Cu
2+
 ion. The primary purpose of Chapter Four is to 
explore the use of US-tube nanocapsules as multimodal imaging agents for use in 
combined MRI/PET (positron emission tomography) imaging. The first part of the 
chapter discusses preliminary experiments utilizing the US-tube nanocapsules to 
encapsulate the positron-emitting radionuclide, 
125
I of molecular iodine (
125
I2). High costs 
caused this project to be abandoned, which lead to the second part of the chapter: 
experiments creating a novel material consisting of the positron-emitting 
64
Cu
2+
-ion 
radionuclide doped within the Gd
3+
-ion clusters of the GNTs (Figure 34). Ultimately, the 
chapter establishes a stable multimodal (PET, T1-weighted MRI, and T2-weighted MRI) 
agent, the 
64
CuGNTs (
64
Cuprogadonanotubes or 
 64
Cu@GNTs, Figure 34, right). 
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Figure 34: Pictorial representation of a US-tube loaded with molecular iodine 
(left) and a 
64
Cuprogadonanotube (
64
CuGNT) (right). Left: Each pair of orange 
spheres represents a molecule of iodine (I2), drawn roughly to scale. Right: 
Green spheres represent Gd
3+
 ions and blue spheres represent Cu
2+ 
ions, drawn 
roughly to scale.  
 
DIAGNOSTIC IMAGING 
The primary purposes of this section are to introduce another powerful diagnostic 
imaging technique (PET), describe the powerful information that arises when this 
technique is coupled with MRI (described extensively in Chapter 2), provide a summary 
of the state-of-the-art for combined PET/MRI agents and to summarize previous 
experiments which internalized molecular iodine (I2) within US-tube nanocapsules. 
 
Positron Emission Tomography 
While MRI’s resolution renders great anatomical and physiological information, its 
relative lack of sensitivity makes molecular imaging nearly impossible. Luckily, Nuclear 
Medicine (NM) offers high sensitivity combined with the accurate quantification required 
for efficient molecular imaging.  More specifically, positron emission tomography (PET) 
has a sensitivity ranging from 100 to 1000 times higher than single photon emission 
computed tomography (SPECT), the second most sensitive NM technique.
191
 PET 
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depends on the triangulation of annihilation photons following positron (β+) decay from 
specific radionuclides.  The most commonly-used PET radionuclides involve radioactive 
nonmetals, such as 
15
O (t1/2 = 2 min), 
11
C (t1/2 = 20 min), and the widely-used 
18
F (t1/2 = 2 
h);
192
 however, radiochemists are exploring various radiohalogens and radiometals as 
well,
193
 such as 
124
I (t1/2 = 4.2 d), 
86
Y (t1/2 = 14.7 h), and 
64
Cu (t1/2 = 12.7 h), to capitalize 
on their extended half-lives for extended studies. 
 
 
Figure 35: Positron Emission Tomography (PET) instrumentation. Beginning at 
“Annihilation” (where emitted β+ annihilates neighboring e-), continuing to a 
circular arrangement of scintillators which detects resultant γ-rays, concluding 
with coincidence processing required to extrapolate position of annihilation for 
image reconstruction. 
 
 
As a β-emitting radioisotope decays, the escaping positron travels a short distance, known 
as ‘positron range,’ before annihilating with an electron to create 1.022 MeV of energy 
according to E=mc
2
 (m being the combined mass of the annihilated positron and electron, 
see “Annihilation” in Figure 35).194  This energy is divided evenly into two high-energy 
γ rays that emerge from the body away from each other at an 180o angle (± 0.25o).195  
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Outside of the body, these photons are then detected by an array of scintillators 
surrounding the patient.  If the coincidence processing unit determines a pair of 
scintillator detectors simultaneously record γ rays, then the annihilation event is expected 
to have occurred somewhere between the detectors.  After a specific number of 
annihilation events are recorded (typically over 100,000), the distribution of triangulated 
annihilations are reconstructed and displayed in a tomographic representation.  
 
Multimodal Imaging 
In many ways, positron emitting radionuclides are purely a CA at a physician’s disposal 
that sacrifices resolution for specificity.  While PET is considered one of the most 
sensitive diagnostic techniques, its lack of resolution can cause misleading anatomical 
information. For example, with spatial resolutions ranging 5-7 mm in clinical PET 
applications, a malignant tumor on the lung can easily be misdiagnosed as either stomach 
cancer or esophageal cancer.  The image produced following a PET scan is simply color 
scaled voxels with the one color of the scale representing no activity, another 
representing the highest recorded activity in a single voxel, and all other colors 
representing a scale in between (most commonly white, black, and shades of grey).  
Unfortunately, there is no anatomical reference to apply to the image, but only reference 
to the circle of scintillators of the PET instrumentation (Figure 35).  Imagine the hiker 
with a global position system (GPS) receiver, yet no map; he may know very intelligent 
information with regards to his location, yet still be completely lost in the woods without 
reference or bearings.  
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To alleviate this problem, the majority of current clinical PET instruments are used in 
“tandem” with a CT imager.196  Using a maneuverable bed, an initial full-body (most 
scans ranging from head to hip) CT scan is taken for anatomical reference, followed by a 
PET scan for sensitive tracing.  There are many advantages for using CT, instead of MRI, 
in conjunction with PET: the CT imager is only a fraction of the cost of an MRI imager, 
it takes under a minute for an anatomical reference scan, and the instrumentation is much 
less sensitive to its external surroundings.
197
  Conversely, the are many disadvantages to a 
CT procedure: the patient receives harmful ionizing radiation, the CT provides low 
resolution scans when monitoring neural activity changes in brain scans compared to high 
resolution fMRI, and it lacks the contrast resolution required for enhanced tissue 
resolution.
198
  Additionally, the radiation dangers associated with CT prevents the ability 
for repetitive scans that MRI allows. 
 
For these reasons, there has been a race among researchers to create the first clinical 
MRI/PET multimodal imager with the first prototypes just now making their way into 
clinics.
199-201
  Currently, images taken with an MRI scanner followed by separate images 
taken with a PET scanner have been overlaid to show great promise with regards to 
clarity, resolution, and identification of a radionuclide tracer.  Figure 36, clearly shows 
the anatomic resolution of rat’s body scan coupled with the amazing contrast that the 
targeted 
124
I provides the tumor.
202
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Figure 36: Colocalization of PET and MRI images. Top: External dorsal view 
showing position of tumor on lower back of mouse. Bottom: Sagittal MR image 
(linear grayscale) through the tumor of the mouse shown in top image overlaid 
with the corresponding PET data (blue-red color scale, adapted from 
203
). 
 
The disadvantage to this method is that the subject must be physically moved between 
images.  This movement leads to inaccuracies when the images are overlaid, ultimately 
creating problems with localization.  The first preclinical fused PET/MRI images were 
created in 2006 by Cherry’s research group at the University of California, Davis,204 and 
the potential strength of combining these two imaging modalities became readily 
apparent as shown in Figure 37: 
 
Figure 37: Simultaneous in vivo imaging with MRI and 
18
F-fluorodeoxyglucose 
(FDG) PET of a rat, showing overlaid cross-sectional images through the head. 
FDG uptake in both muscle and brain is prominent (adapted from 
204
). 
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These images show a cross-sectional brain scan of rat given 
18
F-fluorodexoyglucose 
(FDG), a drug made to resemble glucose to monitor glucose uptake. The MRI scan gives 
both anatomical reference and resolution, while the PET image renders glucose uptake 
with incredible specificity. The overlay of the two shows the power of combined 
MRI/PET imaging. 
 
Unfortunately, there are many obstacles in creating a clinical MRI/PET scanner. First, the 
magnet used in MRI is very sensitive to its surroundings. Simply having the PET 
instrumentation in close proximity can result in inhomogeneity of the magnetic field. 
Furthermore, the RF radiation emitted from a PET scanner can interfere with MRI 
measurements, especially if the RF is at any of the MRI scanner’s resonant frequencies. 
Not only can the PET interfere with the MRI scan, but the opposite is also true, since the 
detectors in the circumference of the gantry of the PET scanner are comprised of 
photomultiplier tubes (PMTs) that are strongly susceptible to magnetic fields.
195
  Despite 
all the inherent obstacles, one interesting benefit, discovered through Monte Carlo 
simulations, is that in the presence of a strong magnetic field (Tesla in strength), β+ 
ranges will actually reduce the effective positron range of radionuclides,
205
 suggesting 
that coupling the two instruments will enhance PET’s resolution before computed 
overlay. 
 
Most recently, on June 10, 2011 the FDA issued a press release clearing the Siemens 
Biograph mMR system, the first approved PET/MRI combined system. Previously, 
physicians could only use a PET and CT scanner to image the body. Repeating much of 
92 
the section above, the press release stated: 
“Advantages of the Siemens Biograph mMR system over current systems 
include simultaneous imaging, reduced radiation dose, and increased soft 
tissue contrast.  
  
‘The Siemens PET/MRI system allows two tests to run simultaneously 
without having to move the patient to a different scanning system,’ 
Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostic 
Device Evaluation and Safety in the FDA’s Center for Devices and 
Radiological Health. ‘Minimizing changes in a patient's position between 
tests allows physicians to compare images more easily and helps them get 
the most accurate information possible.’”  
~June 10, 2011 FDA Press Release 
 
 
The first human MR-PET system installed in the U.S. was the 3T Seimens TIM Trio 60 
cm (RF coil ID) 32 channel MRI at the Charlestown facility associated with the 
Athinoula A. Martinos Center (a collaborative center between Harvard University, 
Massachusets General Hospital, and Massachusetts Institute of Technology) in Boston, 
Massachusetts, shown in Figure 38.  
 
Figure 38: First clinical MR-PET system installed in the U.S. (3T Seimens TIM 
Trio 60 cm (RF coil ID) 32 channel MRI). 
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Multimodal Imaging Agents 
With MRI being the anatomical imager of choice by neurologists and the wealth of 
information stemming 
18
FDG glucose uptake studies, fused images have been developed 
to combine this information into one powerful image, such as Figure 37.
202
  Some 
physicians have even used MRI contrast agents for the MRI scans that they have overlaid 
PET scans atop.
206
  Despite knowing the power of combining these imaging modalities, 
currently, no MRI/PET multimodal imaging agent has been developed. 
 
The literature alludes to the design of single platform, dual PET/MRI imaging agents, yet 
however none have yet been reported. One reference is quite literally only an allusion to 
the eventual possibility of a nanoscale MRI/PET imaging agent: “It should be stressed 
that in PET imaging nanoparticles never have been used as a [CA] and this way can 
substantially increase the sensitivity and performance of this method both for animal and 
human studies, not mention their potential for multimodality.”207  The other two 
proposals in the literature involve taking previously reported nanoparticles functionalized 
with multiple DOTA chelating groups highlighting that DOTA binds strongly to either 
Gd
3+
 ion or 
64
Cu
2+ 
ion.
195
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Figure 39: Proposed designs of dual PET/MRI imaging agents.  Left: The brown 
oval represents bovine serum albumin (BSA) functionalized with DOTA 
chelating both 
64
Cu
2+
 ion (represented by yellow circles) and Gd
3+
 ion 
(represented by pink circles) allowing for both PET and T1-weighted MR 
imaging. Right: A dextran-sulfate-coated SPIO has been functionalized with 
DOTA chelating 
64
Cu
2+
 ion (represented by yellow circles) allowing for both 
PET and T2-weighted MR imaging (adapted from 
208
. 
 
These are both reasonable approaches for creating multimodal MRI/PET agents.  The 
first (Figure 39, left) follows attachment of isothiocyanate functionalized DOTA to a 
common blood serum protein, bovine serum Albumin (BSA).  The other proposed 
method involves dextran sulfate coated SPIO conjugated (also via an isothiocyante 
reaction with a primary amine) to DOTA, capable of chelating 
64
Cu
2+ 
ions, as shown in 
Figure 39, right.  The first proposal would have Gd
3+
 ion and 
64
Cu
2+
 ion, causing it to be 
useful as both a MRI CA for T1-weighted images along with PET images, and the other, 
with superparamagnetic SPIO instead of paramagnetic Gd
3+
 ions, should work for MRI 
CA for T2-weighted images instead.  Though not mentioned in the paper, for both T1 and 
T2 enhancement coupled with PET imaging, the group need only chelate Gd
3+
 ion along 
with 
64
Cu
2+
 ion in the attached DOTA ligands.  The problem with these two DOTA-
functionalized precursors is simply that the precursors are already heavily functionalized, 
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making additional functionalization with targeting moieties, such as antibodies or 
targeting peptide sequences, especially difficult. 
 
Through internalization of both PET radioisotopes and MRI CAs (useful for both T1- and 
T2-weighted enhancement) inside the US-tube nanocapsules, the exterior side wall of the 
nanocapsules remains unobstructed for functionalization with solubility-enhancing 
moieties to decrease the injected dose, targeting agents for enhanced diagnosis, and 
therapeutic agents, such as radiotherapeutics and chemotherapeutics.  For this reason, the 
US-tube nanocapsules would seem to possess ideal potential for the development of 
forefront theranostic agents (therapeutic plus diagnostic, as described in Chapter 1). 
 
Molecular and Mixed Halogens @ US-Tube Nanocapsules 
The aim of the Part One of this chapter is to internalize 
124
I2 (molecular iodine composed 
of positron-emitting [25.6%] radionuclides of iodine with a t1/2 of 4.18 d) within the US-
tube nanocapsules. To lay the groundwork for this experiment, three key experiments 
have been previously reported in the literature which internalized molecular iodine (I2) 
and a mixed radiohalogen (
225
AtCl) inside the US-tube nanocapsules:  
 
The first, an internalization of I2, simply involved sublimation of I2 over the US-tube 
nanocapsules.
92
  Using XPS and ICP-AES, the resultant I2@US-tube nanocapsules are ca. 
25% I2 by mass after removing the externally-adsorbed I2.  The externally-adsorbed I2 
was removed by either (a) reduction of the I2@US-tube nanocapsules with Na
0
/THF or 
by (b) the heating of the I2@US-tube nanocapsules to 300 °C.  This technique, despite its 
96 
effectiveness, is not a possibility as the safety protocols at the Frensley Center for 
Imaging Research at Baylor College of Medicine (where the studies were performed) 
preclude the sublimation of radionuclides.  However, the experiment did suggest that if 
124
I2 could be successfully internalized within the US-tube nanocapsules, that it will 
likely be retained by the US-tube nanocapsule.  Heating of the I2@US-tube nanocapsules 
(following removal of the externally-adsorbed I2) to 500 °C resulted in no measurable 
loss of I2 by XPS or ICP-AES.  Later studies revealed that the US-tube nanocapsules 
could be externally-functionalized with malonodiserinolamide  (Ser) groups via Bingel 
chemistry rendering the water-soluble nanocapsules (ca. 0.25 mg/mL).
10
  These water-
solubilized I2@US-tube nanocapsules are more than twice as opaque to X-rays as the 
empty US-tube nanocapsules. 
  
The second important experiment examined US-tube nanocapsules with 
125
I
-
 ions and 
oxidized 
125
I2.
209
  Both species (
125
I
-
 ions and oxidized 
125
I2) were retained more strongly 
by US-tube nanocapsules than other carbonaceous materials tested: full-length SWNTs, 
fluorinated SWNTs, charcoal, graphite, and fluorinated graphite.  This is believed to be 
owed, in part, to the US-tube nanocapsules’ large surface area: 1180 m2/g.  The t1/2 for 
125
I
-
 ion retention to the US-tube nanocapsules calculated using the wash-off rate of 
iodine by pure water was ca. 4 months (2,720 h); meanwhile, the t1/2 for 
125
I2 retention 
following oxidation via 1 mM H2O2 was almost 2 years (14,300 h).  This method of 
aqueous loading of radiohalides is more applicable for 
124
I2, as it does not involve gas 
phase radionuclide during sublimation. 
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The third experiment followed the aqueous loading and subsequent oxidization above, 
however it was performed on the α-emitting 211At- ion with subsequent oxidation to 
211
AtCl using the chemical oxidant Chloramine-T (ChT).  ChT was utilized, as opposed 
to the H2O2 in the previous study, since ChT has been documented to form I2 and not ICl, 
when oxidizing NaI.
210
  This study also explored the internalization of stable, 
monoisotopic iodine (
127
I) in the form of aqueous NaI oxidized to I2 with ChT within 
both US-tube nanocapsules and full-length SWNTs. XPS and ICP-AES showed no 
internalization of I2 within the full-length SWNTs.  As the full-length SWNTs possess 
closed ends and lack the sidewall defects of the US-tube nanocapsules, this result is not 
unexpected.  More importantly, however, is that the US-tube nanocapsules do retain the 
oxidized molecular iodine (I2) at ca. 1.5-3 % by mass following washing with pure water. 
Moreover, as internally-loaded iodine and externally-physisorbed iodine have different 
Auger spectra (a high-energy shoulder at 520 keV would be expected if the iodine was 
externally-physisorbed), this aqueous loading of iodine is internal only (Figure 39).  This 
aqueous loading of ionic radiohalogen, followed by oxidation with ChT, will also be 
followed in this part of the chapter below.  Again, it should be noted that the first part of 
this chapter, while rendering promising results, was later abandoned due to high costs; 
the cost for the 1 mCi (10 μL) of Na124I utilized for the original study was over $5,000 
(compared to 25.0 mCi of 
64
CuCl2 in Part Two costing under $700). 
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Figure 40: X-ray-induced Auger emission spectrum of nanotube materials 
(adapted from 
92
). 
 
 
PART ONE: PRELIMINARY 
124
I EXPERIMENTS 
 
Materials and Methods 
US-tube Nanocapsules Solution 
1.0 mL of HPLC-grade water was added to 1.0 mg of individualized US-tube 
nanocapsules (synthesized per Chapter 1 from Arc-ablation synthesis, Carbolex AP-
grade).  To this, 1.0 mL of a 2% biocompatible Pluronic® F108 Block Copolymer (a 
nonionic surfactant composed of polyoxypropylene and polyoxyethylene, BASF 
Corporation) prepared with HPLC-grade was added and the solution was bath sonicated 
for 10 minutes. Subsequent centrifugation resulted in no flocculation, suggesting a 
complete suspension (ca. 0.5 mg US-tube nanocapsules/mL 1% Pluronic solution). 
 
 
124
I2@US-tube Nanocapsules  
1.0 mg of US-tube nanocapsules were added to 1.0 mL of HPLC-grade water and bath 
sonicated for 5 min. While actively being sonicated, 200 μL (ca. 200 μg of US-tube 
nanocapsules) were added to 1.0 μCi of Na124I (ca. 33.3 pmol or 3.33 mM, radionuclide 
99 
purity > 99%, specific activity: 30 Ci/mmol, IBA Molecular North America, ca. 12 μL). 
This solution was bath sonicated for 10 min, followed by a 20 min rest to ensure 
equilibration. Then, 100 μL of a 0.30 M ChT solution was added to the initial solution 
and manually shaken in a sealed centrifuge vial. 300 μL of 2% biocompatible Pluronic® 
F108 Block Copolymer, followed by bath sonication for 10 min. 
 
 
Limitations of 
124
I 
The relatively long half-life of 
124
I (4.2 days) is beneficial since it allows for easy 
shipment (clinics need not have costly, on-site radioisotope production), and it permits 
further processing of the material (such as functionalization of the US-tube nanocapsules’ 
sidewalls post-loading). Unfortunately, from another standpoint, this long half-life has 
serious negative consequences due to radionuclide handling regulations. Specifically, 
Baylor College of Medicine requires a period of 10 half-lives of decay prior to removing 
radiowaste from a laboratory for disposal. With a 4.2 d half-life, this equates to ca. 1.5 
months of lab space being occupied with waste. This limitation also prevents membrane 
dialysis, since storage of radioactive waste water following dialysis is impractical.  
 
Mouse Models 
An athmyic nude mouse model was selected for stability since the inhibited immune 
system (missing thymus which results in no T-cell production) does not reject a tumor 
graft. All mice (both 
124
I2@US-tube nanocapsules and Na
124
I control mice, n = 3 for both 
control and experiment) were tumor bearing with SKBR3, a common human breast 
100 
carcinoma cell line. For each set of three mice, two bore the tumor on the left leg and one 
on the right leg to ensure no difference with tumor location.  Control mice were injected 
with ca. 466 μCi Na124I in 200 μL saline solution.  Experimental mice were injected with 
ca. 333 μCi 124I2@US-tube nanocapsules in 200 μL 1% Pluronic.  All injections were 
intravenious, lateral tail vein with a 28 ga. needle.  
 
MicroPET/CT Imaging 
In vivo PET/CT imaging studies were performed using a Siemens INVEON small-animal 
imager with a dedicated PET scanner within a multimodality CT (Siemens Healthcare, 
Knoxville, TN).  The CT imaging parameters included an X-ray voltage of 80 kV with an 
anode current of 500 µA and an exposure time of 260 milliseconds for each of the 120 
rotation steps over a total rotation of 220° at low system magnification.  A MicroCT 
image was taken of all mice pre-injection and 2 hr post-injection.  After CT imaging, 
PET emission scans were performed at 1 hr, 4 hrs, and 24 hrs post-injection.  Each PET 
scan had a 20 minute collection time.  PET images were reconstructed using a two-
dimensional filtered back-projection and CT images were reconstructed using a 
Feldkamp cone-beam algorithm with a ramp filter cutoff at the Nyquist frequency.  Image 
fusion and analysis were performed using ASIPro, Inveon Research Workplace (Siemens 
Preclinical Solutions) and AMIRA (version 3.1; Konrad-Zuse-Zentrum fur 
Informationstechnik, Berlin, Germany). 
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Results 
MicroCT 
The MicroCT images showed no measurable CT enhancement from pre- to post-injection 
with the 
124
I2@US-tube nanocapsules (Figure 41): 
 
Figure 41: MicroCT image of athmyic nude mouse pre- and post-injection with 
prepared 
124
I2@US-tube nanocapsule solution. 
 
MicroPET 
The result from the MicroPET imaging for the tumor-bearing mouse model injected with 
124
I2@US-tube nanocapsule solution is visually displayed in Figure 42.  At the 1 hr time-
point, five distinct regions of activity appeared on the mouse: the mouth, the thyroid, the 
stomach, the bladder, and the tumor (Figure 42, left). The color scale represents the 
injected dose per gram of tissue (% ID/g) ranging from 0 % to 5 % of the total injected 
dose; color saturation is seen at thyroid, which has % ID/g of between 20% and 25%.   At 
the 4 hr time-point, only four of these areas remained as the bladder no longer showed 
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activity (Figure 42, center and Figure 43).  Note: the mice in Figure 42 and Figure 43 
have tumors on opposite legs so as to ensure the tumor is not confused with the bladder. 
By the 24 hr time-point, most all activity was concentrated only in the thyroid (Figure 
42, right).  
 
 
Figure 42: MicroPET image of athmyic nude mouse post-injection with prepared 
124
I2@US-tube nanocapsule solution. Note: Tumor is on left leg.  
 
 
Figure 43: Four hour time-point MicroPET image of athmyic nude mouse post-
injection with prepared 
124
I2@US-tube nanocapsule solution. Note: Tumor is on 
right leg. 
 
These results were visually identical to the control mice injected with Na
124
I in saline; 
with the only significant difference noted between the control and experimental mice 
being the % ID/g (normalized) at a 4 hr time-point data, as shown in Figure 44: 
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Figure 44: Tumor to background ratio. Light blue (left) represents mice injected 
with 
124
I2@US-tube nanocapsule solution while purple (right) represents control 
mice injected with Na
124
I solution. Raw data can be found in Appendix  
 
 
 
Discussion 
Unfortunately, this first round (and only round) of 
124
I experiments was simply a 
preliminary study which had too many variables for firm conclusions to be reached: 
 
(1) There was no washing of the US-tube nanocapsules post-oxidation with ChT 
to remove any weakly bound 
124
I2.  While previous studies suggested that the 
vast majority (if not all) of the I2 was internalized (Figure 40), they also 
suggested that washing can remove a small amount I2.  It is possible that 
filtration and or membrane dialysis would have removed molecular iodine not 
strongly bound to the US-tube nanocapsules following oxidation.  
 
(2) There was no washing of the US-tube nanocapsules post-oxidation with ChT 
to remove the ChT.  It is unlikely that the small amount of oxidant would have 
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played a significant role in imaging; regardless, it should have been removed.  
(3) The control didn’t posses any Pluronic® to see if the surfactant played any 
role.  Had the control contained an equal concentration of the surfactant, 
analysis of the interesting retention in the tumor at the 4 hour time-point could 
be more conclusively attributed to just the US-tube nanocapsules. 
 
As such, this thesis will not attempt to draw many conclusions from this study.  Again, 
cost was the number one reason for transitioning away from further 
124
I2@US-tube 
nanocapsules experiments. 
 
The interesting data stems from the 4 hour time-point.  For all mouse models (n=3), the 
normalized % I.D. for the 
124
I2@US-tube nanocapsules was nearly twice that of free 
Na
124
I in saline.  As near-infrared (NIR) fluorescence spectra have suggested that blood 
proteins displace nanotube surfactant molecules within seconds,
211
 it is likely that the 
only difference at the 4 hour time-point stems purely from the US-tube nanocapsules.  
Drs. Dai and Gambhir previously reported that nonspecific targeting of full-length 
SWNTs functionalized with the chemical polymer polyethylene glycol (PEG) is minimal, 
especially when compared to a the same material with the addition of a cancer targeting 
protein (specifically, using the arginine-glycine-asparatic acid (RGD) peptide capable of 
quantifying integrin αvβ3 expression in cancer patients).
212
  This study used Raman 
spectroscopy to confirm similar results determined by covalently attaching the metal 
chelator ligand DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10- tetraacetic acid) to 
pegylated full-length SWNTs and chelating the PET-active 
64
Cu
2+
 radionuclide.
213
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However, it is important to recall that the pristine nanotubes have a different 
biodistribution from functionalized nanotubes.
214
  More specifically, functionalized, full-
length SWNTs do not accumulate in RES organs,
215,216
 while pristine full-length, 
13
C-
enriched SWNTs do.
214
  Similarly, the US-tube nanocapsules have a different 
biodistribution from full-length SWNTs, escaping the reticuloendothelial system (RES) 
and being excreted through the kidneys and bile ducts.
74
   
 
Conclusions 
As stated above, few conclusions can be drawn from this preliminary study.  As the bulk 
of the activity for both the control and the US-tube nanocapsules was displayed in the 
thyroid (there is no documented accumulation of nanotube materials in the thyroid), the 
most likely conclusion is that the majority of the 
124
I2 was not retained within the US-tube 
nanocapsules.  It remains unclear if this is due to a failure to properly oxidize the Na
124
I 
to 
124
I2, or if the 
124
I2 was leached from the US-tube nanocapsules when challenged in 
vivo. However, the data from the 4 hour time-point suggests further examination of 
untargeted US-tube nanocapsules may prove useful for time-points between 1 and 24 
hours, since the US-tube nanocapsules is the most likely candidate for the increase in 
tumor retention of % I.D.  The most likely reason for the increase in 
124
I isotope in the 
solid tumor is the Enhanced Permeability and Retention (EPR) effect, a property of 
macromolecules and smaller particles to accumulate in tumor tissue due to poor fluid 
transport within tumors stemming from their rapid production of blood vessels.
217
  
 
Ultimately, 
124
I was simply too costly (and therefore impractical) for further examination; 
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examination of the US-tube nanocapsules ability to accumulate in solid tumors over time 
could prove advantageous for the development of US-tube nanocapsule-based imaging 
agents for nuclear medicine. 
 
 
PART TWO: THE 
64
Cu EXPERIMENTS 
 
While the high cost of 
124
I was the primary motivation for searching for a new PET 
radionuclide to encapsulate within the US-tube nanocapsules to develop a dual PET/MRI 
imaging agent, other advantages also arose from the selection of the 
64
Cu radionuclide.  
The primary advantages of the 
64
Cu radionuclide over the 
124
I radionuclide are 
summarized in Table 7 below. 
 
Table 7:  Comparison between the 
124
I and 
64
Cu PET radionuclides. 
 
 
124
I 
64
Cu 
Half-life: 4.2 days 12.7 hours 
Modes of Decay: 
26% β+ emission 
74% electron capture 
26% β+ emission 
43% electron capture 
39% beta decay 
β+ Range*: 2.4 mm 0.57 mm 
Cost: Approx. $6000 / mCi Approx. $40 / mCi 
*Positron Range determined in aqueous media 
 
First, the 
64
Cu radionuclide has the advantage of a significantly shorter half-life at 0.5 
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days as opposed to 4 days for 
124
I.  This half-life still allows for overnight shipment of the 
isotope, yet circumvents the issue of radioactive waste storage.  Standard protocol at 
UTHSC (where these experiments were conducted) requires radionuclides to undergo 10 
half-lives before disposal, which results in only a 5 day storage period for 
64
Cu as 
opposed to a 41 day storage for 
124
I.  Second, while both radionuclides have the same % 
of β+ emission (the decay mode visible through PET imaging), 64Cu also undergoes β- 
decay, as well.  This mode of decay for 
64
Cu has been employed as a radiotherapy agent 
for the treatment of cancer making this radionuclide an inherently theranostic agent.
218,219
  
Finally, 
64
Cu has a significantly shorter positron range in aqueous media.  The positron 
range is the average distance an emitted β+ will travel before encountering an electron to 
annihilate.  Important to note is that PET instrumentation does not triangulate the location 
of where the radionuclide decays but rather the location of where the β+ annihilation 
occurs.  Therefore, the longer the positron range, the more error in the resulting PET 
image.  Also, as discussed extensively above, 
64
Cu is a fraction of the cost of 
124
I. 
 
Methods and Materials 
This section will describe the synthesis of Cu@US-tube nanocapsules, cold CuGNTs, and 
hot (radioactive) 
64
CuGNTs. Additionally, this section describes the protocols used for 
simulating physiological challenges, as well as the imaging protocols used for both the 
MicroCT/PET and MR imaging. 
 
Preparation of Cold Cu@US-tube Nanocapsules 
Prior to tests with 
64
CuCl2, cold copper(II) chloride (99.999% trace metals basis, Sigma) 
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was used to examine loading and retention of Cu
2+
 ions within the US-tube nanocapsules 
prepared as discussed in Chapter 1.  Cu@US-tube nanocapsules were prepared 
following the same protocols found in Chapter 2 for the GNTs.  In short, a 5 mM 
solution of CuCl2 was prepared using DI water. 15.0 mg of US-tube nanocapsules were 
added to 10.0 mL of CuCl2 solution (in triplicate) and bath sonicated for 1 hr.  Following 
sonication, the US-tube nanocapsules samples were filtered and washed seven times with 
DI water.  The filtrate was analyzed via ICP-OES, the collected samples were dried 
overnight in an 80 °C, and the dried samples were digested as described in Chapter 2 for 
ICP-OES analysis.  All samples prepared in triplicate. 
 
Preparation of Cold Cuprogadonanotubes (CuGNTs) 
Cold cuprogadonanotubes were prepared identically to the Cu@US-tube nanocapsules 
described above except for the addition of GdCl3 to the CuCl2 solution.  CuGNTs were 
prepared in solutions with varying ratios of Cu
2+
 ion to Gd
3+
 ion to study the effects of 
the ratio of ions in solution.  Both 5 mM solutions of CuCl2 and GdCl3 were prepared 
using DI water, one with a 1:1 ratio of CuCl2 to GdCl3 and the other with a 1:4 ratio of 
CuCl2 to GdCl3. 15.0 mg of US-tube nanocapsules were added to 10.0 mL of each 
solution (in triplicate) and bath sonicated for 1 hr.  All samples were filtered, washed, 
oven-dried, and analyzed via ICP-OES as described above for the Cu@US-tube 
nanocapsules. 
 
Cold Cu@US-tube Nanocapsule and Cuprogadonanotube Challenges  
The dried samples were introduced to in vitro challenges that would best simulate 
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conditions experienced in vivo: heat (37 °C), serum proteins (specifically bovine serum 
albumin or BSA), and phosphate buffered saline (PBS).  Following 12 hr, 24 hr, and 7 d 
challenge experiments, the samples were filtered with a coarse-grade fritted glass filter 
and the filtrate was analyzed for both Cu
2+
 ion and Gd
3+
 ion via ICP-OES.  All samples 
were challenged in triplicate.  DI water, BSA, and PBS were also analyzed for Cu
2+
 ion 
and Gd
3+
 ion as controls for background levels. 
 
Preparation of
 64
Cuprogadonanotubes (
64
CuGNTs) 
Having established that Cu
2+
 ions leak from the US-tube nanocapsules without the 
presence of Gd
3+
 ions in the above cold experiments, all further loading was performed 
with only GdCl3 and 
64
CuCl2 mixtures.  With the available concentration of 
64
CuCl2 being 
on the picomolar scale in workable volumes, all further combinations were 5 mM GdCl3 
added to as much 
64
CuCl2 as available (this traditionally was collaborator-dependent and 
varied from week to week).  
64
CuCl2 was only available for shipment every 2 weeks, and 
project requirements took varying amounts each week.  All samples were loaded with 
64
CuCl2-spiked GdCl3, with 2-15 mg of US-tube nanocapsules following the same 
loading protocol as for the CuGNTs. Filtration was performed in microcentrifugation 
filters as described in Chapter 5, using a 2 minute spin-down at 6,000 RPM.  All 
washings involving hot 
64
CuGNTs used 18 MΩ water for every set of experiments.  
 
Many protocols were examined, but the final, most successful protocol involved addition 
of strong base at the end of the bath sonication.  In short: 4.1 mCi of 
64
CuCl2 was added 
to 6.2 mg of US-tube nanocapsules in 0.500 mL 1N HCl (aq) and bath sonicated for 30 
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mins. Then, 0.500 mL 1 mM GdCl3 (aq) (pH ~ 5.2) was added and again the sample was 
bath sonicated for 30 minutes.  After 60 minutes of equilibration, 0.600 mL 1N NaOH 
(aq) was added to ensure basic conditions.  The samples were then transferred to 
microcentrifugation filters for initial spin downs, and the filtrate was examined for 
activity.  Following the initial spin downs, all subsequent washings were with 18 MΩ 
water. 
 
64
Cuprogadonanotube Challenges 
Challenge experiments mimicked those of Chapter 4. The only variance was that 50% 
mouse serum was used instead of human plasma. All filtrations were performed in 1.5 
mL microcentrifugation devices with a 100 kDa pore size. All samples were challenged 
for 24 hours in 1 x PBS (pH ~7.9) 40 °C or 50% mouse serum (pH ~7.5) for 24 hr 
challenge at 40 °C. All samples were challenged in triplicate and 1 % Pluronic and 1 % 
Tween-80 surfactants were compared. 
 
MicroCT/PET Phantom Images 
MicroCT and MicroPET imaging were performed on the same Siemens Inveon small-
animal imager used above in Part 1. Each MicroPET scan was a 20 min collection. MR 
images were performed in both 1.5 T and 3.0 T systems. The phantoms were prepared at 
three concentrations (200 μCi/mL, 100 μCi/mL, and 50 μCi/mL) with Tween-80 
surfactant and compared to blanks of DI water and Tween-80 surfactant.  
 
3 T and 1.5 T MR Phantom Images 
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Phantom MR imaging was performed both a 1.5 T and 3.0 T commercial scanner 
(Achieva, Philips Medical Systems, Best, The Netherlands) with a 32-channel 
radiofrequency system.  A 32- or 16-element phased-array surface coil was used for MR 
signal reception.  An inversion recovery sequence was used for image acquisition with 
TR = 9000 ms and TE = 20 ms for 3 T images and TR = 6500 ms and TE = 10 ms for 1.5 
T images.   
 
Results and Discussion 
Cold Cu
2+
-ion Loading and Challenges 
All loading techniques with cold copper(II) chloride only resulted in undetectable levels 
of Cu
2+
 ions in the filtrate of DI washings by the 7
th
 washing; moreover, these materials 
were 2.05 % (w/w) copper as determined via ICP-OES analysis.  Unfortunately, 
significant (>45%) copper leakage occurred at 12 hr for PBS and BSA challenges at 40 
°C, implying that Cu2+ ions are not stable within the US-tube nanocapsules under 
simulated in vivo challenge.  At this point, all further attempts to internalize only Cu
2+
 
ions within US-tube nanocapsules were abandoned.   
 
All the samples prepared with cold CuCl2 and GdCl3 had no measurable Gd
3+
 ions or Cu
2+
 
ions in the filtrate of DI washings by the 7
th
 washing. A 1:1 (Cu:Gd) loading ratio 
resulted in 0.70 % (w/w) copper in the final product, and a 1:4 ratio resulted in 0.38 % 
(w/w) copper.  No measurable Gd
3+
 ions or Cu
2+
 ions leaked from the US-tube 
nanocapsules following in vivo simulated challenge for 7 days. 
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64
Cu
2+
-ion Loading and Challenges 
For the six 0.250 mL aliquots, the average activity was 470.5 μCi (or 1.88 μCi/μL). 
Following the initial spin-down, there was an average of 99.18% retention (or 0.92% of 
the 
64
CuCl2 was removed). The subsequent washings resulted in 0.65 %, 0.49 %, and 
0.23% of the activity removed. It should be noted that the 0.23 % sample had only 1 μCi 
of activity, which is the detection limit of the well counter used. Traditionally, 95% 
retention is considered viable for in vivo experiments, so the washings proved 
unnecessary.  
 
There were no detectable levels of 
64
Cu
2+
 ions in the filtrate of any of the samples after a 
24 hour challenge at 40 °C in PBS, suggesting no problems with salt concentrations that 
could be encountered in vivo.  Unfortunately, there was an average of 36.6% leakage at a 
24 hour time point after being challenged in 50% mouse serum.  All samples were then 
washed with 50 % mouse serum until no 
64
Cu
2+
 ion was detected in the filtrate (an 
average of five washes), and these samples were then challenged again for 24 hours.  At 
the following spin down, only 1-2 μCi (instrumental detection limit) occurred for the all 
of the samples. This agrees with the results in Part 2 of Chapter 4 that revealed there 
were two populations of 
153
Gd
3+
 ions in 
153
GNTs, one that could be removed and one that 
was stable to serum challenge. The initial MRI and PET images for the 
64
CuGNTs are 
displayed in Figure 45.  
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Figure 45: [a] Phantoms of DI water (left) and 
64
CuGNTs (right). [b] Transverse 
MicroPET image of DI water (left) and 
64
CuGNTs (right). [c] Coronal MicroPET 
image of DI water (left) and 
64
CuGNTs (right). [d] MR images of DI water (left) 
and 
64
CuGNTs (right) at various inversion times. 
 
It should be noted that these samples may or may not be contaminated by free 
64
Cu; 
initial iTLC measurements show 18.4 % leached copper (free 
64
Cu
2+
), yet subsequent 
studies determined that the DOTA present in the iTLC protocol could remove even the  
Gd
3+
 ions from stable GNTs. For this reason, the images were repeated for the final, 
serum-washed 
64
CuGNTs as shown in Figures 46 and 47. 
  
Figure 46: 3 T and 1.5 MR images of the 
64
CuGNTs. Left: MR image of 
64
CuGNTs at 200 μCi/mL, 100 μCi/mL, 50 μCi/mL, and 1% Tween-20 surfactant 
at 3 T. Right: MR image of 1% Tween-20 surfactant, 
64
CuGNTs at 50 μCi/mL, 
100 μCi/mL, and 200 μCi/mL at 1.5 T (note: order reversed).  
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Figure 47: MicroPET and MicroCT images of 
64
CuGNTs. Left: MicroPET of 
64
CuGNTs at 200 μCi/mL, 100 μCi/mL, and 50 μCi/mL. Right: Same MicroPET 
with overlay of MicroCT. Uppermost phantom is 18 MΩ and the one below is 
1% Tween-20 polysorbate surfactant.  
 
 
The raw data and T1 and T2 for the MR images of Figure 46 can be found in Appendix 
VI. The most important conclusion is that the 
64
CuGNTs retain the high T1-weighted 
relaxivity (52.7 mM
-1
s
-1
) expected for the GNT material (without copper). With so few 
Cu
2+
 ions present in the 
64
CuGNTs, the lack of a significant change in T1 relaxivity (the 
same as the GNT precursor batch at 53.4 mM
-1
s
-1
) was not unexpected.  
 
Tween-20 was chosen as the surfactant because it better dispersed the US-tube 
nanocapsules, as shown in Figure 48. Though somewhat difficult to discern in the figure, 
the left (1% Pluronic F108) clearly shows the ring about the scintillation vial sidewall 
where the nanocapsules that flocculated out of solution remain, while better dispersion is 
evident on the right (1 % Tween-20).  
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Figure 48: Comparison of surfactants. Left: 1 mg of 
64
Cuprogadonanotubes 
suspended in 1% Pluronic F108. Right: 1 mg of 
64
Cuprogadonanotubes 
suspended in 1 % Tween-20. 
 
Conclusions 
64
Cuprogadonanotubes washed with serum are a capable dual MRI-PET contrast agent 
that shows potential for being among the first targetable dual agents for the MRI-PET 
hardware systems that are only now coming online.  Moreover, the requirement for the 
Gd
3+
 ions presence for a stable species (similar to the results found for 
153
Gd
3+
 ions and 
225
Ac
3+
 ions in Chapter 4) show the importance of the unique pH-dependent lanthanide 
ion chemistry for Gd
3+
 ions to form clusters within the US-tube nanocapsules that cannot 
be stripped away by simulated in vivo challenges.  
  
116 
CHAPTER SIX: CONCLUSIONS AND FUTURE WORK 
 
“Better living through chemistry”  
~Thomas Carlyle, Scottish Essayist 
 
CONCLUSION 
 
Few, if any, agents can boast the customizability of the US-tube nanocapsules.  As the 
future ushers in medicine with unique objectives specific for each patient, the US-tube 
nanocapsules should remain on the forefront of targetable, therapeutic agent design. 
When filled with Gd
3+
-ion clusters, the resulting GNTs are a powerful, dual modal MRI 
agent comprised of two magnetic components: (1) nanoscale, superparamagnetic catalyst 
particles that enhance T2-weighted imaging and (2) nanoscale, paramagnetic Gd
3+
-ion 
clusters that enhance T1-weighted imaging.  Additionally, the paramagnetic Gd
3+
-ion 
clusters are stable to physiological challenges, including heat, human serum, and PBS as 
verified by the γ-emitting 153Gd3+ ion used in the synthesis of 153GNTs.  Furthermore, the 
ability to select medically-active ions suitable to a patient’s needs allows the US-tube 
nanocapsules to be among the first nanoscale theranostic agents for personalized 
medicine. The unique pH-dependent, lanthanide-ion chemistry that occurs within the US-
tube nanocapsules has proven successful for the stable encapsulation of both 
225
Ac
3+
 ions 
for α-radiotherapy and 64Cu2+ ions for production of the first bimodal MRI/PET agent 
based on a SWNT material.  For all of these reasons, the US-tube nanocapsules hold 
great promise for the future of personalized medicine. 
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FUTURE WORK 
 
Future experiments will be designed to probe the true structure of the Gd
3+
-ion clusters 
within the GNTs using high resolution x-ray study.  Additionally, future experiments will 
explore the limitations of doping other medically-interesting ions within the Gd
3+
-ion 
clusters (if any limitations exist).  Finally, future studies will explore the successful 
targeting of the US-tube nanocapsules to diseased and/or cancerous cells.   
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APPENDIX I: ABBREVIATIONS AND SYMBOLS 
 
@  within (x@y = x within y) 
°C   degrees Celsius 
Å  angstrom 
AC  alternating current 
AFM  atomic force microscopy 
B0  external magnetic field 
BCM  Baylor College of Medicine 
BSA  bovine serum albumin 
CA   contrast agent 
CGS  Gaussian centimeter, gram, second units 
ChT  Chloramine-T 
Cm  molar Curie constant 
CoMoCat®  cobalt-molybdenum catalyzed SWNTs  
conc.   concentrated 
CT  computed tomography 
CVD  chemical vapor deposition 
d  day 
DI    deionized 
DOTA  1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DTPA   diethylene triamine pentaacetic acid 
E=mc
2
  mass-energy equivalence 
EDS  energy dispersive X-ray spectroscopy 
EDTA  ethylenediaminetetraacetic acid 
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eV  electronvolt 
FC  field-cooled 
FDA  Food and Drug Administration 
FDG  fluorodeoxyglucose (
18
F) 
FFWW fat-free body weight   
fMRI  functional magnetic resonance imaging 
G  gauss 
ga.  gauge 
GNTs  gadonanotubes or Gd@US-tube nanocapsules 
GPS  global position system 
H  magnetic field 
hr  hour 
Hc  coercive force 
HiPCO high-pressure carbon monoxide CVD process 
HPLC  high-pressure liquid chromatography 
HRTEM high-resolution transmission electron microscopy  
HSVM  high-speed vibration mill 
ICP-OES inductively-coupled plasma – optical emission spectroscopy  
IPR  isolated pentagon rule 
IR  infrared 
IUPAC International Union of Pure and Applied Chemistry  
K  Kelvin 
K  anisotropy energy density 
kB  Boltzmann constant 
L  liter 
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LC  liquid chromatography 
LDPE   low density polyethylene 
LET  linear energy transfer 
LNTs  lutetonanotubes or Lu@US-tube nanocapsules 
M  magnetization 
mAb  monoclonal antibody 
MHRA Medicines and Healthcare products Regulatory Agency  
min  minute 
m   meter 
MPMS  Magnetic Property Measurement System  
MRA   magnetic resonance angiography 
Mrem  remnant magnetization 
MRI  magnetic resonance imaging 
Ms  saturation magnetization 
MSC  mesenchymal stem cells 
MWNT multi-walled carbon nanotube 
Nd:YAG neodymium-doped yttrium aluminum garnet  
NIR  near infrared spectroscopy 
NM  nuclear medicine  
NMR  nuclear magnetic resonance  
NMV  net magnetization vector 
NMWL nominal molecular weight limit  
NSF/NFD nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy  
Oe  Oersted 
PET  positron emission tomography 
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PHA  Public Health Advisory 
PMT  photomultiplier tube 
ppb  parts per billion (microgram per liter) 
ppm  parts per million (milligram per liter) 
ppt  parts per thousand (gram per liter) 
PTFE  polytetrafluoroethylene 
RAIT  radioimmunotherapy 
RBM  radial breathing mode 
rem  Röntgen equivalents 
RF  radio frequency  
RT  room temperature 
SEA  Shared Equipment Authority  
SEM  scanning electron microscopy 
Ser  malonodiserinolamide 
SI  Système international d'unités (International System of Units) 
SPECT single photon emission computed tomography  
SPIO  small particles of iron oxide 
SQUID superconducting quantum interference device  
STM  scanning tunneling microscope  
SWeNT SouthWest NanoTechnologies Inc.  
SWNT  single-walled carbon nanotube 
T  Tesla 
T1  spin-lattice relaxation 
T2  spin-spin relaxation 
t1/2  half-life  
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TαT  targeted alpha therapy 
TB  blocking temperature 
Tc  Curie temperature 
TEM  transmission electron microscopy  
TGA  thermal gravimetric analysis  
THF  tetrahydrofuran 
TαT  targeted α-particle therapy 
V  volume 
XPS  X-ray photoelectron spectroscopy  
ZFC  zero-field-zooled 
α   alpha particle (4He2+) 
β-  beta particle (an electron) 
β+  positron 
γ  gamma emission 
γ  gyromagnetic ratio 
θ  angle 
χ  magnetic susceptibility 
ω  Larmor frequency or resonant frequency 
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APPENDIX II: GUIDELINES FOR QUOTATION OF EXCERPTS 
 
This appendix is a direct copy of the 2008 GUIDELINES FOR QUOTATION AND 
OTHER ACADEMIC USES OF EXCERPTS FROM JOURNAL ARTICLES (Version 2) 
stating official guidelines for use of excerpts from scholarly journals according to The 
International Association of Scientific, Technical & Medical Publishers (“STM”) and the 
Professional Scholarly & Publishing division of the Association of American Publishers 
(“PSP”): 
“The International Association of Scientific, Technical & Medical Publishers (“STM”) 
and the Professional Scholarly & Publishing division of the Association of American Publishers 
(“PSP”) believe it is in the interest of the scholarly and professional community as well as 
scholarly and professional publishers, to set out some common principles with respect to the use 
of limited amounts of journal article content in other published academic works and for 
educational use, and to reduce legal uncertainty with respect to such uses. STM and PSP have 
with other trade associations recently published a White Paper in May 2007 on the general 
subject of academic re-use entitled Author and Publisher Rights For Academic Use: An 
Appropriate Balance. 
Publishers accept that scholarly articles often require the direct reproduction of 
illustrative material (such as figures, tables, structures) for the purposes of discussion or 
comparison with other data, and that the electronic version of an article needs to contain the 
same illustrative material in order to maintain the authenticity of the record in both print and 
digital form. Publishers accept that the use of short quotations is normal in scholarship, 
generally intended to place the new work in scholarly context or to comment on the quoted work 
or its impact, and that there is minimal potential in such practices of negatively impacting the 
demand for the original work. Publishers also understand that in the development of course-
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packs (including for distance education), whether in print or electronic form, universities often 
wish to use similar quotations or limited excerpts. 
With respect to the use of small portions of journal articles by academics and scholars, 
or the institutions in which they conduct their research or educational work, that scholars (or 
their institutions with respect to course-packs) may (without obtaining explicit permission from 
publishers): 
• Use a maximum of two figures (including tables) from a journal article or five figures 
per journal volume (unless a separate copyright holder is identified in such figure, in 
which event permission should be sought from that holder); 
• Use single text extracts of less than 100 words or series of text extracts totaling less 
than 300 words for quotation; and  
• Use such excerpts in all media and in future editions. 
The following conditions apply: 
• The purpose of the use is scholarly comment or non-commercial research or 
educational use; 
• Certain complex illustrations such as anatomical drawings; cartoons; maps; poetry; 
works of art; or photographs, will still require normal permissions requests of 
publishers (or other copyright holder) as the journal article author(s) is unlikely to 
own the copyright in these; 
• Full credit should be given to the author(s) and publisher(s) of the material(s) used, 
consistent with normal scholarly practice; and  
• The quotation or excerpt must never be modified. 
Note that some scholarly societies that own journals published on their behalf by another 
publisher may have more restrictive policies on permissions than those of the publisher, and the 
publisher, journal administrator or the journal’s web site may need to be consulted with respect 
to such policies (check the copyright notice to see if there is a copyright owner other than the 
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publisher). These Guidelines are intended to help reduce legal uncertainty and improve and 
simplify administrative procedures with respect to the use of short excerpts of scholarly and 
professional information from journal articles. The participating publishers believe that by 
establishing clear guidance, research and scholarship as a whole is improved and scientific 
communication and education are made more effective and efficient. 
Publisher signatories: 
 American Chemical Society 
 BMJ Publishing Group Ltd 
 Elsevier 
 Institute of Physics 
 International Union of Crystallography 
 John Wiley & Sons (including Blackwell) 
 Oxford University Press journals 
 Portland Press Limited 
 Royal Society of Chemistry 
 SAGE Publications 
 Springer Science+ Business Media 
 Taylor & Francis” 
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APPENDIX III: RAW MPMS DATA 
Table 8:  M(H) Data for Raw Arc SWNTs. 
 
Field (T) Field (Oe) Long Moment (emu) emu/g emu/g of catalyst 
0 0 0.027615 2.060792537 7 
0 2000 0.103199 7.701447761 26 
0 4000 0.112190 8.372373134 28 
1 6000 0.114923 8.57630597 29 
1 8000 0.116303 8.679335821 29 
1 10000 0.117157 8.743074627 29 
1 12000 0.117740 8.786597015 30 
1 14000 0.118168 8.818522388 30 
2 16000 0.118497 8.843074627 30 
2 18000 0.118761 8.862776119 30 
2 20000 0.119066 8.885514925 30 
2 22000 0.119153 8.892037313 30 
2 24000 0.119307 8.903492537 30 
3 26000 0.119439 8.91338806 30 
3 28000 0.119619 8.926776119 30 
3 30000 0.119718 8.934186567 30 
3 32000 0.119795 8.939940299 30 
3 34000 0.119871 8.945559701 30 
4 36000 0.119937 8.950507463 30 
4 38000 0.119925 8.949634328 30 
4 40000 0.119964 8.952567164 30 
4 42000 0.120015 8.956328358 30 
4 44000 0.120083 8.961440299 30 
5 46000 0.120084 8.9615 30 
5 48000 0.120093 8.962134328 30 
5 50000 0.120194 8.969716418 30 
5 48000 0.120167 8.967664179 30 
5 46000 0.120184 8.968940299 30 
4 44000 0.120156 8.966873134 30 
4 42000 0.120038 8.958037313 30 
4 40000 0.119990 8.954455224 30 
4 38000 0.119940 8.950708955 30 
4 36000 0.119960 8.952208955 30 
3 34000 0.119818 8.941604478 30 
3 32000 0.119755 8.936925373 30 
3 30000 0.119683 8.931552239 30 
3 28000 0.119661 8.929925373 30 
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3 26000 0.119558 8.922246269 30 
2 24000 0.119323 8.904701493 30 
2 22000 0.119185 8.894380597 30 
2 20000 0.119106 8.888507463 30 
2 18000 0.118644 8.854029851 30 
2 16000 0.118547 8.846820896 30 
1 14000 0.118229 8.823037313 30 
1 12000 0.117797 8.790835821 30 
1 10000 0.117238 8.74908209 29 
1 8000 0.116369 8.684253731 29 
1 6000 0.115020 8.583559701 29 
0 4000 0.112310 8.381313433 28 
0 2000 0.104726 7.815358209 26 
0 0 0.050367 3.758716418 13 
0 -2000 -0.101895 -7.604067164 -26 
0 -4000 -0.112158 -8.369992537 -28 
-1 -6000 -0.114919 -8.576007463 -29 
-1 -8000 -0.116376 -8.684776119 -29 
-1 -10000 -0.117233 -8.748761194 -29 
-1 -12000 -0.117808 -8.791656716 -30 
-1 -14000 -0.118235 -8.823470149 -30 
-2 -16000 -0.118562 -8.847895522 -30 
-2 -18000 -0.118826 -8.867626866 -30 
-2 -20000 -0.119039 -8.883470149 -30 
-2 -22000 -0.119216 -8.896738806 -30 
-2 -24000 -0.119370 -8.908223881 -30 
-3 -26000 -0.119499 -8.917858209 -30 
-3 -28000 -0.119609 -8.926037313 -30 
-3 -30000 -0.119719 -8.934276119 -30 
-3 -32000 -0.119798 -8.940141791 -30 
-3 -34000 -0.119866 -8.945253731 -30 
-4 -36000 -0.119933 -8.950253731 -30 
-4 -38000 -0.119991 -8.954529851 -30 
-4 -40000 -0.120035 -8.957828358 -30 
-4 -42000 -0.120081 -8.961253731 -30 
-4 -44000 -0.120062 -8.959850746 -30 
-5 -46000 -0.120064 -8.959985075 -30 
-5 -48000 -0.120100 -8.962649254 -30 
-5 -50000 -0.120121 -8.964276119 -30 
-5 -48000 -0.120208 -8.970708955 -30 
-5 -46000 -0.120093 -8.962164179 -30 
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-4 -44000 -0.120167 -8.967701493 -30 
-4 -42000 -0.120030 -8.957432836 -30 
-4 -40000 -0.119990 -8.9545 -30 
-4 -38000 -0.119949 -8.95141791 -30 
-4 -36000 -0.119873 -8.945708955 -30 
-3 -34000 -0.119809 -8.941 -30 
-3 -32000 -0.119745 -8.936208955 -30 
-3 -30000 -0.119570 -8.923156716 -30 
-3 -28000 -0.119579 -8.923791045 -30 
-3 -26000 -0.119468 -8.915492537 -30 
-2 -24000 -0.119352 -8.906835821 -30 
-2 -22000 -0.119202 -8.895701493 -30 
-2 -20000 -0.119028 -8.882679104 -30 
-2 -18000 -0.118901 -8.873238806 -30 
-2 -16000 -0.118665 -8.85558209 -30 
-1 -14000 -0.118333 -8.830813433 -30 
-1 -12000 -0.117818 -8.792350746 -30 
-1 -10000 -0.117236 -8.748955224 -29 
-1 -8000 -0.116395 -8.686186567 -29 
-1 -6000 -0.115027 -8.584097015 -29 
0 -4000 -0.112366 -8.385522388 -28 
0 -2000 -0.104811 -7.821738806 -26 
0 0 -0.050509 -3.769322388 -13 
0 2000 0.101943 7.607686567 26 
0 4000 0.112185 8.371977612 28 
1 6000 0.114957 8.578843284 29 
1 8000 0.116333 8.681567164 29 
1 10000 0.117180 8.744776119 29 
1 12000 0.117770 8.78880597 30 
1 14000 0.118184 8.819686567 30 
2 16000 0.118512 8.844164179 30 
2 18000 0.118860 8.87011194 30 
2 20000 0.119075 8.886179104 30 
2 22000 0.119173 8.893529851 30 
2 24000 0.119326 8.90491791 30 
3 26000 0.119451 8.914261194 30 
3 28000 0.119566 8.922820896 30 
0 0 0.000151 0.011250716 0 
0 200 0.017880 1.334332836 4 
0 400 0.040280 3.005965672 10 
0 600 0.056294 4.20101791 14 
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0 800 0.072551 5.414270149 18 
0 1000 0.084247 6.287104478 21 
0 1200 0.089007 6.642319403 22 
0 1400 0.093032 6.942686567 23 
0 1600 0.097777 7.296777612 25 
0 1800 0.101300 7.559671642 25 
0 2000 0.103840 7.749283582 26 
0 2200 0.105243 7.85391791 26 
0 2400 0.106446 7.943716418 27 
0 2600 0.107460 8.019373134 27 
0 2800 0.108348 8.085701493 27 
0 3000 0.109268 8.154320896 27 
0 4000 0.112207 8.373619403 28 
1 5000 0.113819 8.49391791 29 
1 6000 0.114937 8.577402985 29 
1 7000 0.115709 8.635014925 29 
1 8000 0.116301 8.679171642 29 
1 9000 0.116770 8.714171642 29 
1 10000 0.117153 8.742723881 29 
1 7500 0.116034 8.659276119 29 
1 5000 0.113879 8.498410448 29 
0 2500 0.107617 8.031119403 27 
0 2000 0.104699 7.81338806 26 
0 1800 0.103169 7.699156716 26 
0 1600 0.101357 7.563962687 25 
0 1400 0.099134 7.398079851 25 
0 1200 0.096405 7.194418657 24 
0 1000 0.093037 6.943031343 23 
0 800 0.088831 6.629208209 22 
0 600 0.083529 6.233526866 21 
0 400 0.076457 5.705710448 19 
0 200 0.066615 4.971302239 17 
0 0 0.050755 3.787665672 13 
0 -200 0.022166 1.65414403 6 
0 -2500 -0.106425 -7.942149254 -27 
-1 -5000 -0.113822 -8.494156716 -29 
-1 -7500 -0.116016 -8.657940299 -29 
-1 -10000 -0.117143 -8.742014925 -29 
-1 -7500 -0.116031 -8.659044776 -29 
-1 -5000 -0.113892 -8.49941791 -29 
0 -2500 -0.107678 -8.035664179 -27 
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0 -2000 -0.104781 -7.819485075 -26 
0 -1750 -0.102851 -7.675477612 -26 
0 -1500 -0.100396 -7.492246269 -25 
0 -1250 -0.097229 -7.255926119 -24 
0 -1000 -0.093200 -6.9552 -23 
0 -750 -0.087833 -6.554697015 -22 
0 -500 -0.080514 -6.008475373 -20 
0 -250 -0.069756 -5.205669403 -17 
0 0 -0.051113 -3.814380597 -13 
0 250 -0.014031 -1.047079104 -4 
0 500 0.026143 1.950981343 7 
0 750 0.055388 4.133420896 14 
0 1000 0.073985 5.521284328 19 
0 1250 0.085606 6.388540299 21 
0 1500 0.093135 6.950382836 23 
0 1750 0.098216 7.329585075 25 
0 2000 0.101830 7.599276119 26 
0 2250 0.104486 7.797455224 26 
0 2500 0.106469 7.945410448 27 
0 2750 0.107992 8.059104478 27 
0 3000 0.109194 8.148783582 27 
0 -200 0.021875 1.632489552 5 
0 -400 -0.011523 -0.859936567 -3 
0 -600 -0.039866 -2.975041045 -10 
0 -800 -0.060328 -4.502123881 -15 
0 -1000 -0.074446 -5.555673134 -19 
0 -1200 -0.084267 -6.288580597 -21 
0 -1400 -0.091103 -6.798732836 -23 
0 -1600 -0.096020 -7.16565597 -24 
0 -1800 -0.099634 -7.435385075 -25 
0 -2000 -0.102383 -7.640514925 -26 
 
 
 
 
Table 9:  M(H) Data for US-tube Nanocapsules. 
 
Field (T) Field (Oe) Long Moment (emu) emu/g emu/g of catalyst 
0 0 0.007206267 0.439406524 24.651981 
0 100 0.009309825 0.567672256 31.848060 
0 200 0.0119883 0.730993902 41.010878 
131 
0 300 0.01458613 0.889398171 49.897817 
0 400 0.01654984 1.009136585 56.615490 
0 500 0.01821808 1.110858537 62.322386 
0 600 0.01966613 1.199154268 67.276033 
0 700 0.02092132 1.275690244 71.569923 
0 800 0.02202822 1.343184146 75.356527 
0 900 0.02299573 1.402178659 78.666290 
0 1000 0.023848 1.454146341 81.581828 
0 2000 0.02978714 1.816289024 101.899083 
0 4000 0.0323492 1.972512195 110.663656 
1 6000 0.03337728 2.0352 114.180624 
1 8000 0.03409056 2.078692683 116.620690 
1 10000 0.03466011 2.113421341 118.569068 
1 12000 0.03516192 2.144019512 120.285714 
1 14000 0.03560226 2.170869512 121.792077 
2 16000 0.03601002 2.195732927 123.186987 
2 18000 0.03638837 2.218803049 124.481288 
2 20000 0.03674952 2.24082439 125.716749 
2 22000 0.03707451 2.260640854 126.828510 
2 24000 0.03737551 2.278994512 127.858203 
3 26000 0.03765223 2.295867683 128.804837 
3 28000 0.03790776 2.31144878 129.678982 
3 30000 0.03813078 2.325047561 130.441913 
3 32000 0.0383482 2.338304878 131.185687 
3 34000 0.03855152 2.350702439 131.881226 
4 36000 0.0387284 2.361487805 132.486316 
4 38000 0.03889152 2.371434146 133.044335 
4 40000 0.03903016 2.379887805 133.518610 
4 42000 0.03919085 2.389685976 134.068316 
4 44000 0.03930434 2.396606098 134.456554 
5 46000 0.0394347 2.404554878 134.902504 
5 48000 0.03952765 2.410222561 135.220478 
5 50000 0.03965056 2.417717073 135.640941 
5 48000 0.03955506 2.411893902 135.314245 
5 46000 0.03944436 2.405143902 134.935550 
4 44000 0.03933035 2.398192073 134.545532 
4 42000 0.03919285 2.389807927 134.075157 
4 40000 0.03905559 2.381438415 133.605603 
4 38000 0.03889159 2.371438415 133.044574 
4 36000 0.03872806 2.361467073 132.485153 
3 34000 0.03856011 2.35122622 131.910612 
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3 32000 0.03835836 2.33892439 131.220443 
3 30000 0.03815059 2.326255488 130.509681 
3 28000 0.03791591 2.311945732 129.706862 
3 26000 0.03766305 2.296527439 128.841851 
2 24000 0.03738273 2.279434756 127.882902 
2 22000 0.03708943 2.26155061 126.879550 
2 20000 0.03675662 2.241257317 125.741037 
2 18000 0.03640343 2.219721341 124.532807 
2 16000 0.03602979 2.196938415 123.254618 
1 14000 0.0356213 2.172030488 121.857211 
1 12000 0.03517716 2.14494878 120.337849 
1 10000 0.03468534 2.114959756 118.655378 
1 8000 0.03411804 2.080368293 116.714696 
1 6000 0.0334182 2.037695122 114.320608 
0 4000 0.03242111 1.976896951 110.909654 
0 2000 0.03025973 1.845105488 103.515770 
0 0 0.01297439 0.791121341 44.384202 
0 -2000 -0.02968115 -1.80982622 -101.536501 
0 -4000 -0.03233251 -1.971494512 -110.606561 
-1 -6000 -0.0333843 -2.035628049 -114.204639 
-1 -8000 -0.0340906 -2.078695122 -116.620826 
-1 -10000 -0.0346607 -2.113457317 -118.571086 
-1 -12000 -0.03515934 -2.143862195 -120.276888 
-1 -14000 -0.03560541 -2.171061585 -121.802853 
-2 -16000 -0.03601295 -2.195911585 -123.197010 
-2 -18000 -0.0363918 -2.219012195 -124.493021 
-2 -20000 -0.03674375 -2.240472561 -125.697010 
-2 -22000 -0.03707252 -2.260519512 -126.821702 
-2 -24000 -0.03737737 -2.279107927 -127.864566 
-3 -26000 -0.03765699 -2.296157927 -128.821121 
-3 -28000 -0.03790281 -2.311146951 -129.662048 
-3 -30000 -0.03813417 -2.325254268 -130.453510 
-3 -32000 -0.03834959 -2.338389634 -131.190442 
-3 -34000 -0.03854722 -2.350440244 -131.866516 
-4 -36000 -0.03873435 -2.36185061 -132.506671 
-4 -38000 -0.03889001 -2.371342073 -133.039169 
-4 -40000 -0.03904624 -2.380868293 -133.573618 
-4 -42000 -0.03918617 -2.38940061 -134.052306 
-4 -44000 -0.03931521 -2.397268902 -134.493740 
-5 -46000 -0.03945867 -2.406016463 -134.984503 
-5 -48000 -0.03954424 -2.411234146 -135.277230 
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-5 -50000 -0.03964573 -2.417422561 -135.624418 
-5 -50000 -0.03962424 -2.416112195 -135.550903 
-5 -48000 -0.03955354 -2.41180122 -135.309045 
-5 -46000 -0.03944484 -2.405173171 -134.937192 
-4 -44000 -0.03931826 -2.397454878 -134.504174 
-4 -42000 -0.03919797 -2.390120122 -134.092672 
-4 -40000 -0.03908606 -2.383296341 -133.709839 
-4 -38000 -0.03890988 -2.372553659 -133.107143 
-4 -36000 -0.03873839 -2.362096951 -132.520491 
-3 -34000 -0.03855655 -2.351009146 -131.898433 
-3 -32000 -0.03835992 -2.339019512 -131.225780 
-3 -30000 -0.03817092 -2.327495122 -130.579228 
-3 -28000 -0.03791258 -2.311742683 -129.695471 
-3 -26000 -0.03766233 -2.296483537 -128.839388 
-2 -24000 -0.03738474 -2.279557317 -127.889778 
-2 -22000 -0.03707885 -2.260905488 -126.843357 
-2 -20000 -0.03676147 -2.241553049 -125.757629 
-2 -18000 -0.03640417 -2.219766463 -124.535338 
-2 -16000 -0.03602747 -2.196796951 -123.246682 
-1 -14000 -0.03562053 -2.171983537 -121.854577 
-1 -12000 -0.03517669 -2.144920122 -120.336241 
-1 -10000 -0.03468146 -2.114723171 -118.642105 
-1 -8000 -0.03411801 -2.080366463 -116.714594 
-1 -6000 -0.03341917 -2.037754268 -114.323926 
0 -4000 -0.03241594 -1.976581707 -110.891968 
0 -2000 -0.03026116 -1.845192683 -103.520662 
0 0 -0.01300334 -0.792886585 -44.483238 
0 2000 0.02967516 1.809460976 101.516010 
0 4000 0.03233261 1.97150061 110.606903 
1 6000 0.03337687 2.035175 114.179221 
1 8000 0.03408342 2.078257317 116.596264 
1 10000 0.03466186 2.113528049 118.575055 
1 12000 0.03515979 2.143889634 120.278428 
1 14000 0.03560569 2.171078659 121.803811 
2 16000 0.03601271 2.195896951 123.196189 
2 18000 0.03638897 2.218839634 124.483340 
2 20000 0.03674504 2.24055122 125.701423 
2 22000 0.03707625 2.260746951 126.834462 
2 24000 0.03737444 2.278929268 127.854543 
3 26000 0.03765122 2.295806098 128.801382 
3 28000 0.03790955 2.311557927 129.685105 
134 
3 30000 0.03813174 2.325106098 130.445197 
3 32000 0.03833687 2.337614024 131.146928 
3 34000 0.03854309 2.350188415 131.852388 
4 36000 0.03872627 2.361357927 132.479030 
4 38000 0.0388899 2.371335366 133.038793 
4 40000 0.03903876 2.380412195 133.548030 
4 42000 0.0391824 2.389170732 134.039409 
4 44000 0.03930926 2.396906098 134.473385 
5 46000 0.03940902 2.402989024 134.814655 
5 48000 0.0395023 2.408676829 135.133758 
 
 
 
 
 
 
Table 10:  M(H) Data for GNTs. 
 
Field (Oe) Temp (K) Long Moment (emu) emu/g emu/g of catalyst 
0 5 0.005172031 0.315367744 25.437886 
100 5 0.006704644 0.408819756 32.975821 
200 5 0.00861478 0.525291463 42.370549 
300 5 0.01048227 0.639162805 51.555528 
400 5 0.01190106 0.72567439 58.533642 
500 5 0.01310437 0.799046951 64.451948 
600 5 0.01416125 0.863490854 69.650059 
700 5 0.01505289 0.917859146 74.035461 
800 5 0.0158538 0.966695122 77.974621 
900 5 0.01654783 1.009014024 81.388107 
1000 5 0.01717349 1.047164024 84.465326 
2000 5 0.0214734 1.309353659 105.613811 
4000 5 0.02328765 1.419978659 114.536937 
6000 5 0.02399894 1.46335 118.035314 
8000 5 0.02449423 1.49355061 120.471326 
10000 5 0.02488873 1.517605488 122.411617 
12000 5 0.02522589 1.538164024 124.069890 
14000 5 0.02552768 1.556565854 125.554200 
16000 5 0.02579338 1.572767073 126.861007 
18000 5 0.02604643 1.588196951 128.105597 
20000 5 0.02628165 1.602539634 129.262493 
22000 5 0.02649947 1.615821341 130.333809 
24000 5 0.02670329 1.62824939 131.336268 
26000 5 0.02687302 1.63859878 132.171060 
135 
28000 5 0.02703905 1.648722561 132.987655 
30000 5 0.02718716 1.657753659 133.716113 
32000 5 0.02730373 1.664861585 134.289445 
34000 5 0.02744873 1.673703049 135.002607 
36000 5 0.02756098 1.680547561 135.554692 
38000 5 0.02766357 1.686803049 136.059266 
40000 5 0.02775994 1.692679268 136.533248 
42000 5 0.02780606 1.695491463 136.760083 
44000 5 0.02792305 1.702625 137.335481 
46000 5 0.02798032 1.706117073 137.617155 
48000 5 0.02811337 1.714229878 138.271542 
50000 5 0.02813486 1.715540244 138.377238 
48000 5 0.02805435 1.710631098 137.981261 
46000 5 0.0279885 1.706615854 137.657387 
44000 5 0.02792157 1.702534756 137.328202 
42000 5 0.02786144 1.698868293 137.032461 
40000 5 0.02778209 1.694029878 136.642190 
38000 5 0.02766111 1.686653049 136.047167 
36000 5 0.02756769 1.680956707 135.587694 
34000 5 0.02746516 1.674704878 135.083415 
32000 5 0.02733201 1.666585976 134.428536 
30000 5 0.02719778 1.65840122 133.768345 
28000 5 0.02706758 1.650462195 133.127976 
26000 5 0.02687885 1.638954268 132.199734 
24000 5 0.02670642 1.628440244 131.351662 
22000 5 0.02651032 1.616482927 130.387173 
20000 5 0.0262789 1.602371951 129.248967 
18000 5 0.02605966 1.589003659 128.170667 
16000 5 0.02581602 1.574147561 126.972359 
14000 5 0.02553857 1.557229878 125.607761 
12000 5 0.02524054 1.539057317 124.141944 
10000 5 0.02490484 1.518587805 122.490852 
8000 5 0.02451908 1.495065854 120.593547 
6000 5 0.02404032 1.465873171 118.238835 
4000 5 0.02333865 1.423088415 114.787773 
2000 5 0.02181036 1.3299 107.271100 
0 5 0.009276926 0.56566622 45.627218 
-2000 5 -0.02139143 -1.304355488 -105.210653 
-4000 5 -0.0232859 -1.419871951 -114.528330 
-6000 5 -0.02401088 -1.464078049 -118.094039 
-8000 5 -0.02450444 -1.494173171 -120.521542 
136 
-10000 5 -0.02487997 -1.517071341 -122.368532 
-12000 5 -0.02522362 -1.53802561 -124.058725 
-14000 5 -0.02552399 -1.556340854 -125.536052 
-16000 5 -0.02579701 -1.572988415 -126.878861 
-18000 5 -0.02604836 -1.588314634 -128.115090 
-20000 5 -0.02628359 -1.602657927 -129.272034 
-22000 5 -0.02649885 -1.615783537 -130.330759 
-24000 5 -0.02669388 -1.62767561 -131.289986 
-26000 5 -0.0268734 -1.638621951 -132.172929 
-28000 5 -0.02703936 -1.648741463 -132.989180 
-30000 5 -0.02719149 -1.658017683 -133.737409 
-32000 5 -0.02731079 -1.665292073 -134.324169 
-34000 5 -0.02744798 -1.673657317 -134.998918 
-36000 5 -0.02754024 -1.679282927 -135.452685 
-38000 5 -0.02766301 -1.686768902 -136.056512 
-40000 5 -0.02776318 -1.692876829 -136.549184 
-42000 5 -0.02784291 -1.697738415 -136.941324 
-44000 5 -0.02791467 -1.702114024 -137.294265 
-46000 5 -0.02798152 -1.706190244 -137.623057 
-48000 5 -0.02804758 -1.710218293 -137.947964 
-50000 5 -0.02810264 -1.71357561 -138.218768 
-50000 5 -0.02809338 -1.713010976 -138.173224 
-48000 5 -0.02804987 -1.710357927 -137.959227 
-46000 5 -0.02799214 -1.706837805 -137.675290 
-44000 5 -0.0279191 -1.702384146 -137.316054 
-42000 5 -0.02784795 -1.698045732 -136.966113 
-40000 5 -0.02774129 -1.691542073 -136.441521 
-38000 5 -0.02766639 -1.686975 -136.073136 
-36000 5 -0.02756868 -1.681017073 -135.592563 
-34000 5 -0.02745612 -1.674153659 -135.038953 
-32000 5 -0.02733267 -1.66662622 -134.431782 
-30000 5 -0.02719603 -1.658294512 -133.759738 
-28000 5 -0.02705455 -1.649667683 -133.063889 
-26000 5 -0.02688635 -1.639411585 -132.236622 
-24000 5 -0.02670639 -1.628438415 -131.351515 
-22000 5 -0.02651096 -1.616521951 -130.390321 
-20000 5 -0.02629509 -1.603359146 -129.328595 
-18000 5 -0.0260617 -1.589128049 -128.180700 
-16000 5 -0.02581024 -1.573795122 -126.943931 
-14000 5 -0.02553941 -1.557281098 -125.611893 
-12000 5 -0.0252411 -1.539091463 -124.144698 
137 
-10000 5 -0.02490974 -1.518886585 -122.514952 
-8000 5 -0.02452358 -1.495340244 -120.615680 
-6000 5 -0.02403903 -1.465794512 -118.232491 
-4000 5 -0.02335182 -1.423891463 -114.852548 
-2000 5 -0.02182169 -1.330590854 -107.326825 
0 5 -0.009314422 -0.567952561 -45.811637 
2000 5 0.02139782 1.304745122 105.242081 
4000 5 0.0233115 1.421432927 114.654240 
6000 5 0.02401863 1.46455061 118.132156 
8000 5 0.02450396 1.494143902 120.519182 
10000 5 0.02488248 1.51722439 122.380877 
12000 5 0.02523069 1.538456707 124.093498 
14000 5 0.02553066 1.556747561 125.568857 
16000 5 0.02580276 1.573339024 126.907141 
18000 5 0.02605583 1.588770122 128.151830 
20000 5 0.02628929 1.603005488 129.300069 
22000 5 0.02650613 1.616227439 130.366565 
24000 5 0.02670128 1.628126829 131.326382 
26000 5 0.02688735 1.639472561 132.241540 
28000 5 0.02704095 1.648838415 132.997000 
30000 5 0.02719071 1.657970122 133.733573 
32000 5 0.02731798 1.665730488 134.359532 
34000 5 0.02745407 1.674028659 135.028871 
36000 5 0.02757904 1.68164878 135.643518 
38000 5 0.02766428 1.686846341 136.062758 
40000 5 0.02773483 1.691148171 136.409748 
42000 5 0.02784691 1.697982317 136.960997 
44000 5 0.02779741 1.694964024 136.717539 
46000 5 0.02795679 1.704682317 137.501426 
48000 5 0.02805154 1.710459756 137.967440 
 
 
 
 
Table 11:  M(H) Data for LNTs. 
 
Field (Oe) Temp (K) Long Moment (emu) emu/g emu/g of catalyst 
0 5 0.005172031 0.315367744 25.437886 
100 5 0.006704644 0.408819756 32.975821 
200 5 0.00861478 0.525291463 42.370549 
300 5 0.01048227 0.639162805 51.555528 
400 5 0.01190106 0.72567439 58.533642 
138 
500 5 0.01310437 0.799046951 64.451948 
600 5 0.01416125 0.863490854 69.650059 
700 5 0.01505289 0.917859146 74.035461 
800 5 0.0158538 0.966695122 77.974621 
900 5 0.01654783 1.009014024 81.388107 
1000 5 0.01717349 1.047164024 84.465326 
2000 5 0.0214734 1.309353659 105.613811 
4000 5 0.02328765 1.419978659 114.536937 
6000 5 0.02399894 1.46335 118.035314 
8000 5 0.02449423 1.49355061 120.471326 
10000 5 0.02488873 1.517605488 122.411617 
12000 5 0.02522589 1.538164024 124.069890 
14000 5 0.02552768 1.556565854 125.554200 
16000 5 0.02579338 1.572767073 126.861007 
18000 5 0.02604643 1.588196951 128.105597 
20000 5 0.02628165 1.602539634 129.262493 
22000 5 0.02649947 1.615821341 130.333809 
24000 5 0.02670329 1.62824939 131.336268 
26000 5 0.02687302 1.63859878 132.171060 
28000 5 0.02703905 1.648722561 132.987655 
30000 5 0.02718716 1.657753659 133.716113 
32000 5 0.02730373 1.664861585 134.289445 
34000 5 0.02744873 1.673703049 135.002607 
36000 5 0.02756098 1.680547561 135.554692 
38000 5 0.02766357 1.686803049 136.059266 
40000 5 0.02775994 1.692679268 136.533248 
42000 5 0.02780606 1.695491463 136.760083 
44000 5 0.02792305 1.702625 137.335481 
46000 5 0.02798032 1.706117073 137.617155 
48000 5 0.02811337 1.714229878 138.271542 
50000 5 0.02813486 1.715540244 138.377238 
48000 5 0.02805435 1.710631098 137.981261 
46000 5 0.0279885 1.706615854 137.657387 
44000 5 0.02792157 1.702534756 137.328202 
42000 5 0.02786144 1.698868293 137.032461 
40000 5 0.02778209 1.694029878 136.642190 
38000 5 0.02766111 1.686653049 136.047167 
36000 5 0.02756769 1.680956707 135.587694 
34000 5 0.02746516 1.674704878 135.083415 
32000 5 0.02733201 1.666585976 134.428536 
30000 5 0.02719778 1.65840122 133.768345 
139 
28000 5 0.02706758 1.650462195 133.127976 
26000 5 0.02687885 1.638954268 132.199734 
24000 5 0.02670642 1.628440244 131.351662 
22000 5 0.02651032 1.616482927 130.387173 
20000 5 0.0262789 1.602371951 129.248967 
18000 5 0.02605966 1.589003659 128.170667 
16000 5 0.02581602 1.574147561 126.972359 
14000 5 0.02553857 1.557229878 125.607761 
12000 5 0.02524054 1.539057317 124.141944 
10000 5 0.02490484 1.518587805 122.490852 
8000 5 0.02451908 1.495065854 120.593547 
6000 5 0.02404032 1.465873171 118.238835 
4000 5 0.02333865 1.423088415 114.787773 
2000 5 0.02181036 1.3299 107.271100 
0 5 0.009276926 0.56566622 45.627218 
-2000 5 -0.02139143 -1.304355488 -105.210653 
-4000 5 -0.0232859 -1.419871951 -114.528330 
-6000 5 -0.02401088 -1.464078049 -118.094039 
-8000 5 -0.02450444 -1.494173171 -120.521542 
-10000 5 -0.02487997 -1.517071341 -122.368532 
-12000 5 -0.02522362 -1.53802561 -124.058725 
-14000 5 -0.02552399 -1.556340854 -125.536052 
-16000 5 -0.02579701 -1.572988415 -126.878861 
-18000 5 -0.02604836 -1.588314634 -128.115090 
-20000 5 -0.02628359 -1.602657927 -129.272034 
-22000 5 -0.02649885 -1.615783537 -130.330759 
-24000 5 -0.02669388 -1.62767561 -131.289986 
-26000 5 -0.0268734 -1.638621951 -132.172929 
-28000 5 -0.02703936 -1.648741463 -132.989180 
-30000 5 -0.02719149 -1.658017683 -133.737409 
-32000 5 -0.02731079 -1.665292073 -134.324169 
-34000 5 -0.02744798 -1.673657317 -134.998918 
-36000 5 -0.02754024 -1.679282927 -135.452685 
-38000 5 -0.02766301 -1.686768902 -136.056512 
-40000 5 -0.02776318 -1.692876829 -136.549184 
-42000 5 -0.02784291 -1.697738415 -136.941324 
-44000 5 -0.02791467 -1.702114024 -137.294265 
-46000 5 -0.02798152 -1.706190244 -137.623057 
-48000 5 -0.02804758 -1.710218293 -137.947964 
-50000 5 -0.02810264 -1.71357561 -138.218768 
-50000 5 -0.02809338 -1.713010976 -138.173224 
140 
-48000 5 -0.02804987 -1.710357927 -137.959227 
-46000 5 -0.02799214 -1.706837805 -137.675290 
-44000 5 -0.0279191 -1.702384146 -137.316054 
-42000 5 -0.02784795 -1.698045732 -136.966113 
-40000 5 -0.02774129 -1.691542073 -136.441521 
-38000 5 -0.02766639 -1.686975 -136.073136 
-36000 5 -0.02756868 -1.681017073 -135.592563 
-34000 5 -0.02745612 -1.674153659 -135.038953 
-32000 5 -0.02733267 -1.66662622 -134.431782 
-30000 5 -0.02719603 -1.658294512 -133.759738 
-28000 5 -0.02705455 -1.649667683 -133.063889 
-26000 5 -0.02688635 -1.639411585 -132.236622 
-24000 5 -0.02670639 -1.628438415 -131.351515 
-22000 5 -0.02651096 -1.616521951 -130.390321 
-20000 5 -0.02629509 -1.603359146 -129.328595 
-18000 5 -0.0260617 -1.589128049 -128.180700 
-16000 5 -0.02581024 -1.573795122 -126.943931 
-14000 5 -0.02553941 -1.557281098 -125.611893 
-12000 5 -0.0252411 -1.539091463 -124.144698 
-10000 5 -0.02490974 -1.518886585 -122.514952 
-8000 5 -0.02452358 -1.495340244 -120.615680 
-6000 5 -0.02403903 -1.465794512 -118.232491 
-4000 5 -0.02335182 -1.423891463 -114.852548 
-2000 5 -0.02182169 -1.330590854 -107.326825 
0 5 -0.009314422 -0.567952561 -45.811637 
2000 5 0.02139782 1.304745122 105.242081 
4000 5 0.0233115 1.421432927 114.654240 
6000 5 0.02401863 1.46455061 118.132156 
8000 5 0.02450396 1.494143902 120.519182 
10000 5 0.02488248 1.51722439 122.380877 
12000 5 0.02523069 1.538456707 124.093498 
14000 5 0.02553066 1.556747561 125.568857 
16000 5 0.02580276 1.573339024 126.907141 
18000 5 0.02605583 1.588770122 128.151830 
20000 5 0.02628929 1.603005488 129.300069 
22000 5 0.02650613 1.616227439 130.366565 
24000 5 0.02670128 1.628126829 131.326382 
26000 5 0.02688735 1.639472561 132.241540 
28000 5 0.02704095 1.648838415 132.997000 
30000 5 0.02719071 1.657970122 133.733573 
32000 5 0.02731798 1.665730488 134.359532 
141 
34000 5 0.02745407 1.674028659 135.028871 
36000 5 0.02757904 1.68164878 135.643518 
38000 5 0.02766428 1.686846341 136.062758 
40000 5 0.02773483 1.691148171 136.409748 
42000 5 0.02784691 1.697982317 136.960997 
44000 5 0.02779741 1.694964024 136.717539 
46000 5 0.02795679 1.704682317 137.501426 
48000 5 0.02805154 1.710459756 137.967440 
 
 
 
 
Table 12:  M(T) Data for raw SWNTs. 
 
Field (Oe) Temperature (K) Long Moment (emu) emu/g emu/g of catalyst 
1000 2 0.077045 5.749621642 19.319965 
1000 3 0.078205 5.83619403 19.610867 
1000 4 0.079043 5.898707463 19.820926 
1000 5 0.079783 5.953990299 20.006688 
1000 6 0.080505 6.007842537 20.187643 
1000 7 0.081200 6.059696269 20.361883 
1000 8 0.081647 6.093047015 20.473948 
1000 9 0.082119 6.128264179 20.592286 
1000 10 0.082538 6.159542537 20.697388 
1000 2 0.080789 6.029030597 20.258839 
1000 3 0.081322 6.068827612 20.392566 
1000 4 0.081815 6.105616418 20.516184 
1000 5 0.082145 6.130259701 20.598991 
1000 6 0.082478 6.155087313 20.682417 
1000 7 0.082804 6.179437313 20.764238 
1000 8 0.082989 6.193201493 20.810489 
1000 9 0.083198 6.208786567 20.862858 
1000 10 0.083403 6.22408209 20.914254 
1000 15 0.084397 6.29830597 21.163663 
1000 20 0.085144 6.354016418 21.350862 
1000 25 0.085694 6.395041045 21.488713 
1000 30 0.086037 6.420700746 21.574935 
1000 35 0.086331 6.44264403 21.648669 
1000 40 0.086554 6.459254478 21.704484 
1000 45 0.086706 6.470570149 21.742507 
1000 50 0.086797 6.477389552 21.765422 
1000 55 0.086844 6.480904478 21.777233 
1000 60 0.086858 6.481945522 21.780731 
142 
1000 65 0.086839 6.480495522 21.775859 
1000 70 0.086788 6.476723881 21.763185 
1000 75 0.086714 6.471189552 21.744589 
1000 80 0.086614 6.463720149 21.719490 
1000 85 0.086490 6.45448209 21.688448 
1000 90 0.086341 6.443332836 21.650984 
1000 95 0.086178 6.431181343 21.610152 
1000 100 0.085998 6.41776194 21.565060 
1000 2 0.091302 6.813595522 22.895146 
1000 3 0.091250 6.809689552 22.882021 
1000 4 0.091177 6.804270896 22.863813 
1000 5 0.091131 6.800841791 22.852291 
1000 6 0.091080 6.796998507 22.839377 
1000 7 0.091031 6.793342537 22.827092 
1000 8 0.090981 6.78961791 22.814576 
1000 9 0.090929 6.785735075 22.801529 
1000 10 0.090880 6.78209403 22.789294 
1000 15 0.090641 6.764248507 22.729330 
1000 20 0.090402 6.746430597 22.669458 
1000 25 0.090162 6.728502985 22.609217 
1000 30 0.089918 6.710291045 22.548021 
1000 35 0.089666 6.691523881 22.484959 
1000 40 0.089412 6.672546269 22.421190 
1000 45 0.089158 6.653553731 22.357371 
1000 50 0.088896 6.634058955 22.291865 
1000 55 0.088633 6.614373881 22.225719 
1000 60 0.088366 6.594476119 22.158858 
1000 65 0.088095 6.574239552 22.090859 
1000 70 0.087822 6.553856716 22.022368 
1000 75 0.087544 6.533162687 21.952832 
1000 80 0.087259 6.511849254 21.881214 
1000 85 0.086969 6.490248507 21.808631 
1000 90 0.086675 6.468272388 21.734786 
1000 95 0.086377 6.446009701 21.659979 
1000 100 0.086090 6.424660448 21.588241 
1000 105 0.085861 6.407548507 21.530741 
1000 110 0.085654 6.392117164 21.478888 
1000 115 0.085435 6.375764179 21.423939 
1000 120 0.085221 6.359775373 21.370213 
1000 125 0.085013 6.344229851 21.317977 
1000 130 0.084818 6.329729851 21.269254 
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1000 135 0.084642 6.316587313 21.225092 
1000 140 0.084490 6.305220149 21.186896 
1000 145 0.084360 6.295537313 21.154359 
1000 150 0.084238 6.286453731 21.123836 
1000 155 0.084121 6.277673134 21.094332 
1000 160 0.083992 6.268037313 21.061953 
1000 165 0.083877 6.259510448 21.033301 
1000 170 0.083762 6.250861194 21.004238 
1000 175 0.083636 6.241466418 20.972669 
1000 180 0.083499 6.231287313 20.938465 
1000 185 0.083374 6.221914179 20.906970 
1000 190 0.083236 6.211656716 20.872502 
1000 195 0.083079 6.199899254 20.832995 
1000 200 0.082934 6.189130597 20.796810 
1000 205 0.082748 6.17519403 20.749980 
1000 210 0.082560 6.161196269 20.702944 
1000 215 0.082394 6.148832836 20.661401 
1000 220 0.082191 6.133671642 20.610456 
1000 225 0.082016 6.120576119 20.566452 
1000 230 0.081834 6.106978358 20.520761 
1000 235 0.081644 6.092833582 20.473231 
1000 240 0.081430 6.07686194 20.419563 
1000 245 0.081210 6.060416418 20.364302 
1000 250 0.080976 6.042969403 20.305677 
1000 255 0.080721 6.023936567 20.241722 
1000 260 0.080444 6.003271642 20.172284 
1000 265 0.080140 5.980607463 20.096127 
1000 270 0.079844 5.958518657 20.021904 
1000 275 0.079519 5.934247015 19.940346 
1000 280 0.079192 5.909873134 19.858445 
1000 285 0.078869 5.885718657 19.777280 
1000 290 0.078564 5.862984328 19.700888 
1000 295 0.078249 5.839470149 19.621876 
1000 300 0.077919 5.814887313 19.539272 
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Table 13:  M(T) Data for US-tube nanocapsules. 
 
Field (Oe) Temperature (K) Long Moment (emu) emu/g 
10 5 0.090 0.739 
10 10 0.090 0.739 
10 15 0.090 0.741 
10 20 0.090 0.742 
10 25 0.090 0.744 
10 30 0.090 0.745 
10 35 0.090 0.744 
10 40 0.089 0.737 
10 45 0.088 0.725 
10 50 0.086 0.711 
10 55 0.085 0.697 
10 60 0.083 0.682 
10 65 0.081 0.667 
10 70 0.079 0.652 
10 75 0.077 0.638 
10 80 0.076 0.624 
10 85 0.074 0.610 
10 90 0.072 0.596 
10 95 0.071 0.583 
10 100 0.069 0.570 
10 105 0.068 0.558 
10 110 0.066 0.546 
10 115 0.065 0.536 
10 120 0.064 0.526 
10 125 0.063 0.516 
10 130 0.062 0.507 
10 135 0.061 0.499 
10 140 0.060 0.490 
10 145 0.059 0.483 
10 150 0.058 0.476 
10 155 0.057 0.470 
10 160 0.056 0.463 
10 165 0.056 0.457 
10 170 0.055 0.452 
10 176 0.054 0.446 
10 181 0.054 0.441 
10 186 0.053 0.436 
10 191 0.052 0.431 
10 196 0.052 0.426 
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10 201 0.051 0.422 
10 206 0.051 0.418 
10 211 0.050 0.413 
10 216 0.050 0.408 
10 221 0.049 0.404 
10 226 0.049 0.400 
10 231 0.048 0.396 
10 236 0.048 0.392 
10 241 0.047 0.389 
10 246 0.047 0.385 
10 251 0.046 0.382 
10 256 0.046 0.378 
10 261 0.045 0.374 
10 266 0.045 0.370 
10 271 0.045 0.367 
10 276 0.044 0.364 
10 281 0.044 0.360 
10 286 0.043 0.356 
10 291 0.043 0.353 
10 296 0.042 0.350 
10 301 0.042 0.346 
10 5 0.050 0.412 
10 10 0.050 0.411 
10 15 0.050 0.410 
10 20 0.050 0.409 
10 25 0.050 0.409 
10 30 0.050 0.408 
10 35 0.049 0.407 
10 40 0.049 0.406 
10 45 0.049 0.405 
10 50 0.049 0.404 
10 55 0.049 0.403 
10 60 0.049 0.402 
10 65 0.049 0.401 
10 70 0.049 0.401 
10 75 0.049 0.400 
10 80 0.048 0.399 
10 85 0.048 0.398 
10 90 0.048 0.397 
10 95 0.048 0.396 
10 100 0.048 0.395 
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10 105 0.048 0.394 
10 110 0.048 0.392 
10 115 0.048 0.392 
10 120 0.048 0.391 
10 125 0.047 0.390 
10 130 0.047 0.389 
10 135 0.047 0.388 
10 140 0.047 0.387 
10 145 0.047 0.385 
10 150 0.047 0.384 
10 155 0.047 0.384 
10 160 0.046 0.383 
10 165 0.046 0.379 
10 170 0.046 0.380 
10 175 0.046 0.379 
10 181 0.046 0.378 
10 186 0.046 0.377 
10 191 0.046 0.376 
10 196 0.045 0.375 
10 201 0.045 0.373 
10 206 0.045 0.372 
10 211 0.045 0.371 
10 216 0.045 0.370 
10 221 0.045 0.368 
10 226 0.045 0.367 
10 231 0.044 0.366 
10 236 0.044 0.364 
10 241 0.044 0.363 
10 246 0.044 0.362 
10 251 0.044 0.360 
10 256 0.044 0.359 
10 261 0.043 0.358 
10 266 0.043 0.356 
10 271 0.043 0.355 
10 276 0.043 0.353 
10 281 0.043 0.351 
10 286 0.042 0.350 
10 291 0.042 0.348 
10 296 0.042 0.346 
10 301 0.042 0.344 
100 5 0.054 0.447 
147 
100 10 0.055 0.456 
100 15 0.057 0.467 
100 20 0.058 0.477 
100 25 0.059 0.488 
100 30 0.061 0.499 
100 35 0.062 0.509 
100 40 0.063 0.518 
100 45 0.064 0.527 
100 50 0.065 0.536 
100 55 0.066 0.544 
100 60 0.067 0.553 
100 65 0.068 0.561 
100 70 0.069 0.569 
100 75 0.070 0.577 
100 80 0.071 0.584 
100 85 0.072 0.591 
100 90 0.073 0.599 
100 95 0.074 0.605 
100 100 0.074 0.612 
100 105 0.075 0.618 
100 110 0.076 0.624 
100 115 0.076 0.629 
100 120 0.077 0.635 
100 125 0.078 0.640 
100 130 0.078 0.645 
100 135 0.079 0.649 
100 140 0.079 0.654 
100 145 0.080 0.658 
100 150 0.080 0.662 
100 155 0.081 0.665 
100 160 0.081 0.669 
100 165 0.082 0.673 
100 170 0.082 0.676 
100 176 0.082 0.679 
100 181 0.083 0.682 
100 186 0.083 0.684 
100 191 0.083 0.686 
100 196 0.084 0.688 
100 201 0.084 0.690 
100 206 0.084 0.691 
100 211 0.084 0.693 
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100 216 0.084 0.694 
100 221 0.084 0.695 
100 226 0.084 0.695 
100 231 0.084 0.696 
100 236 0.085 0.696 
100 241 0.085 0.697 
100 246 0.085 0.697 
100 251 0.085 0.696 
100 256 0.085 0.696 
100 261 0.084 0.696 
100 266 0.084 0.695 
100 271 0.084 0.694 
100 276 0.084 0.694 
100 281 0.084 0.693 
100 286 0.084 0.691 
100 291 0.084 0.690 
100 296 0.084 0.689 
100 301 0.083 0.687 
100 5 0.093 0.767 
100 10 0.093 0.765 
100 15 0.093 0.764 
100 20 0.093 0.763 
100 25 0.092 0.761 
100 30 0.092 0.760 
100 35 0.092 0.759 
100 40 0.092 0.758 
100 45 0.092 0.757 
100 50 0.092 0.756 
100 55 0.092 0.755 
100 60 0.092 0.754 
100 65 0.091 0.753 
100 70 0.091 0.753 
100 75 0.091 0.752 
100 80 0.091 0.752 
100 85 0.091 0.751 
100 90 0.091 0.750 
100 95 0.091 0.749 
100 100 0.091 0.748 
100 105 0.091 0.747 
100 110 0.091 0.745 
100 115 0.090 0.744 
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100 120 0.090 0.743 
100 125 0.090 0.741 
100 130 0.090 0.740 
100 135 0.090 0.739 
100 140 0.090 0.737 
100 145 0.089 0.736 
100 150 0.089 0.734 
100 155 0.089 0.733 
100 160 0.089 0.732 
100 165 0.089 0.731 
100 170 0.089 0.730 
100 176 0.089 0.729 
100 181 0.088 0.728 
100 186 0.088 0.726 
100 191 0.088 0.725 
100 196 0.088 0.724 
100 201 0.088 0.722 
100 206 0.088 0.721 
100 211 0.087 0.720 
100 216 0.087 0.718 
100 221 0.087 0.717 
100 226 0.087 0.716 
100 231 0.087 0.714 
100 236 0.087 0.713 
100 241 0.086 0.711 
100 246 0.086 0.710 
100 251 0.086 0.708 
100 256 0.086 0.706 
100 261 0.086 0.705 
100 266 0.085 0.703 
100 271 0.085 0.701 
100 276 0.085 0.699 
100 281 0.085 0.697 
100 286 0.084 0.695 
100 291 0.084 0.693 
100 296 0.084 0.691 
100 301 0.084 0.689 
1000 5 0.200 1.647 
1000 10 0.201 1.652 
1000 15 0.201 1.657 
1000 20 0.202 1.660 
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1000 25 0.202 1.663 
1000 30 0.202 1.664 
1000 35 0.202 1.665 
1000 40 0.202 1.666 
1000 45 0.202 1.667 
1000 50 0.202 1.667 
1000 55 0.202 1.667 
1000 60 0.202 1.668 
1000 65 0.203 1.668 
1000 70 0.203 1.668 
1000 75 0.203 1.668 
1000 80 0.203 1.669 
1000 85 0.203 1.668 
1000 90 0.203 1.668 
1000 95 0.203 1.668 
1000 100 0.202 1.667 
1000 105 0.202 1.667 
1000 110 0.202 1.666 
1000 115 0.202 1.666 
1000 120 0.202 1.665 
1000 125 0.202 1.664 
1000 130 0.202 1.662 
1000 135 0.202 1.662 
1000 140 0.202 1.660 
1000 145 0.201 1.659 
1000 150 0.201 1.657 
1000 155 0.201 1.656 
1000 160 0.201 1.655 
1000 165 0.201 1.654 
1000 170 0.201 1.653 
1000 176 0.201 1.652 
1000 181 0.200 1.650 
1000 186 0.200 1.649 
1000 191 0.200 1.649 
1000 196 0.200 1.648 
1000 201 0.200 1.646 
1000 206 0.200 1.645 
1000 211 0.200 1.644 
1000 216 0.199 1.642 
1000 221 0.199 1.641 
1000 226 0.199 1.639 
151 
1000 231 0.199 1.637 
1000 236 0.199 1.635 
1000 241 0.198 1.633 
1000 246 0.198 1.631 
1000 251 0.198 1.630 
1000 256 0.198 1.628 
1000 261 0.197 1.625 
1000 266 0.197 1.623 
1000 271 0.197 1.621 
1000 276 0.197 1.619 
1000 281 0.196 1.616 
1000 286 0.196 1.614 
1000 291 0.196 1.611 
1000 296 0.195 1.608 
1000 301 0.195 1.605 
1000 5 0.206 1.699 
1000 10 0.206 1.694 
1000 15 0.205 1.691 
1000 20 0.205 1.690 
1000 25 0.205 1.689 
1000 30 0.205 1.688 
1000 35 0.205 1.687 
1000 40 0.205 1.685 
1000 45 0.205 1.684 
1000 50 0.204 1.683 
1000 55 0.204 1.682 
1000 60 0.204 1.681 
1000 65 0.204 1.680 
1000 70 0.204 1.680 
1000 75 0.204 1.679 
1000 80 0.204 1.678 
1000 85 0.204 1.677 
1000 90 0.204 1.676 
1000 95 0.203 1.676 
1000 100 0.203 1.675 
1000 105 0.203 1.674 
1000 110 0.203 1.673 
1000 115 0.203 1.671 
1000 120 0.203 1.671 
1000 125 0.203 1.669 
1000 130 0.202 1.667 
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1000 135 0.202 1.666 
1000 140 0.202 1.664 
1000 145 0.202 1.663 
1000 150 0.202 1.661 
1000 155 0.202 1.660 
1000 160 0.201 1.659 
1000 165 0.201 1.658 
1000 171 0.201 1.657 
1000 176 0.201 1.656 
1000 181 0.201 1.655 
1000 186 0.201 1.653 
1000 191 0.201 1.652 
1000 196 0.200 1.651 
1000 201 0.200 1.650 
1000 206 0.200 1.648 
1000 211 0.200 1.647 
1000 216 0.200 1.645 
1000 221 0.200 1.644 
1000 226 0.199 1.642 
1000 231 0.199 1.640 
1000 236 0.199 1.638 
 
 
 
 
 
 
Table 14:  M(T) Data for GNTs. 
 
Field (Oe) Temperature (K) Long Moment (emu) emu/g 
10 5 0.001 0.016 
10 10 0.001 0.016 
10 15 0.001 0.017 
10 20 0.001 0.019 
10 25 0.001 0.019 
10 30 0.001 0.023 
10 35 0.001 0.025 
10 40 0.001 0.027 
10 45 0.001 0.028 
10 50 0.001 0.030 
10 55 0.001 0.032 
10 60 0.001 0.034 
10 65 0.001 0.035 
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10 70 0.001 0.038 
10 75 0.001 0.039 
10 80 0.002 0.040 
10 85 0.002 0.042 
10 90 0.002 0.043 
10 95 0.002 0.044 
10 100 0.002 0.046 
10 105 0.002 0.047 
10 110 0.002 0.048 
10 115 0.002 0.050 
10 120 0.002 0.051 
10 125 0.002 0.052 
10 130 0.002 0.053 
10 135 0.002 0.054 
10 140 0.002 0.055 
10 145 0.002 0.057 
10 150 0.002 0.058 
10 155 0.002 0.059 
10 160 0.002 0.060 
10 165 0.002 0.061 
10 170 0.002 0.062 
10 175 0.002 0.063 
10 181 0.002 0.064 
10 186 0.002 0.065 
10 191 0.002 0.066 
10 196 0.003 0.067 
10 201 0.002 0.064 
10 206 0.003 0.068 
10 211 0.003 0.069 
10 216 0.003 0.070 
10 221 0.003 0.071 
10 226 0.003 0.072 
10 231 0.003 0.073 
10 236 0.003 0.073 
10 241 0.003 0.074 
10 246 0.003 0.075 
10 251 0.003 0.075 
10 256 0.003 0.083 
10 261 0.003 0.077 
10 266 0.003 0.079 
10 271 0.003 0.078 
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10 276 0.003 0.079 
10 281 0.003 0.079 
10 286 0.003 0.080 
10 291 0.003 0.080 
10 296 0.003 0.081 
10 301 0.003 0.082 
10 5 0.005 0.130 
10 10 0.005 0.128 
10 15 0.005 0.127 
10 20 0.005 0.126 
10 25 0.005 0.126 
10 30 0.005 0.125 
10 35 0.005 0.124 
10 40 0.005 0.123 
10 45 0.005 0.122 
10 50 0.005 0.122 
10 55 0.005 0.121 
10 60 0.005 0.120 
10 65 0.005 0.119 
10 70 0.004 0.117 
10 75 0.004 0.117 
10 80 0.004 0.116 
10 85 0.004 0.115 
10 90 0.004 0.115 
10 95 0.004 0.114 
10 100 0.004 0.113 
10 105 0.004 0.112 
10 110 0.004 0.111 
10 115 0.004 0.110 
10 120 0.005 0.129 
10 125 0.004 0.108 
10 130 0.004 0.107 
10 135 0.004 0.107 
10 140 0.004 0.106 
10 145 0.004 0.105 
10 150 0.004 0.104 
10 155 0.004 0.103 
10 160 0.004 0.102 
10 165 0.004 0.102 
10 171 0.004 0.101 
10 176 0.004 0.100 
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10 181 0.004 0.099 
10 186 0.004 0.099 
10 191 0.004 0.098 
10 196 0.004 0.097 
10 201 0.004 0.097 
10 206 0.004 0.096 
10 211 0.004 0.095 
10 216 0.004 0.094 
10 221 0.004 0.094 
10 226 0.004 0.093 
10 231 0.004 0.092 
10 236 0.003 0.092 
10 241 0.003 0.091 
10 246 0.003 0.090 
10 251 0.003 0.090 
10 256 0.003 0.089 
10 261 0.003 0.088 
10 266 0.003 0.087 
10 271 0.003 0.087 
10 276 0.003 0.086 
10 281 0.003 0.085 
10 286 0.003 0.085 
10 291 0.003 0.084 
10 296 0.003 0.083 
10 301 0.003 0.083 
100 5 0.007 0.182 
100 10 0.007 0.179 
100 15 0.007 0.185 
100 20 0.007 0.194 
100 25 0.008 0.203 
100 30 0.008 0.213 
100 35 0.008 0.222 
100 40 0.009 0.231 
100 45 0.009 0.240 
100 50 0.009 0.248 
100 55 0.010 0.256 
100 60 0.010 0.264 
100 65 0.010 0.272 
100 70 0.011 0.280 
100 75 0.011 0.288 
100 80 0.011 0.295 
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100 85 0.011 0.303 
100 90 0.012 0.310 
100 95 0.012 0.317 
100 100 0.012 0.323 
100 105 0.013 0.330 
100 110 0.013 0.336 
100 115 0.013 0.342 
100 120 0.013 0.348 
100 125 0.013 0.354 
100 130 0.014 0.359 
100 135 0.014 0.364 
100 140 0.014 0.370 
100 145 0.014 0.375 
100 150 0.014 0.379 
100 155 0.015 0.384 
100 160 0.015 0.389 
100 165 0.015 0.393 
100 170 0.015 0.398 
100 176 0.015 0.402 
100 181 0.015 0.405 
100 186 0.016 0.409 
100 191 0.016 0.413 
100 196 0.016 0.416 
100 201 0.016 0.419 
100 206 0.016 0.422 
100 211 0.016 0.425 
100 216 0.016 0.428 
100 221 0.016 0.430 
100 226 0.017 0.436 
100 231 0.017 0.435 
100 236 0.017 0.437 
100 241 0.017 0.439 
100 246 0.017 0.441 
100 251 0.017 0.443 
100 256 0.017 0.445 
100 261 0.017 0.446 
100 266 0.017 0.449 
100 271 0.017 0.450 
100 276 0.017 0.452 
100 281 0.017 0.453 
100 286 0.017 0.455 
157 
100 291 0.017 0.456 
100 296 0.017 0.458 
100 301 0.017 0.459 
100 5 0.021 0.559 
100 10 0.021 0.541 
100 15 0.020 0.535 
100 20 0.020 0.531 
100 25 0.020 0.531 
100 30 0.020 0.527 
100 35 0.020 0.525 
100 40 0.020 0.523 
100 45 0.020 0.522 
100 50 0.020 0.520 
100 55 0.020 0.519 
100 60 0.020 0.518 
100 65 0.020 0.516 
100 70 0.020 0.515 
100 75 0.020 0.514 
100 80 0.019 0.513 
100 85 0.019 0.512 
100 90 0.019 0.510 
100 95 0.019 0.509 
100 100 0.019 0.508 
100 105 0.019 0.507 
100 110 0.019 0.505 
100 115 0.019 0.504 
100 120 0.019 0.503 
100 125 0.019 0.501 
100 130 0.019 0.500 
100 135 0.019 0.499 
100 140 0.019 0.498 
100 145 0.019 0.496 
100 150 0.019 0.498 
100 155 0.019 0.494 
100 160 0.019 0.493 
100 165 0.019 0.492 
100 170 0.019 0.491 
100 175 0.019 0.490 
100 181 0.019 0.489 
100 186 0.019 0.488 
100 191 0.019 0.487 
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100 196 0.018 0.486 
100 201 0.018 0.485 
100 206 0.018 0.484 
100 211 0.018 0.483 
100 216 0.018 0.482 
100 221 0.018 0.481 
100 226 0.018 0.480 
100 231 0.018 0.479 
100 236 0.018 0.478 
100 241 0.018 0.477 
100 246 0.018 0.475 
100 251 0.018 0.474 
100 256 0.018 0.473 
100 261 0.018 0.472 
100 266 0.018 0.471 
100 271 0.018 0.469 
100 276 0.018 0.468 
100 281 0.018 0.467 
100 286 0.018 0.465 
100 291 0.018 0.464 
100 296 0.018 0.463 
100 301 0.018 0.462 
1000 5 0.067 1.767 
1000 10 0.062 1.639 
1000 15 0.061 1.597 
1000 20 0.060 1.577 
1000 25 0.059 1.566 
1000 30 0.059 1.558 
1000 35 0.059 1.553 
1000 40 0.059 1.550 
1000 45 0.059 1.548 
1000 50 0.059 1.545 
1000 55 0.059 1.544 
1000 60 0.059 1.543 
1000 65 0.059 1.542 
1000 70 0.059 1.542 
1000 75 0.059 1.541 
1000 80 0.059 1.542 
1000 85 0.059 1.541 
1000 90 0.059 1.541 
1000 95 0.059 1.541 
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1000 100 0.059 1.541 
1000 105 0.059 1.541 
1000 110 0.059 1.540 
1000 115 0.058 1.539 
1000 120 0.058 1.538 
1000 125 0.058 1.537 
1000 130 0.058 1.537 
1000 135 0.058 1.536 
1000 140 0.059 1.545 
1000 145 0.058 1.533 
1000 150 0.058 1.532 
1000 155 0.058 1.531 
1000 160 0.058 1.529 
1000 165 0.058 1.528 
1000 170 0.058 1.528 
1000 176 0.058 1.527 
1000 181 0.058 1.527 
1000 186 0.058 1.526 
1000 191 0.058 1.525 
1000 196 0.058 1.525 
1000 201 0.058 1.524 
1000 206 0.058 1.523 
1000 211 0.058 1.522 
1000 216 0.058 1.521 
1000 221 0.058 1.519 
1000 226 0.058 1.518 
1000 231 0.058 1.517 
1000 236 0.058 1.515 
1000 241 0.058 1.514 
1000 246 0.057 1.512 
1000 251 0.057 1.510 
1000 256 0.057 1.509 
1000 261 0.057 1.507 
1000 266 0.057 1.505 
1000 271 0.057 1.503 
1000 276 0.057 1.500 
1000 281 0.057 1.498 
1000 286 0.057 1.495 
1000 291 0.057 1.493 
1000 296 0.057 1.490 
1000 301 0.057 1.487 
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1000 5 0.070 1.840 
1000 10 0.065 1.704 
1000 15 0.063 1.656 
1000 20 0.062 1.630 
1000 25 0.061 1.614 
1000 30 0.061 1.603 
1000 35 0.061 1.595 
1000 40 0.060 1.589 
1000 45 0.060 1.584 
1000 50 0.060 1.579 
1000 55 0.060 1.575 
1000 60 0.060 1.573 
1000 65 0.060 1.570 
1000 70 0.060 1.567 
1000 75 0.059 1.565 
1000 80 0.059 1.563 
1000 85 0.059 1.561 
1000 90 0.059 1.560 
1000 95 0.059 1.558 
1000 100 0.059 1.556 
1000 105 0.059 1.555 
1000 110 0.059 1.553 
1000 115 0.059 1.552 
1000 120 0.059 1.550 
1000 125 0.059 1.548 
1000 130 0.059 1.546 
1000 135 0.059 1.544 
1000 140 0.059 1.542 
1000 145 0.059 1.541 
1000 150 0.058 1.539 
1000 155 0.058 1.537 
1000 160 0.058 1.536 
1000 165 0.058 1.535 
1000 170 0.058 1.534 
1000 176 0.058 1.533 
1000 181 0.058 1.532 
1000 186 0.058 1.531 
1000 191 0.058 1.530 
1000 196 0.058 1.528 
1000 201 0.058 1.527 
1000 206 0.058 1.526 
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1000 211 0.058 1.524 
1000 216 0.058 1.523 
1000 221 0.058 1.521 
1000 226 0.058 1.520 
1000 231 0.058 1.518 
1000 236 0.058 1.517 
1000 241 0.058 1.515 
1000 246 0.057 1.513 
1000 251 0.057 1.511 
1000 256 0.057 1.509 
1000 261 0.057 1.507 
1000 266 0.057 1.505 
1000 271 0.057 1.503 
1000 276 0.057 1.500 
1000 281 0.057 1.493 
1000 286 0.057 1.495 
1000 291 0.057 1.492 
1000 296 0.057 1.490 
1000 301 0.056 1.486 
 
 
 
 
Table 15:  M(H) Data for LNTs. 
 
Field (Oe) Temperature (K) Long Moment (emu) emu/g 
10 5 0.001 0.009 
10 10 0.002 0.016 
10 15 0.002 0.021 
10 20 0.003 0.025 
10 25 0.003 0.028 
10 30 0.003 0.030 
10 35 0.003 0.031 
10 40 0.003 0.032 
10 45 0.003 0.032 
10 50 0.003 0.032 
10 55 0.003 0.032 
10 60 0.003 0.031 
10 65 0.003 0.031 
10 70 0.003 0.031 
10 75 0.003 0.030 
10 80 0.003 0.030 
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10 85 0.003 0.030 
10 90 0.003 0.029 
10 95 0.003 0.029 
10 100 0.003 0.028 
10 105 0.003 0.028 
10 110 0.003 0.027 
10 115 0.003 0.027 
10 120 0.003 0.026 
10 125 0.003 0.026 
10 130 0.003 0.026 
10 135 0.003 0.025 
10 140 0.003 0.025 
10 145 0.003 0.024 
10 150 0.002 0.024 
10 155 0.002 0.023 
10 160 0.002 0.023 
10 165 0.002 0.023 
10 170 0.002 0.022 
10 176 0.002 0.022 
10 181 0.002 0.022 
10 186 0.002 0.021 
10 191 0.002 0.021 
10 196 0.002 0.021 
10 201 0.002 0.020 
10 206 0.002 0.020 
10 211 0.002 0.020 
10 216 0.002 0.020 
10 221 0.002 0.019 
10 226 0.002 0.019 
10 231 0.002 0.019 
10 236 0.002 0.019 
10 241 0.002 0.018 
10 246 0.002 0.018 
10 251 0.002 0.018 
10 256 0.002 0.018 
10 260 0.002 0.017 
10 266 0.002 0.017 
10 271 0.002 0.017 
10 275 0.002 0.017 
10 281 0.002 0.017 
10 286 0.002 0.016 
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10 291 0.002 0.016 
10 296 0.002 0.016 
10 301 0.002 0.016 
10 5 0.010 0.093 
10 10 0.009 0.090 
10 15 0.009 0.087 
10 20 0.009 0.083 
10 25 0.008 0.079 
10 30 0.008 0.075 
10 35 0.007 0.072 
10 40 0.007 0.069 
10 45 0.007 0.066 
10 50 0.007 0.063 
10 55 0.006 0.060 
10 60 0.006 0.058 
10 65 0.006 0.055 
10 70 0.006 0.053 
10 75 0.005 0.051 
10 80 0.005 0.050 
10 85 0.005 0.048 
10 90 0.005 0.046 
10 95 0.005 0.045 
10 100 0.005 0.043 
10 105 0.004 0.042 
10 110 0.004 0.041 
10 115 0.004 0.039 
10 120 0.004 0.038 
10 125 0.004 0.037 
10 130 0.004 0.036 
10 135 0.004 0.035 
10 140 0.004 0.034 
10 145 0.003 0.033 
10 150 0.003 0.032 
10 155 0.003 0.032 
10 160 0.003 0.031 
10 165 0.003 0.030 
10 170 0.003 0.029 
10 176 0.003 0.029 
10 181 0.003 0.028 
10 186 0.003 0.027 
10 191 0.003 0.026 
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10 196 0.003 0.026 
10 201 0.003 0.025 
10 206 0.003 0.025 
10 211 0.003 0.024 
10 216 0.002 0.024 
10 221 0.002 0.023 
10 226 0.002 0.022 
10 231 0.002 0.022 
10 236 0.002 0.021 
10 241 0.002 0.021 
10 246 0.002 0.021 
10 251 0.002 0.020 
10 256 0.002 0.020 
10 261 0.002 0.019 
10 266 0.002 0.019 
10 271 0.002 0.018 
10 276 0.002 0.018 
10 281 0.002 0.018 
10 285 0.002 0.017 
10 291 0.002 0.017 
10 296 0.002 0.016 
10 301 0.002 0.016 
100 5 0.010 0.098 
100 10 0.015 0.147 
100 15 0.020 0.188 
100 20 0.023 0.219 
100 25 0.025 0.240 
100 30 0.026 0.254 
100 35 0.028 0.268 
100 40 0.028 0.269 
100 45 0.028 0.271 
100 50 0.028 0.271 
100 55 0.028 0.270 
100 60 0.028 0.268 
100 65 0.028 0.266 
100 70 0.027 0.264 
100 75 0.027 0.261 
100 80 0.027 0.258 
100 85 0.026 0.255 
100 90 0.026 0.252 
100 95 0.026 0.248 
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100 100 0.025 0.245 
100 105 0.025 0.241 
100 110 0.025 0.238 
100 115 0.024 0.234 
100 120 0.024 0.231 
100 125 0.024 0.228 
100 130 0.023 0.224 
100 135 0.023 0.221 
100 140 0.023 0.217 
100 145 0.022 0.214 
100 150 0.022 0.211 
100 155 0.022 0.208 
100 160 0.021 0.205 
100 165 0.021 0.202 
100 170 0.021 0.201 
100 176 0.020 0.196 
100 181 0.020 0.193 
100 186 0.020 0.190 
100 191 0.019 0.188 
100 196 0.019 0.185 
100 201 0.019 0.182 
100 206 0.019 0.180 
100 211 0.018 0.177 
100 216 0.018 0.175 
100 221 0.018 0.172 
100 226 0.018 0.170 
100 231 0.017 0.168 
100 236 0.017 0.166 
100 241 0.017 0.163 
100 246 0.017 0.161 
100 251 0.017 0.159 
100 256 0.016 0.157 
100 261 0.016 0.155 
100 266 0.016 0.153 
100 271 0.016 0.151 
100 276 0.015 0.149 
100 281 0.015 0.147 
100 286 0.015 0.145 
100 291 0.015 0.144 
100 296 0.015 0.142 
100 301 0.015 0.140 
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100 5 0.059 0.572 
100 10 0.058 0.560 
100 15 0.057 0.545 
100 20 0.055 0.529 
100 25 0.053 0.511 
100 30 0.051 0.494 
100 35 0.050 0.477 
100 40 0.048 0.461 
100 45 0.046 0.446 
100 50 0.045 0.431 
100 55 0.043 0.417 
100 60 0.042 0.404 
100 65 0.041 0.392 
100 70 0.040 0.380 
100 75 0.038 0.369 
100 80 0.037 0.359 
100 85 0.036 0.349 
100 90 0.035 0.340 
100 95 0.034 0.331 
100 100 0.033 0.322 
100 105 0.033 0.314 
100 110 0.032 0.306 
100 115 0.031 0.298 
100 120 0.030 0.291 
100 125 0.030 0.284 
100 130 0.029 0.277 
100 135 0.028 0.271 
100 140 0.028 0.265 
100 145 0.027 0.259 
100 150 0.026 0.253 
100 155 0.026 0.248 
100 160 0.025 0.242 
100 165 0.025 0.237 
100 171 0.024 0.232 
100 176 0.024 0.227 
100 181 0.023 0.223 
100 186 0.023 0.218 
100 191 0.022 0.214 
100 196 0.022 0.210 
100 201 0.021 0.205 
100 206 0.021 0.201 
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100 211 0.021 0.197 
100 216 0.020 0.194 
100 221 0.020 0.190 
100 226 0.019 0.186 
100 231 0.019 0.183 
100 236 0.019 0.179 
100 241 0.018 0.176 
100 246 0.018 0.173 
100 251 0.018 0.169 
100 256 0.017 0.166 
100 261 0.017 0.163 
100 266 0.017 0.160 
100 271 0.016 0.157 
100 276 0.016 0.154 
100 281 0.016 0.151 
100 286 0.015 0.149 
100 291 0.015 0.146 
100 296 0.015 0.143 
100 301 0.015 0.141 
1000 5 0.074 0.713 
1000 10 0.084 0.809 
1000 15 0.092 0.886 
1000 20 0.098 0.946 
1000 25 0.102 0.985 
1000 30 0.105 1.010 
1000 35 0.107 1.026 
1000 40 0.108 1.035 
1000 45 0.108 1.040 
1000 50 0.108 1.041 
1000 55 0.108 1.041 
1000 60 0.108 1.039 
1000 65 0.108 1.037 
1000 70 0.107 1.033 
1000 75 0.107 1.029 
1000 80 0.106 1.025 
1000 85 0.106 1.019 
1000 90 0.105 1.014 
1000 95 0.105 1.008 
1000 100 0.104 1.001 
1000 105 0.103 0.995 
1000 110 0.103 0.988 
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1000 115 0.102 0.981 
1000 120 0.101 0.974 
1000 125 0.100 0.967 
1000 130 0.100 0.960 
1000 135 0.099 0.953 
1000 140 0.098 0.946 
1000 145 0.097 0.938 
1000 150 0.097 0.931 
1000 155 0.096 0.924 
1000 160 0.095 0.916 
1000 165 0.094 0.909 
1000 170 0.094 0.902 
1000 175 0.093 0.894 
1000 181 0.092 0.887 
1000 186 0.091 0.880 
1000 191 0.091 0.873 
1000 196 0.090 0.866 
1000 201 0.089 0.858 
1000 206 0.088 0.851 
1000 211 0.088 0.844 
1000 216 0.087 0.837 
1000 221 0.086 0.830 
1000 226 0.085 0.823 
1000 231 0.085 0.816 
1000 236 0.084 0.809 
1000 241 0.083 0.802 
1000 246 0.083 0.794 
1000 251 0.082 0.787 
1000 256 0.081 0.780 
1000 261 0.080 0.772 
1000 266 0.079 0.765 
1000 271 0.079 0.758 
1000 276 0.078 0.751 
1000 281 0.077 0.743 
1000 286 0.076 0.736 
1000 291 0.076 0.729 
1000 296 0.075 0.722 
1000 301 0.074 0.714 
1000 5 0.133 1.283 
1000 10 0.133 1.277 
1000 15 0.132 1.268 
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1000 20 0.131 1.259 
1000 25 0.130 1.248 
1000 30 0.128 1.236 
1000 35 0.127 1.224 
1000 40 0.126 1.213 
1000 45 0.125 1.201 
1000 50 0.124 1.189 
1000 55 0.122 1.177 
1000 60 0.121 1.165 
1000 65 0.120 1.154 
1000 70 0.119 1.143 
1000 75 0.118 1.135 
1000 80 0.116 1.120 
1000 85 0.115 1.109 
1000 90 0.114 1.098 
1000 95 0.113 1.087 
1000 100 0.112 1.076 
1000 105 0.111 1.066 
1000 110 0.110 1.055 
1000 115 0.109 1.045 
1000 120 0.107 1.035 
1000 125 0.106 1.024 
1000 130 0.105 1.014 
1000 135 0.104 1.004 
1000 140 0.103 0.994 
1000 145 0.102 0.985 
1000 150 0.101 0.975 
1000 155 0.100 0.965 
1000 160 0.099 0.956 
1000 165 0.098 0.947 
1000 171 0.097 0.937 
1000 176 0.096 0.928 
1000 181 0.095 0.919 
1000 186 0.095 0.910 
1000 191 0.094 0.901 
1000 196 0.093 0.892 
1000 201 0.092 0.883 
1000 206 0.091 0.875 
1000 211 0.090 0.866 
1000 216 0.089 0.857 
1000 221 0.088 0.849 
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1000 226 0.087 0.840 
1000 231 0.086 0.832 
1000 236 0.085 0.823 
1000 241 0.085 0.814 
1000 246 0.084 0.806 
1000 251 0.083 0.798 
1000 256 0.082 0.789 
1000 261 0.081 0.781 
1000 266 0.080 0.772 
1000 271 0.079 0.764 
1000 276 0.079 0.756 
1000 281 0.078 0.747 
1000 286 0.077 0.739 
1000 291 0.076 0.731 
1000 296 0.075 0.723 
1000 301 0.074 0.715 
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APPENDIX IV: HYDROXYLATION OF GADONANOTUBES 
 
“A thing long expected takes the form of the unexpected when at last it comes” ~ Mark 
Twain 
 
INTRODUCTION 
 
This appendix explores the effects of adding hydroxyl functional groups to the exterior 
sidewalls of the GNTs, as shown in Figure 49, and serves as an investigative study of 
relaxivity manipulation of the GNTs.  This project originally began as an attempt to 
increase the water solubility of the GNTs while simultaneously increasing relaxivity 
(Chapter 2), as previously recorded for gadofullerenols.
220
  While significant water-
solubilization was never achieved, GNT relaxivity was greatly enhanced (ca. 25% 
increase). It should be noted that this project was abandoned upon realization that water-
solubility was not significant enhanced following hydroxylation.  
 
 
Figure 49. Pictorial representation of a hydroxylated Gadonanotube. 
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HYDROXYLATION 
 
Hydroxyl Radical 
It is important to start by acknowledging the misnomer of “hydroxylation.”  This term is 
traditionally reserved for the oxidative process converting a C-H bond to a C-OH bond; 
however, as the goal was to coat the carbon exterior of the US-tube nanocapsules with 
hydroxyl functional groups, the term seems both appropriate and descriptive. 
 
As shown in Table 16, hydroxyl radical, or the neutral form of the hydroxide ion denoted 
•OH, is highly reactive.  As such, the radical is very short lived and must be produced in 
the laboratory setting.  Two common techniques for creation of the hydroxyl radical are 
the employment of Fenton chemistry and the photodissociation of H2O2 with UV-
light.
221,222
  Occasionally, the two will be coupled in what is known as a photoassisted 
Fenton reaction or Photo-Fenton reaction.
223
  
 
Table 16. Oxidation potentials of some common chemical oxidants.
224
 
 
Reactive Species Oxidation Potential (V) 
Fluorine 3.03 
Hyroxyl radical 2.80 
Singlet oxygen 2.42 
Ferryl ion (FeO
2+
) ~2.0 
225
 
H2O2 1.78 
Permanganate 1.68 
Chlorine dioxide 1.15 
Cl2 / Br2 / I2 1.00 / 0.80 / 0.54 
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A third hydroxylation technique specific for carbonaceous nanomaterials is a solid-phase 
mechanochemical reaction that involves a mechanical mill and sodium hydroxide.
226
 
 
Fenton Chemistry 
Previous, unpublished experiments employing a Fenton reaction resulted in a failure to 
significantly increase the water-solubility of the US-tube nanocapsules to eliminate the 
requisite surfactants and/or emulsifiers currently used prior to in vivo injection.  These 
experiments were briefly repeated for both comparison and verification.  
 
This century-old hydroxyl radical reaction is still not completely understood, and the 
once assumed reaction with a hydroxyl radical intermediate is currently being examined 
against a ferryl ion intermediate (see Table 17),
227
 despite the hydroxyl radical having a 
higher oxidation potential than the ferryl ion (Table 16).
225
. Regardless of the 
intermediate step, the reaction is an established and efficient hydroxylating reaction. 
 
Table 17. Two proposed key intermediates in Fenton reaction. 
227
 
 
Key 
Intermediate 
Hydroxyl radical (•OH) Ferryl ion (FeO2+) 
Initiation 
Step 
H2O2 + Fe
2+
 → Fe3+ + OH− + •OH H2O2 + Fe
2+
 → FeO2+ + H2O 
Propagation 
Step(s) 
•OH + H2O2 → H2O + •OOH 
•OOH + Fe3+ → O2 + Fe
2+
 + H
+
 
FeO
2+
 + H2O2 → Fe
2+
 + H2O + O2 
Termination 
Step 
•OH + Fe2+ → Fe3+ + OH− FeO2+ + Fe2+ + 2H+ → 2Fe3+ + H2O 
Substrate 
Oxidation 
•OH + RH → R• + H2O → 
hydroxylated product 
FeO
2+
 + RH →  
hydroxylated product 
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pH is important for the reaction rate of Fenton’s reagent.  As shown in Table 18, the pH 
values of DI water and H2O2 at various strengths remain ca. 4.5 – 5.0 in pH strength. The 
optimum pH range, however, for the Fenton reaction is less than 3.0 or more than 6.0 
(Figure 50).
228
  Additionally, the reaction will not occur at pH values higher than 10.
229
  
As hydrogen peroxide is more stable at lower pHs, many producers add mineral acids 
(e.g., phosphoric or nitric acids) to further lower the pH.  It is also important to obtain 
reagent grade hydrogen peroxide that won’t contain acidic phosphonic acid, a common 
commercial stabilizer that will prevent the desired hydrogen peroxide degradation.  
Finally, it should be noted that the mixture of Fe
2+
 ions and H2O2 is known as Fenton’s 
reagent. 
 
Table 18. Hydrogen peroxide pH at various concentrations in water.
230
 
 
% H2O2 0 10 20 30 40 50 60 70 80 90 100 
pH @ 25 
o
C 7.0 5.3 4.9 4.7 4.6 4.5 4.5 4.5 4.6 4.9 6.2 
 
 
 
Figure 50. Effect of pH on Fenton’s Reagent.228 
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Fenton’s reagent has been used to previously functionalize MWNTs.229  The MWNTs 
were functionalized with -OH, -COOH, and quinone groups, and the investigators 
proposed that the •OH attacked the MWNTs through electrophilic addition on defect sites 
and/or unsaturated C=C bonds.  These authors did not report any increase in water 
solubility for the product. 
 
UV Photolysis 
Photolysis, also known as photodissociation or photodecomposition, of H2O2 is another 
common method employed for hydroxyl radical formation.  The mechanism is simply:  
 
H2O2  
  
→  2  OH 
 
For this reaction, the optimal wavelength for the UV light source is 206–270 nm,227 with 
a high molar absorption coefficient of the peroxide anion at 253.7 nm (ε253.7 nm = 18.6 M
-1
 
cm
-1
).
224
  This high molar absorptivity is important as lower wattage light sources can be 
used, ultimately reducing the amount of heat added to the system.  Heat produces the 
degradation of H2O2 according to: 
 
2 H2O2 → 2 H2O + O2 
 
by a 2.2 factor increase for every 10 
o
C increase.
230
  This degradation of hydrogen 
peroxide into oxygen and water is also seen at higher pH levels, however this is mitigated 
by the fact that more alkaline conditions also increase the photodecomposition 
efficiency.
224
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Mechanochemical Hydroxylation Reactions 
The simplest form of mechanochemistry is the use of a mortar and pestle, yet the first 
reported mechanochemical hydroxylation reaction on carbonaceous nanomaterials 
employed the use of a high-speed vibration mill (HSVM), specifically a commercially-
available Wig-L-Bug.
231
  In short, a mixture of 45 mg of C60 and 900 mg of KOH in a 
stainless steel mill with milling ball was shaken for 1 h in the Wig-L-Bug at room 
temperature in air.  The resulting brown homogenous solution was filtered and 
precipitated in methanol rendering 62 mg of C60(OH)n (n=27.2), yield: 84%. 
 
 
Figure 51. XPS and Raman spectra for “SWNTols” prepared through 
mechanochemical reaction. Left: XPS C 1s spectra of (a) the pristine SWNTs and 
(b) the SWNTols. (The dashed curve that peaks at 286.4 eV represents C-O) 
Right: Raman spectra of the pristine SWNTs (solid curve) and the SWNTols 
(dash curve).
232
 
 
Later that year, the same group published similar results for forming “carbon nanotubols” 
or “SWNTols” (hydroxylated SWNTs) following a similar mechanochemical reaction 
177 
involving KOH and HiPCO SWNTs.
232
  While keeping the ratio of mass of carbon 
nanomaterial to KOH the same, yet doubling the reaction time to 2 hr, the workers were 
able to produce hydroxylated SWNTs with a solubility of 3 mg/mL in water and 
insoluble in organic solvents.  The group verified the hydroxylation, in part, through an 
increase of percentage content of the C-O curve (286.4 eV) comprising the 1s electron 
configuration for carbon (C1s) spectra from 3.4% to 14.9% (Figure 51, left [note increase 
of dashed curve peaking at 286.4 eV from a to b]); the increase of this left shoulder 
strongly suggests that the binding energy for the C1s spectra is comprised of more alcohol 
groups (C-OH) than before.  It should be noted that while this elemental scan renders 
information that the C1s has more alcohol character, it is not a dependable method for 
quantification of alcohol groups as it depends on a user-biased peak-fitting.  
 
The group further verified hydroxylation of the SWNTs using Raman spectroscopy. The 
D:G ratio on the Raman spectra decreased from 1:18 for HiPCO SWNTs to 1:1.2 for 
SWNTols (Figure 51, right).  This method has the advantage of being solvent free and 
adds approximately one -OH group per 10 carbon atoms. 
 
MATERIALS AND METHODS 
 
Materials 
US-tube nanocapsules from electric-arc discharge SWNTs with Ni/Y catalyst (AP Grade, 
CarboLex, Inc., Lexington, Kentucky) were prepared as discussed in Chapter 1. Full-
length SWNTs from the same batch were also used.  Similarly, GNTs prepared from 
178 
these US-tube nanocapsules were prepared as discussed in Chapter 2.  30% H2O2 
(TraceSELECT® Ultra for trace analysis, pH = 4.1, Fluka) was purchased for each round 
of experiments.  All water was high-performance liquid chromatography (HPLC) grade 
(Amber glass, Fluka).  Both ferrous chloride and titanium dioxide (or titania) samples 
were puriss. grade from Fluka (purris. grade ≥ 98.5% purity, purum ≥ 95.0% purity, 
technical grade ≥ 90% purity).  Solutions of 0.01 mM, 0.10 mM, and 1.00 mM of both 
FeCl2 (aq) and TiO2 (aq) were prepared using HPLC-grade H2O. 
 
Fenton Chemistry 
Four 10.0 mg samples of each material (US-tube nanocapsule and GNT, 8 samples in 
total) were dispersed in 10.0 mL of 30% H2O2 via 6 minutes of bath sonication.  1.0 mL 
of FeCl2 at each concentration (0.01 mM, 0.10 mM, and 1.00 mM) was added to each 
sample with one sample receiving no FeCl2 as a control.  After 6 hours, the reaction was 
quenched by the addition of excess Na3PO4.  All samples were then gravity-filtered over 
a coarse (‘C’) fritted glass filter.  The filtered material was removed from the filter 
through pipette aspiration with DI water, collected on a watch glass, and dried overnight 
in a 40 
o
C oven. All samples were analyzed prior and post reaction via Raman 
spectroscopy (Renishaw Raman microscope, using a 633 nm laser).  Additionally, the 
GNT sample filtrate was analyzed using inductively-coupled plasma optical emission 
spectrometry (ICP-OES, Perkin-Elmer Optima 3200V) for the presence of Gd.  This 
procedure was repeated in triplicate, and then repeated in triplicate substituting titania for 
ferrous chloride. 
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Mechanochemistry 
For this technique, a published method was followed.
232
  In short, 10.0 mg of sample 
(both full-length SWNTs and US-tube nanocapsule, GNTs not tested) and 200.0 mg of 
KOH flakes were added to a Wig-L-Bug amalgamator (Bratt 3110-B) mill with a 
stainless steel milling ball.  Samples were milled in air for 2 hours (8 cycles of 15 min on, 
5 min off to prevent instrument overheating).  Resulting mixture was dissolved in 10 mL 
of DI water and precipitated into 100 mL of methanol.  Precipitation was repeated until 
the methanol solution became neutral (to ensure removal of potassium hydroxide 
residues). Following centrifugation, the upper layer of liquid was removed and the 
resulting black solid analyzed via Raman spectroscopy and TGA as described above.  
 
UV Photolysis 
Luzchem Photoreactor 
In order to prevent the unwanted loading of metal ions, it was important to devise a 
method that would need no metal catalyst (such as a Fenton reagent) to create reactive 
hydroxyl radicals for US-tube nanocapsules sidewall derivitization.  Initial experiments 
were performed in a Luzchem Photoreactor (LZC-4V).  The photoreactor was comprised 
of fourteen UV bulbs (6 lining top, 8 on left and right, G8T5 Bulbs: 8W, 254 nm). 
Preliminary studies explored 10.0 mg of US-tube capsules in 10.0 mL of 30% H2O2 for 
20 minutes in the photoreactor.  The results suggested no increase in functionalization: 
(a) there was no measurable change prior to post-reaction via Raman spectroscopy D:G 
ratio, (b) there was no apparent change in solubility, and (c) a comparison of  prior and 
post-reaction 30% H2O2 was titrated with potassium permanganate (0.5 M KMnO4 (aq)) 
180 
and showed no difference according to: 
 
2 MnO
4–
 + 5 H2O2 + 6 H
+
  2 Mn+2 + 5 O2 + 8 H2O 
 
suggesting that the 30% H2O2 went unchanged for the duration of the experiment. 
 
Custom Photolysis Apparatus 
 To better control the UV photolysis reaction conditions, an elementary photolysis 
apparatus (Figure 52) was constructed from a bass wood box, ca. 18 cm x 10 cm x 8 cm. 
This apparatus allowed an 8 W, 115 V, 254 nm UV light source to irradiate samples (an 8 
W bulb was the minimum wattage commercially-available to minimize heat addition to 
the system; 254 nm was selected for the high molar absorption coefficient described in 
the section above).  An inert gas inlet was also installed on the apparatus to permit 
flushing the system with argon gas.  The aim of this feature was to prevent any unwanted 
chemistry where the mixture could interact with the native atmosphere.  Also, it should 
be noted that common scintillation vials did not allow significant amounts of UV light to 
pass, despite being excellent with light transmission.  For this reason, a container made of 
quartz (which did allow 254 nm UV light to pass) was utilized. 
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Figure 52: Photolysis Apparatus.  
 
To ensure that the apparatus was functional, 10.0 mL of 30% H2O2 with 10.0 mg US-tube 
nanocapsules was introduced into the reaction chamber and flooded with Ar (g).  The UV 
light source was placed atop, and photolysis was allowed to occur for 30 minutes.  
Following reaction, the nanocapsules were removed using a medium-grade fritted-glass 
filter, and 1.00 mL of the reacted H2O2 was titrated 0.5 M KMnO4 (aq) to determine the 
concentration of H2O2. 
 
This procedure was repeated lengthening the reaction time by 30 min for four time points 
(t = 30 min, 60 min, 90 min, and 120 min) and was compared to values of 10.0 mL of 
30% H2O2 introduced to the reaction apparatus with a standard fluorescent 8 W bulb (to 
simulate the same heat addition).  The entire procedure was then repeated  by also bath 
sonicating the 30% H2O2 for 6 min prior to irradiation (both UV and fluorescent) to 
measure the effects of sonication on H2O2 degradation. 
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Reaction Conditions 
A 10.0 mg of each sample (US-tube nanocapsule and GNT) were bath sonicated in 30% 
H2O2 for 6 min and irradiated for 12 hours in the photolysis apparatus.  Prior to 
introducing the sample dispersed in H2O2 to the apparatus, the system was flushed with 
Ar (g).  Additionally, Ar (g) was continuous added to the apparatus for the 12 hr duration. 
Once loaded, the sample chamber was covered with the duct-tape barrier and the UV 
light source placed atop the apparatus.  Following 12 hours, all samples were filtered, 
dried, and analyzed as for the Fenton reactions above.  As a control 10.0 mg of each 
sample underwent the same set-up, however a desk lamp with an 8 W incandescent light 
bulb (Federal Signal) replaced the UV light source to best simulate heat effects.  XPS 
data was collected on all samples (prior and post reaction) pressed onto indium foil, using 
a PHI Quantera spectrometer.  Raman spectra were also collected as described above.  A 
pre- and post-treatment sample of the GNTs were lyophilized for 6 hours to dryness and 
shipped to Galbraith Laboratories for Karl Fisher titration analysis.  This was repeated 
nine times for both US-tube nanocapsules and the GNTs (due to cost, only 3 samples 
were analyzed via Karl Fisher titration). 
 
Relaxivity Measurements 
A Bruker mq60 MiniSpec operating at 60 MHz (1.41 Tesla) and 37 °C was used to 
collect all relaxivity measurements, and an inversion recovery pulse sequence was used 
to measure the longitudinal relaxation time (T1).  Samples were prepared and analyzed for 
Gd
3+
-ion content as described in Chapter 2.  pH of samples were varied with the addition 
of HCl and NaOH to see pH effects on both the GNTs and the resulting Gadonanotubols. 
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Strange Occurrence 
Very strange (yet reproducible, n=2) results occurred when using the above protocol for 
the photolysis reactor on full-length Arc (Carbolex) synthesized SWNTs that had been 
sonicated in 5.0 mM GdCl3 (aq.) and gravity filtrated with HPLC-grade water prior to 
reaction in the reactor. These observations were never explored; the observations are 
described in detail in Appendix V.   
 
RESULTS & DISCUSSION 
 
Fenton Chemistry 
The reaction was vigorous, instantly releasing O2 (confirmed with flame test – glowing 
splint relit) upon addition of ferrous chloride or titania, and became increasingly more 
vigorous at higher concentrations.  This method, however, was quickly abandoned upon 
analysis of the ICP-OES results showing US-tube nanocapsules retained Fe (1.6 ± 0.5 wt. 
%) and Ti (1.2 ± 0.5 wt. %) for ferrous chloride and titania respectively.  This very 
undesirable side-effect ended further studies for the Fenton reaction.  Furthermore, while 
the Raman spectra on the post-Fenton reaction GNTs did show a significant increase in 
D:G ratio for all samples, the increases were all less than the increase in D:G ratio results 
for US-tubes treated via UV photolysis.  It should be noted, however, that the lowest 
concentrations of metal (0.01 mM) had the largest effects on increasing the D:G ratio; 
however, despite the lower concentration of metal in solution, the metal loading 
percentages were roughly the same. No further analysis was attempted. 
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Mechanochemistry 
This method was attempted eleven times on three different HSVM devices, and none 
supported the documented 2 hour experimental run-time.  All three HSVM devices 
acquired were designed for 60 second run-times – for this reason, the instruments 
encountered problems with overheating, as well as breaking the mechanical arms that 
support the mill (4 sets of arms, both plastic and steel, were broken attempting to allow 
the 2 hour milling – personal apologies to the Barron Group’s instrument that sacrificed 
its metal arms in the name of science).  A few years after this project was abandoned, 
curiosity drove me to test fullerenes in the apparatus, and in as little as 15 minutes, a 
brown solid formed that was soluble in water (indicating successful synthesis of 
fullerenols); this prompted further review of instrumentation, and an industrial grade 
amalgamator, with a 1 hour time frame (as opposed to the 1 minute time frame of the 
previously tested instruments) was discovered.   
 
UV Photolysis 
Apparatus  
The reaction chamber showed a 3 fold increase in the rate of H2O2 decomposition via UV 
photolysis when compared to a control (fluorescent bulb) over the measured 2 hr period 
(as shown in Figure 53). Additionally, the reaction with the UV light source was 
bubbling; when a glowing (smoldering) wooden splint was introduced, it relit suggesting 
this released gas was O2. Bath sonication of the H2O2 prior to reaction in the photolysis 
apparatus showed no measurable difference for both the UV and fluorescent light 
sources. These results suggest that the photolysis apparatus successfully decomposes 
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H2O2 with an 8W, 254 nm UV light source. 
 
 
Figure 53: Effectiveness of Photolysis Apparatus (volume of 0.5 M KMnO4 
required to titrate treated H2O2 sample; dark diamonds represent 8W fluorescent 
bulb; gray squares represent 8W UV light source). 
 
Raman Spectra  
The Raman spectroscopy spectra were taken using a 633 nm laser attached to a Renishaw 
Raman microscope. Samples were in dried powder form atop a glass microscope slide. 
Representative spectra are displayed in Figure 54:  
 
Figure 54: Raman spectra of US-tube nanocapsules pre- and post-UV treatment 
(633 nm laser). 
 
Analysis of 5 different samples pre- and post treatment resulted in an average D:G ratio 
increase from 0.31 ± 0.02 to 0.57 ± 0.05. US-tube nanocapsules placed in H2O2 under the 
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8W fluorescence bulb showed a D:G ratio increase from 0.31 ± 0.02 to 0.34 ± 0.02. A 
sample calculation of the D:G ratio determination is shown in the Table 19. While the 
D:G ratio shouldn’t be used for quantitative purposes, the significant D:G ratio increase 
strongly suggests a significant increase in the concentration and distribution of functional 
groups on the surface of the US-tube nanocapsules.   
 
Table 19. D:G ratio increase of US-tube nanocapsules following UV photolysis reaction 
 Pre-Treatment Post-Treatment 
Counts at Carbon sp
3
 peak  
(D-band, ca. 1319 cm
-1
) 
6211 4444 
Counts at carbon sp
2
 peak  
(G-band, ca. 1588 cm
-1
) 
19791 7587 
D:G ratio 0.3138 0.5857 
 
 
XPS Spectra 
Atomic concentrations were calculated for the XPS spectra using the following relative 
sensitivity factors determined for the XPS system: C1s 0.314, O1s 0.733. Atomic 
Concentration Percentage (C1s and O1s only) pre-treatment was 96.4 ± 0.8 % C and 3.6  ± 
0.8 % O. Similarly, post-treatment was 83.0 ± 0.6  % C and 17.0 ± 0.6  % O. An example 
of the difference of pre- and post-treatment oxygen content can be seen in the overlay of 
Figure 55. (Please note that the survey scan of Figure 55 was not used for data analysis. 
More focused XPS scans, such as shown in Figure 56, were used for data analysis).  
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Figure 55: Overlay of XPS survey scans of US-tube nanocapsules pre- and post-
treatment. Note: Not used for analysis, displayed to show increase in oxygen 
content. 
 
Examination of the post-treatment nanocapsules via XPS (Figure 56) revealed a 
significant increase of a left shoulder, which strongly suggested that the binding energy 
for the C1s spectra is comprised of more alcohol groups (C-OH) than before.  Normalizing 
the best-fit area of the shoulder pre- and post-treatment showed an increase in the ratio of 
C-O-R bonding to C-C bonding of 0.072 pre-treatment to 0.230 post-treatment.  This 
again suggested that the nanocapsules had been functionalized with –OR functional 
groups.  
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    Pre-treatment       Post-Treatment 
 
  
 
Figure 56. XPS C 1s spectra of US-tube nanocapsules pre-treatment (left) and 
post-treatment (right).  
 
This XPS data coupled with Karl Fisher titration results acquired by Galbraith 
Laboratories to determine the water content inside oven-dried GNTs shows that there is 
approximately one oxygen atom for every 6-8 carbon atoms, suggesting a high degree of 
hydroxylation occurred. 
 
CONCLUSIONS 
 
The main conclusions from this chapter are simply (a) hydroxylation can be achieved 
through UV-photolysis of hydrogen peroxide and (b) this hydroxylation does not 
significantly alter the solubility of GNTs and/or US-tube nanocapsules. Again, the final 
relaxivity measurements came after this project was abandoned because hydroxylation 
did not increase water solubility (the primary motivation behind this series of 
experiments).  
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APPENDIX V: A STRANGE OCCURRENCE 
Very strange results occurred when using the photolysis reactor on full-length Arc 
synthesized SWNTs that had been bath sonicated in 5.0 mM GdCl3 (aq.). As strange 
results can often be scientifically-interesting, the results are summarized here: 
 
Method 
5.0 mg of full-length arc-ablation synthesized SWNTs (Carbolex, Batch 8594 M) were 
bath sonicated for 60 min in a 5.0 mM GdCl3 solution prepared in HPLC-grade water. 
Following sonication, the resultant SWNTs were gravity-filtered over a coarse-grade 
fritted glass filter with 500 mL of HPLC-grade water. The filtered SWNTs were dried 
overnight in an 80 
o
C oven. 3.6 mg of the resultant SWNTs were suspended in 10.0 mL 
of 30% H2O2 in a test tube (10 min), then poured the full volume into the weighing dish 
base of the photolysis apparatus for a 6 hour reaction. This was repeated in duplicate with 
a fresh GdCl3 solution and fresh H2O2. 
 
Results 
The blackish/grey solution turned a flesh tone (pink/purple in color). This purple solution 
was reduced to dryness using a rotary evaporator which produced a dry layer of 
grey/brownish material. Upon removing the vacuum, this layer instantly turned yellow. 
ICP-OES results of the SWNTs prior to reaction in the photolysis apparatus showed less 
than 0.2 % Gd by mass (remember, the US-tube nanocapsules load Gd
3+
 ions to 
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approximately 2-5 % by mass). This low Gd
3+
-ion percentage is not surprising consider 
full-length SWNTs lack the sidewall defects and open ends of the US-tube nanocapsules. 
No further analysis was attempted. 
 
Conclusions 
The most-likely explanation is contamination. A duplicate-only study (n=2) is not 
reliable enough to truly draw conclusions. However, these preliminary results are 
included in this appendix should others decide to repeat these experiments in the future.  
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APPENDIX VI: PROPERTIES OF GADOLINIUM 
 
Gadolinium lies in the section of elements on the periodic table commonly referred to as 
the rare earth metals;
233
 while not incredibly rare, the element is found within the earth 
(metallic oxide) known as gadolinia (Gd2O3). Gadolinium is both malleable and ductile.  
Additionally, gadolinium has strong paramagnetic properties (7 unpaired f electrons) and 
the highest thermal neutron capture cross-section of any tested element. The metal will 
form both hydroxides and carbonates from CO2 and H2O absorption; chlorides are 
formed from heating in a solution of ammonia chloride at 300
o
C. Most gadolinium metal 
is obtained from reduction of GdCl3; this metal is silvery-white and very reactive. The 
trivalent state is the most common of all the lanthanides.
233
   
 
By far, the most stable and common gadolinium complexes involve chelating ligands.
233
 
Under highly basic conditions, anionic catecholate complexes ([Gd(cat)4]
5-
 and 
[Gd2(cat)6]
6-
 with coordination numbers 8 and 7 respectively) can be obtained as 
crystalline salts. Gadolinium will also form sesquichlorides ([Gd4
6+
(Cl
-
)6]n), which are 
infinite chains of gadolinium atoms in octahedral,
234
 as shown in Figure 54: 
 
Figure 54: Gadolinium sesquichloride ([Gd4
6+
(Cl
-
)6]n, adapted from 
234
). 
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APPENDIX VII: PROPERTIES OF COPPER 
 
Elemental copper is unique in that it has a single s electron outside a filled 3d shell;
233
 
while this may be reminiscent of alkali metals, the electrons of the d shell electrons are 
directly involved in metallic bonding. Because of the d shell electron’s interactions, Cu 
compounds tend to be more covalent and have higher lattice energies than closely related 
alkali metals (atomic radii: Cu
+ 
ion
 
is 0.93 Å and Na
+
 ion is 0.95 Å). The majority of 
copper is refined via electrolysis, resulting in a tough, soft, ductile metal with a reddish 
color. This elemental copper is second only to silver in electrical conductivity at room 
temperature. Considering the relative costs of the two metals, copper wiring’s prevalence 
becomes readily apparent. Elemental copper reacts with molecular oxygen to yield CuO 
and, at higher temperatures, Cu2O, rendering the two most common oxidative states of 
copper: copper(I) and the more stable copper(II). 
 
The copper(I) compounds range from mononuclear, binuclear with halide bridges, 
polynuclear, or even in infinite chains;
233
 however, as these compounds are readily 
oxidized to Cu
2+
 compounds (and this thesis involves CuCl2 as a precursor), the 
chemistry of copper(II) will be the focus of this section. Typically, comparison via 
electron paramagnetic resonance (EPR) [also known as electron spin resonance (ESR)], 
between Cu
1+
 and Cu
2+
 compounds is vividly clear, as Cu
1+ 
is diamagnetic and Cu
2+
 is 
paramagnetic (making only the Cu
2+
 ion visible via EPR);
235
 unfortunately, preliminary 
study in collaboration between the Wilson and Palmer Groups at Rice University, carbon 
nanotubes demonstrate significant signal over a wide range of magnetic field rendering 
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electronic-state determination difficult; the literature suggests that this large amount of 
field results from superparamagnetic catalyst presence in the tubes.
236,237
  
 
Bridging Ligands and Copper 
Bridged copper ions are well established, the most common being simply dihydroxo-
bridged copper(II) species.
238
 In 1978, the first single hydroxyl-bridged binuclear 
copper(II) species was discovered.
239
 As more complicated organic ligand structures were 
discovered, such as the N3S-type ligand with phenylthioether of Figure 58, left,
234
 
dihydroxo-bridged copper (II) species began taking on novel configurations, as shown in 
the square planar configuration of Figure 58, right.  
      
Figure 58: Dihydroxyl-bridged, binuclear copper (II) complex (right) formed 
from N3S-type ligand with phenylthioether (left, adapted from 
234
). 
 
Furthermore, this hydroxyl-bridging has been witnessed beyond simple binuclear species; 
in once case, a copper(II) ion was conjugated to a nucleoside (glycosamine precursors to 
the phosphorylated nucleotide building blocks of both DNA and RNA) creating infinite 
chains of hydroxyl-bridged copper(II).
240
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Figure 59: Two principle arrangements of peroxo-bridged copper(II) [adapted 
from 
241
]. 
 
Finally, oxo-bridging is not limited to hydroxyl-bridging. Molecular oxygen has been 
demonstrated to bridge copper(I) ions, effectively oxidizing them to their copper(II) 
state.
241
  Peroxo bridging between copper(II) has been witnessed,
242
 as shown in Figure 
59, and these species exist in equilibrium as established via kinetic, spectroscopic, and 
crystallographic studies.
243
  Peroxido complexes, like those in Figure 60, have also been 
established, 
244
 being the only other stable oxo-bridged copper complexes in the literature 
(note: superoxo complexes are incredibly short lived).
241 
 
 
Figure 60: Dinuclear side-on peroxido-bridged copper(II) cluster (His = 
histidine, adapted from 
244
). 
 
Gadolinium/Copper Complexes 
Gadolinium/copper complexes took over the literature with the push for high Tc 
superconductors and rare earth copper oxides. Prior to this push, most coupling of 
gadolinium and copper use very elaborate organic ligands developed to successfully 
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chelate both copper and gadolinium ions. The modified DOTA chelate in Figure 61 is 
used for copper ion detection, as the gadolinium ion will form seven (7) bonds to the 
DOTA segment of the ligand, using its final bond to one of the terminal carboxylic acids 
attached to the amino group.
245
 However, as soon as copper ions are present, the 
carboxylic acids chelate the Cu
2+
 ions, causing an open site on the Gd
3+
 ion. This free site 
will then bind to water from the aqueous environment, and, through spin cohesion, 
decrease the time it takes for surrounding water protons to relax in solution. This 
decrease in T1 can then be monitored via an MRI instrument. 
 
Figure 61: Organic ligand (left) based on DOTA for chelation of both Cu
2+
 and 
Gd
3+
 ions (right, adapted from 
245
). 
 
Copper has been shown to bind to gadolinium in non-high Tc superconductors via oxo-
bridges.
245
 This cation forces a distorted pentagonal bipyramid conformation on the 
gadolinium ion. This particular ion, [(CuHAPen)2Gd(H2O)3]
3+
, was originally formed to 
study magnetic interactions between transition metals and rare earths. The gadolinium to 
copper coupling was shown to be both ferromagnetic and fairly substantial.  Finally, 
copper has been shown to bind directly with gadolinium.
246
 The thermochemistry of the 
copper-gadolinium interface has been determined via valance-band photoemission, 
showing that the copper binds strongly to the gadolinium. By coating Gd sheets with Cu, 
the binding energy of the 3d electrons increases over 0.7 eV. 
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APPENDIX VIII: U.T.M.D. 
64
Cu LOADING PROTOCOL 
This appendix contains the original 
64
Cu loading protocol established at the Department 
of Experimental Diagnostic Imaging in the U. T. M. D. Anderson Cancer Center on 15 
July 2008.  
 
SUBJ:   STANDARD OPERATING PROCEDURE (SOP) FOR IN VIVO 
64
Cu
3+
 
LOADING WITHIN GADONANOTUBES 
 
1. Purpose: The purpose of this memorandum is to present a SOP following Good 
Laboratory Practices (GLP) to the Department of Experimental Diagnostic 
Imaging at the U. T. M. D. Anderson Cancer Center (UTMD). 
 
2. Scope: The scope of this memorandum will be studies aimed for preliminary 
investigations on 
64
CuCl3 loading and retention under simulated 
physiological challenge within ultra-short carbon nanotubes with 
internalized gadolinium ions (gadonanotubes). 
 
 
3. Outline of 
    Procedures:  
3-2. Ensure that all Personal Protective Equipment (PPE) is in place 
and worn as according to UTMB’s safety protocols 
3-3. Add 5 mCi 64CuCl3 to “US-Tube Solution” 
3-3.1. US-tube solution will be provided by Rice 
University in a disposable centrifuge tube marked 
“US-Tube Solution” 
3-3.2. US-tube solution will contain ~3mg of reduced, cut, 
open, debundled SWNTs in 3.0 mL of 18 MΩ 
deionized water 
3-4. Bath sonicate the US-Tube/64CuCl3solution for 20 minutes. 
3-5. Add 1.0 mL  of 15 mM GdCl3 (aq) 
3-5.1. 15 mM GdCl3 (aq) will be provided by Rice  
3-6. Bath sonicate the US-Tube/ 64CuCl3 / GdCl3 solution for 20 
minutes. 
3-7. Filter the solution using a coarse grade fritted glass filter. 
3-7.1. Coarse grade filter will be provided by Rice. 
3-7.2. Collect each filtrate in a disposal centrifuge tube to 
analyze activity. 
3-7.3. Continue filtration until filtrate shows no activity, 
but no less than a minimum of 8 washings. 
3-8. Add collected tubes to 1% F108 Pluronic solution. 
3-8.1. Bath sonicate for 20 minutes 
3-9. Sample ready for injection – dosage determined by UTMD staff 
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APPENDIX IX: 1.5 T AND 3.0 T MRI PHANTOM RAW DATA 
 
 
Table 20. 1.5 T and 3.0 T MRI phantom raw data for 3 concentrations (200 μCi/mL, 100 
μCi/mL, and 50 μCi/mL) of 64CGNTs compared to 1% Tween control phantom. 
 
T1 or T2 
200 
μCi/mL 
100 
μCi/mL 
50 μCi/mL 1 % Tween-20 
TR 
(ms) 
TE 
(ms) 
T1 
(3T) 
(ms) 
2362 2166 2135 2107 
9000 20 
2008 2094 1928 1531 
2717 2239 2342 2683 
0.9791 0.9989 0.9909 0.9322 
T2 
(3T) 
(ms) 
88 159 267 1097 
9000 25 
81 149 263 988 
94 169 271 1205 
0.995 0.995 0.9997 0.9831 
T1 
(1.5T) 
(ms) 
1822 1757 1726 1878 
6500 10 
1793 1715 1668 1794 
1851 1798 1784 1963 
0.9999 0.9997 0.9995 0.999 
T2 
(1.5T) 
(ms) 
94 171 295 1780 
9000 35 
90 162 289 1670 
98 180 302 1890 
0.9987 0.997 0.9993 0.9943 
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APPENDIX X: RAW DATA FOR 
124
I EXPERIMENT 
 
 
Table 21. Raw data for 
124
I experiment summarized in Chapter 4 and displayed in 
Figure 44. 
 
Time Points 1hr 4hr 24hr 
 
Free 
124
I 
Mouse 1 2.52875 4.037594 1.003942 
Mouse 2 3.693727 4.166462 1.397997 
Mouse 3 3.289859 3.021809 1.182813 
Avg. 3.170778 3.741955 1.194917 
Std Dev. 0.591547 0.626984 0.197306 
 
124
I2@US-tube Nanocapsules 
Mouse 1 2.949897 1.526432 2.088905 
Mouse 2 2.004826 2.080629 1.008427 
Mouse 3 1.561098 1.835249 1.550329 
Avg. 2.17194 1.814103 1.54922 
Std Dev. 0.709321 0.277703 0.54024 
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